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This thesis describes various measurements made in blood
platelets and erythrocytes from patients suffering from affective
disorders, and the effect a variety of therapies have on these
measures.
No significant differences were detected in either platelet
membrane ATPase or adenyl cyclase specific activity in any of the
groups of patients studied, when compared to values obtained in
control subjects. However, unipolar depressed and bipolar manic
patients were shown to have a reduced erythrocyte membrane Na++K+-
ATPase and Ca2++Mg2+-ATPase activity, respectively. It is suggested
that membrane enzyme changes found in some peripheral cells in
patients suffering from affective disorders, are not common to all
peripheral cells, and may or may not reflect central nervous system
changes. The decreased Na++ K+-ATPase activity in erythrocytes was
found to be correlated with a reduction in the number of sodium pump
sites. This reduction did not appear to be caused by a change in
the phospholipid composition of the membrane.
Neither amitripty1ine nor mianserin, in vivo or in vitro,
affected platelet membrane ATPase activity. Lithium, in vitro,
however, stimulated platelet Mg2+-ATPase activity. Both amitriptyline
and mianserin therapy, and subsequent recovery, caused erythrocyte
membrane Na++K+-ATPase activity in unipolar depressives to approach
control values. In vitro neither drug affected the erythrocyte
membrane. ECT did not affect the reduced Na++ K+-ATPase activity
of erythrocyte membranes in unipolar depressed patients. After a
course of treatment a slight increase in Ca2+-ATPase activity in
erythrocyte membranes was observed. Although it is considered likely
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that an observed reduction in erythrocyte membrane Na++ K+-ATPase
activity indicates a susceptibility to depression, increases in
that Na++ K+-ATPase activity do not seem to be obligatory for
clinical improvement to take place.
A reduced Vmax for the 5"HT uptake process into platelets was
observed in both unipolar and bipolar depressed patients, while
Vmax values were found to be elevated in untreated unipolar well
patients. Whole blood 5_HT levels in these patients were found to
be normal.
Lithium administration did not appear to affect platelet 5"HT
uptake. Mianserin therapy and recovery caused a change towards normal
Vmax values in unipolar depressed patients. Amitriptyline therapy
and recovery caused reduced Vmax values to decrease further, Km values
for the process to increase, and whole blood 5~HT levels to fall
dramatically, in vitro, the two drugs acted in a similar manner,
causing a decrease in Vmax and an increase in Km- As Vmax values
appear to be independent of clinical condition in treated patients,
a reduced Vmax for 5-HT uptake into platelets from untreated patients
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1. THE NATURE OF AFFECTIVE ILLNESS
Affective illness is a term which encompasses a large group
of mental disturbances which are characterized by phases of depression
and elation (mania), either alone or alternately, with lucid
intervals. Depression and elation are not the only symptoms of
this disorder. Depression is often associated with insomnia,
anorexia, feelings of guilt, self-reproach and suicidal tendencies.
Associated with elation may be hyperactivity, flight of ideas and
marked pressure of thoughts. In severe manic-depressive illnesses,
patients often experience delusions and hallucinations (Clare, 1976).
Psychiatrists have unfortunately failed to produce a classi¬
fication scheme which adequately covers all facets of the disorder
(Lewis, 1938; Kendall, 1978; Van Praag, 1978). This is hardly
surprising as the aetiology of the illness remains unknown, the
pathology uncertain, and the symptomatology is often the subject of
debate.
This controversy has stimulated research along several lines.
As examination of brain tissue from living patients suffering from
affective illness is not possible, the metabolism of these patients
has been investigated using urine, blood and cerebrospinal fluid
(CSF) in the hope that some abnormality might be detected which
would relate to the cause, or at least the progression, of the
illness (Van Praag, 1978). Use has likewise been made of post¬
mortem brain samples taken from individuals who have committed
suicide (Lloyd, Farley, Deck and Horneykiewicz, 197*0. Tricyclic
antidepressants (Kuhn, 1957, 1958; Kielholz and Battegay, 1958),
monoamine oxidase inhibitors (Crane, 1956, 1957; Loomer, Saunders
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and Kline, 1957), 'novel' antidepressants (Bridges, 1978), lithium
(Goodwin, Murphy, Dunner and Bunney, 1972; Schou, 1973) and
electroconvulsive therapy (ECT) (Medical Research Council, 1965)
have all been shown to be effective in treating these disorders,
investigations have been made of the effects of these treatments
in man and animals in the hope that clues might be found to the
nature of the illness. More recently workers have investigated a
possible genetic involvement (Mendlewicz and Rainer, 1977; Schlesser,
Winokur and Sherman, 1979) and the use of animal models has also
been considered (Boissier, Godefroy, Soubrie, Thiebot and Weil-
Fugazza, 1976; Porsolt, Le Pichon and Jalfre, 1977).
Many hundreds of investigations have been carried out in the
hope of detecting metabolic changes in patients with affective
disorders and assessing the effects of various therapies. An
examination of the results reveals that there are few unequivocal
conclusions to be drawn (see reviews byCoppen, 1967; Baer, Platman
and Fieve, 1970b; Davis, 1970; Curzon, 1972; Schildkraut, 1973;
Hull in, 1976; Jain, 1976; Moyes and Moyes, 1976; Ridges, 1976;
Van Praag, 1978).
However, this has not prevented several hypotheses from being
advanced to explain the cause of affective illness.
2. HYPOTHESES OF AFFECTIVE ILLNESS
(a) Monoamine hypotheses
Tricyclic antidepressants and monoamine oxidase inhibitors
became available for clinical use in the late fifties. It was
noticed that the new, chemically unrelated, drugs had two character-
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isties in common. Both were efficacious in the treatment of
endogenous depressions and both could act like monoamine agonists,
albeit through different mechanisms (Van Praag, 1978).
These observations led several workers to suggest that the
therapeutic action of these drugs was related to their ability to
potentiate monoamines which, for some unknown reason, were depleted
in depression. This suggestion was supported by the fact that
reserpine, which at that time was used in high doses to treat
hypertension, could produce depression in as many as 15% of
patients treated with this drug, presumably by reducing the
concentration of monoamines in the brain (Bunney and Davis, 1965).
Two theories were advanced, namely the indoleamine hypothesis
(Ashcroft, Crawford, Eccleston, Sharman,MacDouga11 , Stanton and
Binns, 1966; Coppen, Shaw, Herzberg and Maggs, 1967; Lapin and
Oxenkrug, 1969) and the catecholamine hypothesis (Bunney and Davis,
1965; Schildkraut, 1965) which related the depressive syndrome to
a central 5-hydroxytryptamine (5~HT) or catecholamine deficiency,
respectively. Mania, if considered at all, was thought to exist
at the other end of the biological continuum of mood, and to occur
when there was an 'excess' of monoamines in the central nervous
system.
(i) Urinary studies
Results of investigations measuring indoleamines, catecholamines
and their respective metabolites in urine from patients suffering
from affective illness have been used to test these hypotheses.
Studies of urinary 5~ hydroxyindoleacetic acid (5"HIAA;
the major metabolite of 5_ HT in both the CNS and the periphery,
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Lovenberg and Engelman, 1971), cannot provide a relevant answer.
As only 1 to 2% of the 5~ HT in the whole body is found in the
brain (Cooper, Bloom and Roth, 1978), changes observed in urinary
5-HIAA cannot possibly reflect CNS changes, and thus cannot be
used to test the proposed hypotheses.
When results obtained in these studies are assessed it can
be seen that there are no consistent 'whole body1 changes either.
The 2A-hour excretion of 5-HIAA has been found to be decreased
(Pare and Sandler, 1959; Van Praag and Leijnse, 1963 a,b), normal
(Cazullo, Mangoni and Mascherpa, 1966) and increased (Tissot, 1962)
during depression.
Variations in values obtained may have been due to differences
in diet. It is known that a variety of foods, especially fruits,
contain 5 - HT (Crout and Sjoerdsma, 1959).
In a 'longitudinal' study 5-HIAA excretion was found to be
greater in mania than during depressive phases (Strom-01 sen and Weil-
Malherbe, 1958). Although patients acted as their own controls in
this study, the influence of diet cannot be ruled out.
Tryptamine excretion has also been investigated. This
compound is formed from tryptophan by the action of amino acid
decarboxylase, and an alteration in its concentration might
indicate a reciprocal change in that of 5 - HT. However, tryptamine
excretion has been observed to be both decreased (Coppen, Shaw,Ma 11eson,
Eccleston and Grundy, 1965b)and increased (McNamee, Moody and
Naylor, 1972) in depression.
Use has also been made of radioactive1y-1abel1ed precursers
administered to patients, to monitor urinary excretion of radio-
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actively labelled metabolites. A study where 1^C-L-tryptophan
was administered to 5 severely depressed patients (Coppen, Brooksbank
and Eccleston, 197*0 failed to reveal any difference in the urinary
excretion of 5 — {1LfC}HlAA either between pre- and post-therapy
values, or between patients and controls. The authors commented
in their paper that a marked inter- and intra-individua1 variation
existed. An earlier study, which used unlabelled tryptophan
(Cazullo et al, 1966) had also revealed that urinary 5 - HIAA
excretion was normal.
Three studies did find that the urinary excretion of xanthurenic
acid and kynurenine was higher in depressed patients, both basal ly
and after administration of tryptophan, compared to control subjects
(Cazullo et al, 1966; Rubin, 1967; Curzon, 1969)- Only a small
amount of tryptophan is used for the synthesis of the indole
derivatives 5 - HT and tryptamine. A much larger amount is converted
via kynurenine andxanthurenic acid to the B- vitamin nicotinic acid,
or is utilized in protein synthesis. It is conceivable that in the
patients investigated, less tryptophan was available in the peripheral
circulation, for the synthesis of 5 - HT. However, plasma levels of
tryptophan were not measured. It is possible that the changes
observed were due to alterations in the renal clearance of kynurenine
and xanthurenic acid. It is also possible that the Increase
observed in kynurenine andxanthuren i c acid occurred at the expense
of tryptamine and not 5 - HT. It is interesting to note in this
context that urinary 5 - HIAA excretion was found to be normal in
these patients (Cazullo et al, 1966).
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Urinary levels of noradrenaline (NA), dopamine (DA) and
their respective metabolites cannot test the hypotheses stringently,
either.
The major metabolites of NA in urine are 3~methoxy-it-hydroxy-
mandelic acid (VMA) and 3~methoxy-4-hydroxypheny1g1ycol (MHPG)
(Goodall and Rosen, 1963)- Enzyme studies in animals indicate that
aldehyde reductase activity predominates in the brain, while
aldehyde dehydrogenase activity predominates in the periphery
(Erwin, 1973). This suggests that the aldehyde metabolites of NA
would follow a predominantly reductive pathway (to the glycol)
in the CNS and an oxidative pathway (to the acid) in peripheral
tissues. Several animal studies have provided data which suggests
that 25 " 60% of the urinary MHPG originates from the metabolism of
NA in the brain (Maas and Landis, 1968; Schanberg, Schildkraut,
Breese and Kopin, 1968; Maas, Dekirmenjian, Garver, Redmon and
Landis, 1973a\ In man, Ebert and Kopin (1975), using {lltC}-DA
infusions in patients and in control subjects, have suggested that
as much as 60% of urinary MHPG originates from brain pools of NA,
while virtually all of the urinary VMA results from metabolism of
peripheral NA. However, even if these estimates are accurate, it
is not possible to say with certainty that an observed change in
MHPG excretion reflects a change in NA metabolism in the CNS.
DA is metabolized principally to 3-methoxy-it-hydroxypheny 1-
acetic acid (HVA) and to a lesser extent to 3 ,^-dihydroxypheny1 -
acetic acid (DOPAC) (Goodall and Alton, 1968). However, the
proportion of urinary DA metabolites that originate from the brain
is uncertain. In patients suffering from Parkinsonism, where a
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degeneration of the nigro-striat a 1 pathway (a system using dopamine
as neurotransmitter) is known to occur, some workers have found
urinary HVA excretion to be reduced, while others have found it to
be normal (Rine and Sonninen, 1968; Wei 1-Maiherbe and Van Buren,
1969; Calne, Karoum, Ruthven and Sandler, 1969; Tyce, Muenter and
Owen, 1970).
NA and DA are also present in urine. However, because of
the possibility of peripheral contributions, measurement of the
concentration of these compounds in urine cannot provide a measure
of CNS activity .
Studies measuring urinary catecholamine levels suggest that
there may be a change in 'whole body1 catecholamine metabolism in
affective illness.
The excretion of NA and normetanephrine (a methylated NA
metabolite formed in the metabolic pathway from NA to VMA) has been
found to be lower in patients in a depressive state compared to
when they are symptom free (Greenspan, Schildkraut, Gordon, Levy
and Durell, 1969; Bunney, Murphy and Goodwin, 1970). Decreased NA
and normetanephrine excretion is thought to occur in cases of
retarded depressions (Schildkraut, 1975)-
These differences may well be due to differences in physical
activity. It is known that catecholamine excretion can be
influenced by muscular activity (Karki, 1956). So, it is possible
that the observed decrease in NA and normetanephrine excretion is
related to a reduction in activity of the patients concerned.
However, Takahashi, Nagao, Tsuchiya, Takamizawa and Kobayashi
(1968a1 failed to demonstrate a decrease of activity in depression.
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It is interesting to note that in manic syndromes (Greenspan et al
1969) and in agitated depressions (Sloane, Hughes and Haust , 1966),
conditions which are accompanied by motor hyperactivity, the
excretion of both NA and normetanephrine has been found to be
raised.
Bunney et al (1970) found that NA excretion was raised on the
day preceding the manic phase in a number of manic depressed
patients with rapid phase alteration. This observation raises
the possibility that NA excretion might not be exclusively motor
determined.
MHPG excretion has been found to be decreased in depressed
patients, and also in agitated depressed patients who have an
increased excretion of NA and normetanephrine (Maas, Fawcett and
Dekirmenjian, 1968 ; Greenspan, Schildkraut, Gordon, Baer, Aranoff
and Du rel1, 1970).
Maas, Dekirmenjian and Jones (1973b) found that this reduction
occurred in both bipolar and unipolar depressed patients. However,
a more recent study, investigating a larger number of patients, found
a reduction in MHPG excretion in bipolar patients and an increase
in excretion in unipolar patients, when they were compared to control
subjects (Goodwin and Beckmann, 1975).
Urinary excretion of MHPG has been found to be higher in the
manic phase compared to the depressed phase (Greenspan et al, 1970;
Bond, Jenner and Sampson, 1972; Jones, Maas, Dekirmenjian and
Fawcett, 1973). In two manic-depressive patients, MHPG excretion
was seen to increase during the days preceding the manic phase
(Bond et a1, 1972). This observation suggests that the raised
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excretion is not due entirely to a change in motor activity.
Increases in MHPG excretion have been observed in response to
various types of stress (Rubin, Miller, Clark, Poland and Arthur,
1970; Maas, Dekirmenjian and Fawcett, 1971). It is possible
that observed changes reflect changes in adrenal medulla activity
or in CNS metabolism.
The position with regard to VMA is controversial and does
not help in deciding the contribution made by central sources.
Campanini, Catalano, Derisio and Mardighian (1970) observed an
increase in the excretion of VMA in manic patients. However,
Greenspan et al (1969) measured normal VMA excretion, even in
manic patients with raised NA and normetanephrine excretion.
Values obtained for DA excretion are similar to many
obtained for NA and MHPG, i.e. increased in mania and slightly
reduced in depression (Messiha, Agallianos and Clower, 1970;
Schi1dkraut, 1975) .
Studies of urinary cyclic adenosine monophosphate (cAMP)
levels have also been undertaken with a view to gaining some insight
into CNS metabolism. An important role has been postulated for
cAMP in transmission at monoaminergic synapses (for review see
Walton, 1977). It is thought that when a neurotransmitter diffuses
across the synaptic cleft, it stimulates adenylate cyclase, situated
post-synaptica11y , which causes an increase in cAMP concentration.
This increase has been suggested as being responsible for the
subsequent response in the effector cell.
Urinary cAMP excretion has been found to be reduced in
depressive and increased in manic phases of affective illness
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(Abdullah and Hamadah, 1970; Paul, Ditzion, Pauk and Janowski, 1970;
Paul, Cramer and Goodwin, 1971)• The most severely depressed patients
were shown to have the greatest reduction in cAMP (Paul et al, 1970).
A reduction has been shown to occur in both endogenous and personal
depressions (Sinanan, Keatine, Beckett and Love, 1975)*
It is more than likely that these changes in cAMP levels relate
to motor status (Berg and Glinsmann, 1970; Eccleston, Loose, Pullar
and Sugden, 1970) rather than CNS metabolism.
(ii) Plasma studies
Results of studies measuring plasma levels of monoamine
precursers in patients suffering from affective disorders have been
used to test the monoamine hypotheses. As with urinary studies, it is
difficult to assess whether a change observed in plasma levels of
precurser would necessarily reflect a change in monoamine levels in
the CNS.
Coppen, Brooksbank and Eccleston (1974) demonstrated a
slightly reduced tryptophan tolerance in depression. They measured
total tryptophan levels in blood at different intervals after i.v.
tryptophan administration. During the first three hours after loading,
the tryptophan concentration in depressed patients was slightly higher
than in controls. This result could be interpreted as being due to an
impaired ability of the patients to metabolize tryptophan, or it could.
be that in the depressed patients the tryptophan was distributed
throughout a smaller volume.
Rees, Alltop and Hullin (1974) investigated two patients with
rapidly alternating manic and depressive phases. They found that the
total plasma tryptophan concentration was decreased in the depressive
phase and increased during the manic phase.
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It is important, however, to consider the concentration of free
tryptophan (i.e. that which is not "bound to plasma proteins) for it is
this fraction that can be transported across the blood-brain barrier.
The plasma concentration of free tryptophan in females with
a depressive illness (no mania) was found to be reduced compared with
that in an age-matched control group (Coppen, Eccleston and Peet, 1973).
These workers found that after recovery the free tryptophan concen¬
tration increased in these patients, but did not attain normal levels.
This might have been due to a decrease in the amount of: tryptophan:
bound to plasma proteins. It is interesting to speculate upon; what:
might have produced the change in binding. There was no diet control
in the study. Variations in food intake might have been an import¬
ant factor. Patients did not receive drugs which are known to alter
the degree of tryptophan binding (e.g. salicylates), however other
substances are known to interfere with this binding. Free fatty acids
(FFA) in plasma can influence protein binding of tryptophan (Coppen et al,
1973; Lipsett, Madras, Wurtman and Munro, 1973). This fat fraction
responds strongly to psychological stress, so it is quite possible
that any change monitored in free tryptophan concentration was a non¬
specific phenomenon.
It is impossible to determine if 5~HT. concentration in the brains
of depressed patients are reduced as a consequence of reduced plasma
free tryptophan levels. The transport of tryptophan across the
blood-brain barrier can be influenced in many ways (see review by
Green and Grahame-Smith, 1975)*
High levels of circulating hydrocortisone (cortisol) have been
found in depression (Hullin, Bailey, McDonald, Dransfield and Milne,
1967). Corticosteroids from the adrenal cortex can stimulate.
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the synthesis of tryptophan pyrrolase in the liver (Knox and
Auerbach, 1955) which is the first enzyme in the conversion of
tryptophan via the kynurenine route. These observations tie in with
the reported increased urinary excretion of xanthurenic acid and
kynurenine i n depression.
Rubin (1967) found that the increased kynurenine excretion
he observed correlated with an increased plasma Cortisol level.
It is likely that activation of tryptophan pyrrolase can
withdraw a substantial amount of tryptophan from 5 - HT synthesis.
Acutely administered hydrocortisone induces in rats an activation of
liver pyrrolase, a decrease in plasma tryptophan and a decrease of
approximately 30% in cerebral 5~ HT and 5~ HIAA concentrations
(Curzon and Green, 1968). When animals are given a pyrrolase
inhibitor in advance, hydrocortisone no longer causes a decrease in
intracerebral 5~ HT (Green and Curzon, 1968). Another compound,
a-methy1tryptophan, which also activates liver pyrrolase but
independently of the adrenal cortex, also causes a decrease in
central 5~ HT concentration (Curzon, 1969). It may be that in
depression, as a result of a raised plasma Cortisol level, 5~ HT
concentration in the brain of depressives is reduced. However, it
should be noted that Rubin (1967) did not measure plasma tryptophan
1 eve 1s.
Results available from studies of plasma tyrosine levels are
eguivoca1.
In patients with endogenous or vital depressions fasting
plasma tyrosine levels were found to be no different from controls
(Takahashi, Utena, Machiyama, Kurihama, Otsuka, Nakamura and
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Konamura, 1968b). However, when tryosine was administered orally,
plasma tyrosine levels were higher in patients than in controls.
In complete contradiction to this study, Benkert, Renz, Marano
and Matussek (1971) found a decreased plasma tyrosine level in
depressed patients in the morning hours, but after oral administra¬
tion of tyrosine, no change in levels was observed.
Prolactin levels (Sachar, Frantz, Altman and Sassin, 1973)
and the growth hormone response (Gruen, Sachar, Altman and Sassin,
1975) after L-dopa administration were found to be normal in patients
with unipolar and bipolar depressions. The growth hormone response
to insu1in-induced hypoglycemia, however, was lower in females (all
post-menopausal) with unipolar depression than in a control group
(Gruen et al, 1975). These are interesting observations. The
secretion of prolactin by the anterior hypophysis is regulated by
dopaminergic neurons of the tuberoinfundibu1 ar DA system. Secretion
is inhibited by an increase, and stimulated by a decrease in DA
activity. This is believed to occur via an increase or decrease,
respectively, of the secretion of prolactin-inhibiting factor (PIF),
a substance formed by neuroendocrine cells in the hypothalamus
(Meites, Lu, Wuttke, Welsch, Nagasawa and Quadrie, 1972). Growth
hormone secretion is increased with increased central catechol aminergic
activity and decreases with its decrease (Martin, 1973)- This
regulation is probably effected via an increase and decrease
respectively of the secretion of growth hormone releasing factor
(GRF) by neuroendocrine cells in the hypothalamus. There are
indications that NA (Toivola and Gale, 1972) as well as DA (Muller,
Pecile, Felici and Cocchi, 1970) are involved in the regulation of
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growth hormone. L-dopa administration (precursor of DA as well as
NA) causes a decrease in plasma prolactin and an increase in plasma
growth hormone concentrations in humans (Kleinberg, Noel and Frantz,
1971, Kansal, Buse, Talbert and Buse, 1972). The growth hormone
level also rises in response to insu1in-induced hypoglycemia, which
is probably a catecholaminergic effect, for it disappears following
administration of reserpine (which depletes monoamine stores) and
a -methy1-p-tryosine (which inhibits catecholamine synthesis)
(Millar, Sawano and Arimura, 1967). Gruen et al (1975) findings
would seem to suggest that a malfunction in a catechol aminergic
system exists in depression. However, no final conclusions can be
made until an investigation is made of the peripheral metabolism of
prolactin and growth hormone in these patients.
(iii) Platelets and erythrocytes
Several investigators have proposed that the blood platelet
can serve as a model for the amine-storing presynaptic nerve terminal
in the central nervous system (Sneddon, 1973; Stahl , 1977).
Platelets and synaptosomes have many similar characteristics, as
detailed in Table 1.1 (see Sneddon, 1973; Stahl, 1977 and Gordon
and Olverman, 1978 for references). The proposal that platelets can
serve as models of nerve-endings is very attractive in terms of
research into affective disorders. Blood samples are easily obtained
from patients, and platelets can be readily separated from other
blood cells by differential centrifugation. Enzyme activities of,
and monoamine uptake into, platelets are measures that have been
made in patients with affective illness. However, it is not known
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TABLE 1.1: A comparison of platelets and synaptosomes
Platelet Synaptosome
Limiting membrane Yes Yes
Mitochondria Yes Yes
Storage granules Yes Yes
Lysosomes Yes Yes
Glycogen particles Yes Yes
Microtubules Yes Yes
MicrofiIaments Yes Yes
Active transport mechanism for:





Ad renaline No Yes
Anabolic enzymes present:
Tryptophan hydroxylase Di sputed Yes
Aromatic amino acid decarboxylase Dis puted Yes
Tyrosine hydroxylase 7 Yes
Dopamine-B-hydroxylase No Yes
Phenyl-ethanolamine-N-methyI
t rans fe rase ? Yes
Catabolic enzymes present:
Monoamine oxidase Yes Yes
Aldehyde reductase Yes Yes
Aldehyde dehydrogenase No Yes
Catechol-0-methyl transferase No Yes
Storage of monoamines Yes Yes
Release of stored monoamines Yes Yes
in the studies which will be described below, how the activities
compared with those in the CNS of the patients investigated.
Red blood cells from patients have also been used to estimate
possible metabolic disturbances present in affective illness.
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These cells, like platelets, are readily obtained. Host investigations
using erythrocytes have involved measurement of intracellular ion
concentrations and activities of various membrane-bound enzymes (see
Section 1, part 2 (c) (iv) of this thesis). It is again not known
to what extent these measures reflect those in the brain.
A 50% reduction in monoamine oxidase (MAO) activity was found
in platelets taken from bipolar depressed patients (Murphy and Weiss,
1972). The MAO activity remained reduced after recovery from depression
and during manic phases. MAO activity in blood platelets is known to
be lower in men than in women (Robinson, Davi Nies, Ravaris and
Sylwester, 1971). However, this fact does not explain the observations
of Murphy and Weiss (1972) as the patients were age and sex-matched
to control subjects. In confirmation of their observation, octopamine
has been shown to accumulate in blood platelets of depressed patients
as a result of reduced MAO activity (Murphy, 1972). However, it is
not known if MAO activity in platelets reflects that present in brain.
If platelet MAO activity did parallel that of the CNS, it is difficult
to reconcile this observation with the monoamine hypotheses, unless
one considers it to represent a compensatory change. However, platelet
MAO activity has been reported as increased in unipolar depressed
patients (Buchsbaum, Landau and Murphy, 1973; Nies, Robinson and Harris,
197A).
Uptake of 5"HT (Hallstrom, Linford Rees, Pare, Trenchard and
Turner, 1976; Mulgirigama, 1976; Tuomisto and Tukianen, 1976) and DA
(Hallstrom et al, 1976; Mulgirigama, 1976) has been found to be reduced
in platelets from depressed patients. Although there is evidence to
suggest that 5"HT uptake into platelets may be similar to 5"HT uptake
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in the brain (Sneddon, 1973), it is doubtful if the same holds true
for DA uptake (Gordon and Olverman, 1977; 1978). The observed
reductions in platelet 5_HT uptake, if reflecting the situation in
the CNS, could be used to either uphold or refute the serotonergic
hypothesis, depending on whether the observed change is considered
to be secondary and compensatory in nature, or is considered to
be a primary response.
Cohn, Dunner and Axel rod (1970) and Dunner, Cohn, Gershon
and Goodwin (1971) measured catecho1-0-methy1 transferase (COMT)
activity in red blood cells in patients with various psychiatric
disorders and found a 50% reduction in females with unipolar
depression and a slight reduction in bipolar females. No such
abnormality was seen in men with either unipolar or bipolar
depression or in schizophrenic women. The reduction was shown by
these workers not to be syndrome-1inked, for when the patients
recovered their COHT activities were still reduced. This suggests
that the reduced COMT activity may indicate a 'pre-disposition 1
to depressive illness at most. However, it is not known if this
reflects any CNS abnormality. If this observation did parallel a
change in the CNS, it is again difficult to reconcile this with the
catecholamine hypothesis, unless one considers it to represent a




Infused NA was found to have a reduced influence on the
systolic blood pressure of depressed patients (Prange, McCurdy and
Cochrane, 1967). However, it is impossible to infer from this
observation whether the metabolism of NA is accelerated or NA
receptors are "impaired" in the CNS.
(v) Carbon dioxide
Coppen, Shaw and Malleson (1965a) observed that when Re¬
labelled 5~hydroxytryptophan (5-HTP) is injected i.v. into depressed
patients, the production of 11+C-carbon dioxide (in expired air)
is decreased when compared to that in a control group. This might
suggest a defect in the conversion of 5~HTP to 5~HT, though not
necessarily in the brain. However, these workers were unable to
reproduce their own results (Coppen, 1967).
(vi) Cerebrospinal fluid
Measurement of levels of indoleamines, catecholamines and
their respective metabolites in cerebrospinal fluid (CSF) might
be expected to produce values which would more closely reflect those
in the brain. Such expectations have prompted many investigations.
In I960 Ashcroft and Sharman found that the concentration of
'substances with a 5~hydroxyindole structure1 in the CSF was
reduced in depressive patients. The same laboratory later demon¬
strated that 5-HIAAwas reduced in depressed patients (Ashcroft,
Crawford, Eccleston, Sharman,MacDougal1, Stanton and Binns, 1966),
a finding which was confirmed by several other groups (Denker, Malm,
Roos and Werdinius, 1966; van Praag, Korf & Puite, 1970; Coppen, Prange,
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Whybrow and. Noguera, 1972b; Mendels, Frazer, Fitzgerald, Ramsay
and Stokes, 1972a). Some workers, however, reported only very
slight decreases in 5-KIAA concentration (Eowers, Heninger and
Gerbode, 1969; Papeschi and McClure, 1971) while others found no
decrease at all (Roos and SjOstrttm, 1969; Wilk, Shopsin, Gershon
and Suhl, 1972; Sjtistrbm and Roos, 1972; Goodwin and Post, 1973).
These inconsistencies might be explained by differences in
the patient groups investigated. A decreased 5-HIAA in lumbar CSF
was always found in patients with vital (endogenous) depressions
but only occasionally found in patients with personal (reactive)
depressions (van Praag, Korf and Puite, 1970). However, the same
group could not repeat their own findings (van Praag, Korf and
Schut, 1973b). Mendels et at (1972a) found that reduced 5-HIAA
seemed to be present more consistently in endogenous rather than
reactive depressions. They also found a tendency for the reduction
to occur more in unipolar than bipolar depressed patients. This
was in agreement with the findings of Ashcroft, Blackburn,
Eccleston, Glen, Hartley, Kinloch, Lonergan, Murray and Pullar (1973a).-
Manic patients have also been shown to have a decreased
lumbar 5-HIAA concentration (Denker et al, 1966; Bowers et a/ ,1969;
Coppen et al, 1972b; Mendels et a! ,1972a). However, normal and
increased 5-EIAA CSF concentrations in mania have also been reported
(Wilk et al, 1972; Goodwin and Post, 1973).
Coppen, Brooksbank and Peet (1972a) found a decreased concen¬
tration of tryptophan in lumbar CSF in 10 patients with unspecified
depressive syndromes. Ashcroft, Crawford, Cundall, Davidson, Dobson,
Dow, Eccleston, Loose and Pullar (1973b) found, however normal levels
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of tryptophan in both unipolar and bipolar depressives.
Reduced CSF levels of HVA have been reported in depressed
patients (Fapeschi and McClure, 1971)- However, many investigations
have revealed normal levels (Roos and SjBstrbm, 1969; Bowers et al, 1969;
van Praag and Korf, 1971)•
In mania reduced CSF levels of HVA have also been observed
(SjBstrOm and Roos, 1972). However, normal values have been reported
(Bowers et al, 1969; Ashcroft and Glen, 1974).
Reports of CSF levels of MHPG in depression are controversial.
Reduced (Post, Kotin, Goodwin and Gordon, 1973) and normal (Filk,
Shopsin, C-ershon and Suhl, 1972) values have been observed.
MHPG in mania has been found to be both equal (Post et al, 1973)
and raised (Filk et al, 1972) compared to a variety of control groups.
It is apparent that the CSF results reported here do not
allow any consistent conclusions to be drawn. It is worthwhile
considering what may cause the wide variation.
The control groups used in these investigations were not
not normal subjects, but hospitalized patients with either neurological
or psychiatric conditions. Any differences obtained between patients
and'control' subjects must therefore be viewed cautiously.
Differences in the ages of the subjects investigated may
cause spurious variations. Bow'ers and Gerbode (1968a) found S-HIAA
concentration in CSF to increase with increasing age and be
significantly higher over, compared with under, the age of sixty
years. Ashcroft et a I (1973a) found a more complicated relationship
between age and CSF 5-KIAA concentration, with minimal values in the
age range forty to fifty years, and higher values in both younger
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and older individuals. Unfortunately, controversy exists here as
well, for other groups have found no age correlation at all (Nordin,
Ottosson and Roos, 1971; Papeschi and McClure, 1971; Goodwin and
Post, 1973).
It is important to consider the motor activity of the sub¬
jects investigated, since differences in movement may be associated
not only with' alterations in amine metabolism itself but also with
changes in CSF mixing, thereby causing 'artificial alterations' in
CSF metabolites (Post, Kotin, Goodwin and Gordon, 1973). In cases of
hyperactivity a raised lumbar CSF 5-HIAA concentration is often
found due to more effective mixing of the CSF (Post et a/, 1973).
In many investigations diet has not been controlled. This
could have important consequences. Dietary tryptophan, for example,
may produce alterations in brain serotonin turnover (Fernstrom
and Wurtman, 1971) and consequently in the levels of 5-HIAA in the
CSF of patients with affective disorders.
Differences in diagnostic criteria are other possible sources
of inconsistency between studies. In many investigations the
nature of the patient populations are not adequately described.
Resuhts obtained may vary according to the severity of the illness,
whether depressed patients are mainly agitated or retarded, or are
unipolar or bipolar .
Investigations after pharmacological manipulation have also
been undertaken.
Ashcroft et al(1973b) have investigated the CSF concentration
of 5-HIAA after tryptophan administration. They found no difference
between unipolar and bipolar depressed patients and controls who
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had neurological complaints. Another study in the same year
investigated changes after tryptophan loading more thoroughly
(van Praag, Flentge, Korf, Dols and Schut, 1973a). They measured
5-HIAA and tryptophan levels in CSF' at one, two, five and eight
hour intervals after tryptophan had been administered to depressed
patients. The tryptophan concentration had tripled in depressed
patients after one hour, while in non-depressed 'control' patients
the values hardly changed. Eight hours after tryptophan admini¬
stration, the concentration of 5-HIAA in the CSF was much higher
in the control group than in the depressed group. These observations
led this group to suggest that tryptophan is less easily converted
to 5-KT in the CNS of depressed patients.
CSF measurements have also been made in various patient
groups after probenecid administration. Probenecid inhibits the
transport of several organic acids, including 5-HIAA and HVA,
intra-renally (Despopoulos and Weissbach, 1957- Werdinius, 1967).
5-HIAA and HVA are eliminated from the CSF by an active transport
process, which is also inhibited by probenecid (Neff, Tozer and
Erodie, 1967; Ashcroft, Dow and Moir, 1968). Probenecid
administration in test animals is followed by an increase in
5-HIAA and HVA concentration in the brain (Werdinius, 1967) and in
the ventricular and cisternal CSF (Guldberg, Ashcroft and Crawford,
1966). The observed increase is a linear one, which lasts for
several hours (Bowers and Gerbode, 1968b; Bowers, 1972). This
suggests that degradation of amines continues for some time
undisturbed, and is not immediately reduced by a feedback mechanism.
Probenecid thus allows an estimate of amine turnover to be made.
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The transport system for MHPGi is relatively unaffected by
probenecid; MHPG shows only a slight accumulation in human CSF
after administration of the drug (Korf, van Praag and Sebens, 1971?
Gordon, Oliver, Goodwin, Chase and Post, 1973). As a result 'HA
turnover' cannot be studied.
There may be other shortcomings to the use of probenecid.
It is possible that it might interfere with CNS amine metabolism
indirectly. Probenecid decreases the serum total tryptophan
concentration (Korf, van Praag and Sebens, 1972) and more import¬
antly, increases the plasma free tryptophan concentration
(Lewander and Sjbstrbm, 1973). In certain circumstances this could
lead to an increase in brain 5-HT levels and therefore to an
increase in CSF 5-HIAA concentration (Fernstrom and Wurtman, 1971).
Intracerebral tryptophan concentration has been found to increase
after probenecid (Korf et a/, 1972). However, these workers did
not observe an increase in 5-HT synthesis. This seems a rather
unlikely observation. Synthesis of brain 5-HT is generally
considered to be dependant on brain tryptophan levels (see review
by Green and Grahame-Smith, 1975). However, work by Barkai, Glus-
man and Rapport (1972) in cats, which measured the rate of appear¬
ance of radioactively labelled 5-HIAA in CSF, confirms that
probenecid has no action on 5~HT synthesis.
Probenecid-induced accumulation of 5-HIAA in depressed patients
has been shown to be both reduced (Roos and Sjbstrbm, 1969; "van
Praag, Korf and Puite, 1970) and normal (Goodwin and Post, 1973).
It is possible that inconsistencies are due to differences
in the types of depressed patients examined. In 1977 van Praag
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found 5-HIAA to be non-significant 1y lower in depressed patients
with a trend toward a bimodal distribution and a low 5-HIAA
sub-group. This observation was in general agreement with
earlier work by Bowers (197*0 who had found 5-HIAA to be high
in unipolar but low in bipolar depressed patients.
HVA accumulation in CSF after probenecid has been found
to be reduced in patients with endogenous depressions (Roos and
Sjostrom, 1969; Sjostrom and Roos, 1972; van Praag et al, 1973b).
This has been considered to reflect the motor retardation seen
^
in this condition (van Praag et al, 1973b). However, normal
values have also been reported (Bowers, 1972).
Manic patients have been found to show a decreased
accumulation of 5-HIAA (Roos and Sjostrom, 1969; Sjostrom and
Roos, 1972). HVA accumulation in mania has been found to be
both normal (Roos and Sjostrom, 1969) and reduced (Sjostrom and
Roos, 1972) .
It can be seen that even with the use of probenecid,
1 ...
results are not entirely consistent.
These inconsistencies did not prevent another theory from
being presented; namely the modified amine hypothesis (Ashcroft,
Eccleston, Murray, Glen, Crawford, Pullar, Shields, Walter,
Blackburn, Connechan and Lonergan, 1972; Ashcroft and Glen, 197*0-
This group considered CSF 5-HIAA measurements made in diagnostic
sub-groups of patients with affective illness to be very interesting
(Ashcroft et al, 1973a). They found that 5-HIAA was 1ow in
recurrent unipolar depression, but normal in bipolar depression and
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mania. No change in 5-HI.AA was observed following recovery in
any of the groups of patients. These workers considered that the
low 5-HIAA seen in unipolar depression did not represent a
deficiency in the activity of tryptophan-5-hydroxylase in these
patients, for when a loading dose of tryptophan was given by
mouth, the concentration of 5-HIAA and of tryptophan in the
CSF of patients and controls was not significantly different
(Ashcroft, Crawford, Cundall, Davidson, Dobson, Dow, Eccleston,
Loose and Pullar, 1973b). These findings suggested to them that j
in unipolar depressjon there is a change in functional release
of 5~HT without a change in the capacity for synthesis. Functional
release was not defined by these workers, and presumably does not
include the release which occurs after a loading dose of tryptophan.
They do not consider alternative explanations for the reduced
5-HIAA seen in unipolar depression i.e. tryptophan deficiency
<*
giving rise to a decrease in 5~HT, which perhaps seems more
likely given their results after tryptophan administration.
J
These workers feel that in bipolar depression and mania an
alternative hypothesis is necessary. Bringing together their
observations of exploratory and stereotyped behaviour patterns
seen in affective illness and linking them with results from
animal studies, they suggest that a change in post-synaptic
receptor sensitivity may be the cause of bipolar depression.
They appreciate though, that measurements of such post-synaptic
changes may be difficult in man.
It is quite possible that fairly gross manipulations
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of the CNS, be they pharmacological or physical, may disturb
the metabolism of the brain and produce changes in the con¬
centration of metabolites in the cerebrospinal fluid (see van
Praag, 1978), However it is not known whether the lesi'onCs)
assumed to exist in the CNS of patients with affective illness
involve a small group of cells in the brain or many groups.
When one considers the complexity of the human brain
and the mechanisms therein that give rise to the 'mood' of
an individual at any one time, it perhaps seems unlikely that
a
differences between so-called normal subjects and manic-¬
depressives (who can be thought of as people who experience
'overshoots' of sadness and happiness) would be revealed from
measurements of metabolite concentrations in the CSF.
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(vii) Post-mortem brain
Although it might be considered that studies on post-mortem
brain could truly test the monoamine hypotheses, such studies are
difficult to interpret because of several factors. Post-mortem
results can probably be influenced by drugs taken prior to death
or in the act of suicide, causes of death in the control subjects,
the interval between death and autopsy, age and sex of the subjects
involved and the duration of the final agony. In addition, psychiatric
ratings of behaviour at the time just preceding death are usually not
avai1able .
Shaw, Camps and Eccleston (1967) found that the hindbrain
5-HT concentration was lower in a group of suicide victims than in
a control group of individuals who had died as a result of accidents
or from acute somatic non-neurologic diseases. They did not measure
the concentration of 5-HIAA. Pare, Yeung, Price and Stacey (1969)
also found a decreased 5-HT concentration in brains from patients who
had committed suicide by coal-gas poisoning, but they reported
normal levels for 5-HIAA. Another investigation (Bourne, Bunney,
Colburn, Davis, Davis, Shaw and Coppen, 1968) found no differences
in 5"HT concentration, but a reduction in 5~HIAA in a suicide group.
A more detailed study was undertaken by Lloyd et al (197*0 who
examined discrete areas of the brainstem from suicide victims.
A reduction in 5-HT concentration was found exclusively in the raphe
nuclei, and that only in the dorsal and the inferior central nucleus.
In both those nuclei, 5-HIAA concentration was only slightly lower
than in the control group.
Forebrain NA concentration in suicide victims (Bourne et al,
1968) was found to be the same as that in controls. Normal levels
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of NA in hypothalamus and DA in caudate have been shown (Pare et al,
1969) .
Gottfries, Oreland and Wiberg (197*0 found MAO activity in
various areas of the brains of suicide victims to be decreased by
between 20 and k0% compared with a control group with a different
cause of death. The decrease was observed whether tryptamine or
B-pheny1ethy1 amine was used as the substrate for the assay. Another
study from the same laboratory (Gottfries, Oreland, Wiberg and Wimblad,
1975) measured MAO activity in thirteen different brain areas in
fifteen suicides (eight of whom were alcoholics) and twenty control
subjects (who had no history of any mental disorder). MAO activity
was found to be reduced in the alcoholic suicides compared to the
controls. No significant difference was observed, however, between
non-alcoholic suicides and controls. Grote, Moses, Robins, Hudgens
and Croninger (197**) could not detect abnormalities in either MAO
or COMT activity in a study in suicide victims. They found no
difference either in dopamine-0-hydroxy1ase activity in these victims
compared with controls. It is interesting to note that although
brain MAO activity in mice can be influenced by certain states of
behaviour (Eleftherion and Boehlke, 19&7) it would seem that in
brains from presumably very disturbed and depressed people, no
change in MAO activity can be convincingly demonstrated.
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(b) "System imbalance" hypotheses
Some workers have suggested that depression occurs when both
catechol aminergic and serotonergic systems exhibit reduced activity.
Mania, on the other hand, has been suggested as occurring when there
is increased activity in catechol aminerg i c systems combined with
subnormal serotonergic function (Kety, 1971; Prange, Wilson, Lynn,
Alltop, Stikeleather and Raleigh, 197*0.
The balance between catecholamine and acetylcholine systems
has also been considered. Janowski, El-Yousef, Davis and Sekerke
(1972) proposed that certain cholinergic and catechol aminergic
systems are reciprocally related and that both could be involved in
affective disorders.
They suggested that if cholinergic activity was relatively
greater than catecholaminergic, motor retardation would occur
concomitantly with a suppressed mood level, and depression would
ensue. On the other hand, if catechol aminergic systems were relatively
more active than cholinergic, motor activity would be stimulated and
mood level would be enhanced, leading eventually to mania. Their
suggestions could explain the action of physostigmine in producing
motor retardation and lowered mood levels in patients with depressive,
manic or mixed schizoaffective syndromes (Janowski, El-Yousef, Davis
and Sekerke, 1973; Janowksi, El-Yousef and Davis, 197*0. Their
proposal can be substantiated by the following five observations
(see their papers for source references). Reserpine, which can be
depressogenic, is a central cholinergic. Tricyclic antidepressants
can act as central anticholinergics. Nerve gases and insecticides
(which are anticholinesterases) produce mood changes and decrease
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motor activity. Methylphenidate, an amphetamine-1ike drug,
increases motor activity and produces a dysphoric or euphoric mood.
These effects are abolished by physostigmine. Patients suffering
from Parkinson's disease improve when given L-dopa and anticholinergic
drugs. It is interesting that these patients often become depressed.
This may occur as a result of their drug therapy, which could be




Another theory of affective illness has centred on the
involvement of disturbances in electrolyte metabolism (Coppen, 1967;
Baer, Platman and Fieve, 1970b). This hypothesis is not so well
defined as the monoamine hypotheses. It suggests that a disturbed
sodium metabolism may be principally responsible fot the disorder,
interest in this proposal exists largely as a result of the use of
lithium in treating affective illness.
(i) Whole body studies
Depressed patients have been found to retain more sodium than
control subjects when 1 salt-1oaded1 (Klein and Nunn, 19^5; Klein, 1950).
These studies also showed water and sodium balance to fluctuate with
mood. A decrease in sodium excretion has been found in normal subjects
during 'depressive phases' and an increase in sodium excretion has
been shown to occur in manic patients (Schottstaedt, Grace and Wolff,
1956; Strom-Olsen and Wei1-Maiherbe, 1958). Not all reports agree with
these findings. Russell (i960) found no change in total sodium balance.
These early studies involved estimating electrolyte concentrations
by flame photometry.
The experimental approach to 'balance studies' became more
sophisticated with the introduction of tracer and isotope dilution
techniques. Using isotopic techniques a decrease in exchangeable
sodium has been found in depression (Gibbons, I960) which did not
change when the patients recovered. 'Exchangeable sodium' is the term
used to describe the mass of sodium in the body which will mix or
'exchange' with a tracer dose of radioactive sodium. An increasing
amount of body sodium exchanges with the isotope over several days;
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measurements are usually taken 2k hours after gi-vrng the i'sotope
('2A-hour exchangeable sodium') or after full equilibration of the
isotope ('total exchangeable sodium'). The lack of effect of recovery-
was confirmed by a later study but little can be deduced from the
results as patients were examined only one day after receiving ECT
(Coppen, Shaw and Mangoni, 1362). A more extensive study which incl¬
uded the use of isotopic bromide to estimate extracellular space,
found recovery to be associated with an increase in total body water
and a decrease in residual sodium (Coppen and Shaw, 1963). Residual
sodium was considered to consist of two components, a component of
slowly exchanging sodium in bone and sodium in the intracellular
compartment of the body. On the basis of these results Coppen and
Shaw (1963) suggested that depression was associated with an
abnormality in sodium transport which resulted in an increase in the
intracellular concentration of sodium, which decreased on recovery.
In agreement with these findings, residual sodium has been found to
be high in both depressed and manic patients (Coppen, Shaw, Malleson
and Costain, 1966; Cox, Pearson and Speight, 1971) with a trend to¬
wards a decrease in residual sodium on recovery (Baer, Durel1 , Bunney,
Levy, Murphy, Greenspan and Cardon, 1970a). Although these studies
provide an approach to the study of electrolyte distribution in vivo,
interpretation of such results is fraught with problems.
Results from studies of exchangeable sodium have provided no
consistent pattern (Jenner, Gjessing, Cox, Davies-Jones, Hull in and
Hanna, 1967; Baer et a 1, 1970a; Cox et a 1, 1971).
Studies of potassium, calcium and magnesium metabolism in
affective illness have not provided any consistent findings (Hullin, 1975).
34
(ii) Blood and cerebrospinal fluid
The transport of isotopic sodium from blood to lumbar
cerebrospinal fluid has been investigated in affective illness.
The results from such studies have been contradictory.
Coppen (i960) investigated the rate of entry of ^Na
into the cerebrospinal fluid of 5 groups of patients. The control
group consisted of twelve patients who were given a spinal
anaesthetic for abdominal operations. The other four groups
consisted of schizophrenics, and depressed patients placed in
one of three categories; depressed and untreated, treated and
recovered, and treated and still depressed. Patients suffering
from a depressive illness were shown to have a rate of entry of
24
Na almost half that of the other patients. Patients who had
recovered had normal rates of entry. Patients who were treated,
but failed to recover, had the same entry rates as the patients
with untreated depression.
Later studies failed to repeat these findings (Potherby,
Ashcroft, Affleck and Forrest, 1963; Carroll, Steven, Pope and
Davies, 1969)- However, Fotherby, Ashcroft, Affleck and Forrest
(1963) did find reduced sodium transport in four patients who
showed severe depression without paranoid symptoms. Baker (l97l)
found sodium entry into cerebrospinal fluid to be reduced in both
manic and depressed patients compared to schizophrenics and other
controls.
Combining results from his own investigations and from
all previous studies on sodium entry into cerebrospinal fluid,
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Carroll (1972) considered, that sodium entry into CSF was
significantly reduced in manic and depressed patients, and that
it increased significantly on recovery.
Fotherhy et al (1963) also obtained results in a group
of patients who were exercised by walking around the wards, with
assistance from nurses if necessary, for the period between
24
injection of the Na and the lumbar puncture. This group
found that exercise significantly increased the transfer rate of
24
ha and suggested that decreased physical activity in depressed




Samples of homogenized fore-brain have been analysed for
water content, total lipids, deoxyribonucleic acid, nitrogen,
sodium, potassium, magnesium and chloride in 19 control subjects
who died from acute physical illness or accident, and in 11
depressed subjects who committed suicide (Shaw, Frizel, Camps
and White, 1969) •
Depressed subjects were observed to have a raised water
content and a reduced sodium concentration (expressed as both
mEq/lOOmg wet weight and mEq/lOOmg water) when compared to
controls.
Shaw et al(1969) draw together their results with those
of other workers who have found normal sodium and potassium
concentrations in CSF in depression and assumed that this means
that concentrations of sodium and potassium in all brain extra¬
cellular spaces are also normal. Following on from this they
suggest that the findings in depressed subjects are due to ab¬
normalities in the relative sizes of intra- and extracellular
compartments and in the composition of the intracellular phase.
They then suggest by a most tenuous argument, that in brains
from depressed subjects, the extracellular space has shrunk, the
potassium concentration in cells is low and the concentration of
sodium in cells is raised.
Other uncertainties exist in this study. Psychiatric
diagnosis was performed after the death of the subjects. At the
end of their study a physician in psychological medicine examined
the coroner's records of the subjects who had died by suicide and
decided if depression had been experienced.
This study cannot add weight to the electrolyte hypothesis.
(iv) Erythrocytes
Red blood cells have been used to study intracellular
electrolyte concentrations and associated transport processes.
Results obtained for sodium have been contradictory. Erythro¬
cyte sodium concentration was reported to be lower in depressed pat¬
ients than in controls (Naylor, McNamee and Moody, 1970a; Mendels,
Frazer and Secunda, 1972b; Glen and Bellinger, 1973) but other
studies have failed to confirm this (Naylor, McNamee and Moody,
1971). Naylor and colleagues found erythrocyte sodium concentration
to decrease as patients recovered from depression (Naylor, McNamee
and Moody, 1971; Naylor, Dick, Dick, Le Poidevin and Whyte, 1973)
but this was not confirmed (Mendels, Frazer, Secunda and Stokes,
1971; Mendels et al, 1972b).
Studies of active sodium transport in the erythrocyte
showed no difference between depressed patients and controls
(Naylor, McNamee and Moody, 1970b). These workers did find
that the passive permeability of the erythrocytes from depressed
patients was lower than that found in four control subjects.
In addition Naylor et al (1970b) found active sodium transport
to increase as the patients recovered from depression.
Other workers have found reduced active sodium transport
in erythrocytes from manic-depressive patients during the
manic phase of the illness (Hokin-Neaverson, Spiegel and Lewis,
197*0 •
As active sodium transport is considered to be brought
+ +
about by the activity of Na + K - ATPase, changes in active
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sodium transport might come about as a result of altered
Na+ + K+ - ATPase activity. Such considerations led to a series
■f "f • # •
of studies of Na + K - ATPase activity in erythrocyte prep¬
arations from depressed patients. The results of such studies
have shown the ATPase activity to increase as patients recovered
from depression (Naylor et al, 1373) as predicted if depression
is associated with reduced sodium transport which increases on
recovery. Naylor and his co-workers (1973) suggested that
• 4* 4*
depression was associated with a decrease in Na + K - ATPase j
*f
activity, a decrease in active sodium transport and an increase
in intracellular sodium concentration. However, they appreciated
that their results did not provide the evidence for such a
hypothesis.
In a later unsuccessful attempt to sort out the controversy
Naylor, Dick, Dick and Moody (197*0 found erythrocyte Na+ + K+ -
ATPase to increase on recovery from depression with no change
in sodium concentration.
j
Other laboratories have made fairly intensive studies
of ATPase activity and electrolyte concentrations in erythrocytes
in affective illness (Hesketh, 1976; Hesketh, Glen and Reading,
1977; Hesketh, Loudon, Reading and Glen, 1978). Untreated
unipolar depressive patients were shown to have a reduced Na+ + K+
ATPase activity compared to control subjects (Hesketh, Glen and
Reading, 1977) which was found to increase on recovery (Hesketh,
Loudon, Reading and Glen, 1978) with a concomitant increase in
the erythrocyte sodium concentration. These workers considered
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that this apparent anomaly (i.e. increased Na + K ATPase
activity and increased sodium concentration on recovery) might
have been caused by lithium (the drug used to treat the patients)
increasing the intracellular sodium concentration by inhibiting
active efflux of sodium.
Erythrocyte membrane Na+ + K+ - and Ca^+ - ATPase activities
have been found to be lower in women suffering from endogenous
depression compared to age-matched controls (Choi, Taylor and
Abrams, 1977). These workers did not measure intra- erythrocyte
electrolyte concentrations. -
More recent work by Frazer , Mendels, Brunswick and Ramsay
22
(1978) investigated the efflux of Na from erythrocytes in vitro,
under experimental conditions which allowed the measurement of efflux
due to active transport, passive diffusion and exchange diffusion.
Their data, from 7 male bipolar depressives, did not provide
22
evidence either for an abnormality in Na transfer across the red ce
membrane or for an effect of the lithium ion on such a transfer. Thi
group did not measure ATPase activity, however.
A recent report (Akagawa, Watanabe and Tsukada, 1980) suggests




The sodium content of saliva has been estimated in patients
suffering from affective disorders (Glen, Ongley and Robinson, 1968).
Using a small-volume microelectrode system measuring sodium
concentration as pNa, patients with manic-depressive or recurrent
depressive illness were compared with healthy individuals-
Salivary flow rate was also monitored. This is an important
measure. The final composition of the saliva depends on the
rate of flow and the rates of selective reahsorption or secretion
of ions across the collecting duct walls of the salivary gland.
A greatly increased sodium concentration (corrected for
flow rate) was found in the patient group examined, some of
whom were depressed and some of whom were manic. Glen et a/(1968)
concluded that this increased sodium concentration came as a
result of diminished sodium transport across the duct walls.
Data presented in a scatter diagram in their paper, suggests
that the manic patients were no different from the depressed
patients.
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(d) Pheny1ethy1 amine hypothesis
In 197^4 Sabelli and Mosnaim advanced the hypothesis that a
deficiency of 2-phenylethylamine (PEA) in the brain could be a
factor in the precipitation of depression.
PEA has been found in human brain (Mosnaim, Inwang &Sabel1i,
197*0 and in human urine (Jepson, Lovenberg and Zaltzman, I960)
in the same concentration as catecholamines and 5~HT. PEA is
produced from phenylalanine by aromatic amino acid decarboxylase,
and is structurally related to amphetamine. Monoamine oxidase-B
has been shown to act on PEA to produce pheny1 aceta1dehyde (Neff
and Yang, 197*+). It is interesting that tricyclic antidepressants
inhibit MAO-B preferentially (Edwards and Burns, 197*+; Roth and
Gillis, 197*+). If it is true that a PEA deficiency is responsible
for depression, the action of tricyclic antidepressants could be
explained by their ability to retard the metabolism of this substance,
thereby causing an increase in its concentration in the brain.
Both tricyclics and monoamine oxidase inhibitors have been shown
to cause an increase in the intracerebral concentration after
administration to rats (Fischer, Spatz, Heller and Reggiani, 1972a;
Fischer, Spatz, Saaverdra, Reggiani, Moir and Heller, 1972b;
Sabelli and Mosnaim, 197*+).
However, although the urinary excretion of PEA has been
observed to be reduced in endogenously depressed patients (Fischer,
Heller and Miro, 1968; Fischer et al, 1972a; Sabelli and Mosnaim,
197*+) it is not known if a similar reduction is present in the brains
of these patients. It must also be remembered that the physiological
role of PEA is unknown, although its structural similarity to amphetamine
might suggest that it could act as an 'endogenous stimulant1.
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3. THE TREATMENT OF AFFECTIVE ILLNESS
(a) Tricyclic antidepressants
Imipramine (a dibenzazepine derivative), amitripty1ine
(a dibenzocycloheptadiene derivative), and other closely related
compounds are the drugs currently most widely used in the treatment
of depression and are often classified as the tricyclic antidepressants
because of their structure.
Although synthesized in the 19^0s, it was not until the late
1950s, that the antidepressant action of imipramine was established
(Kuhn, 1958).
Several chemically related compounds have since been shown to
possess antidepressant activity. In addition to the dibenzazepines ,
imipramine and its secondary-amine congener (and major metabolite)
desipramine, and its 3~chloro analog; clomipramine, there are
amitripty1ine and its N-methylated product nortriptyline (dibenzo-
cycloheptadienes), as well as doxepin (a dibenzoxepine) and
protripty1ine (a dibenzocyc1oheptatriene). There is little evidence
to suggest that there are any important differences in the efficacy
of these compounds (Gilman, Goodman and Gilman, 1980).
If these drugs are given over a period of time to depressed
patients, an elevation of mood occurs. About 2 to 3 weeks must
pass before the therapeutic effects of the drug are evident. The
explanation of the slow onset of effects is a matter of conjecture.
One might expect an effective antidepressant drug to have a
mood-elevating or stimulating effect when given to a normal subject.
This does not in fact occur. Often unpleasant anticholinergic
effects appear and the subject becomes very anxious (Gilman, Goodman
and Gilman, 1980) .
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Tricyclic antidepressants can potentiate the action of biogenic
amines in the CNS by blockade of their major means of physiological
inactivation ; re-uptake at nerve terminals. However,there is
increasing doubt that this is either a necessary or sufficient
explanation of the antidepressant action of these drugs. Similar
doubts concerning the role of altered amine metabolism in the patho-
biochemistry of manic-depressive illness have already been discussed.
This reservation concerning the mode of action of antidepressants
is supported by the observation that several antidepressants are
unable to potentiate the effects of biogenic amines. Moreover,
other agents that are potent inhibitors of the transport of NA,
noteably amphetamine and cocaine, are poor antidepressants, despite
the fact that they have stimulant and even euphoric effects in some
people.
There are additional interactions between antidepressants and
amine neurotransmitters that are less completely understood. These
include apparent a-adrenergic antagonistic actions (U1Pritchard ,
Greenberg, Sheehan and Snyder, 1978), a gradually increasing release
of NA (apparent release in quantum released per nerve impulse) that
may be related to pre-synaptic a-adrenergic autoreceptors (Crews and
Smith, 1978), neurophysiologica11y defined stabilizing effects on
NA-containing cells of the locus coeruleus (Svenssen and Usdin, 1978)
and a gradually evolving increased sensitivity of forebrain neurons
to 5-HT (DeMontigny and Aghajanian, 1978). In addition, desensitiza-
tion of g-adrenergic systems may occur as a sequel to the prolonged
exposure of the synapse to NA, due to the inhibition of uptake,
perhaps as a result of reduction of the number of available receptors
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(see Sulser and Robinson, 1978)• It has yet to be determined
that slowly evolving changes in receptor number or sensitivity,
or the activity of central noradrenergic systems can help to
account for the typically prolonged onset of the clinical effects
of anti-depressant drugs.
It has been suggested (van Praag, 1978) that if disorders
in central monoamine metabolism play a part in the pathogenesis
of depression, then it is to be expected that not all tricyclic
compounds will be equally effective i.e. a depressive patient with
a presumed central 5-HT deficiency would benefit most from a
relatively selective inhibitor of 5-HT uptake, whereas a patient
with a suspected NA deficiency would respond better to a compound
which chiefly inhibits NA uptake. Maas, Dekirmenjian and Jones
(1973b) found that the therapeutic efficacy of imipramine and
desipramine (block uptake of NA more than 5-HT) is higher when
the pre-therapeutic MHPG excretion in urine is low than when the
excretion is normal or increased. The low MHPG excretors responded
to d-amphetamine by an improvement of mood, whereas the normal
MHPG excretors did not. The patients who improved in response
to imipramine, desipramine and d-amphetamine showed a moderate
increase in renal MHPG excretion; this was not observed in patients
who showed no improvement. However, it is unlikely that renal




Several new drugs have recently been developed which have
formulae unrelated to the antidepressant compounds previously
available (Bridges, 1978).
One of these drugs, mianserin, has a structure which is
dramatically different from the conventional antidepressants.
Mianserin, a tetracyclic piperazino-azepine compound, was
first synthesized in 1966 (Van der Burg, Bonta, Delobelle, Ramon
and Vargaftig, 1970). It was hoped that it would show anti~5~HT
and anti-histamine activity, and thus be potentially useful in
treating migraine and asthma. Initial studies, however, gave
disappointing results. It was noted, however, that mianserin seemed
to have a marked mood elevating effect in some subjects (Peet and
Behagel, 1978). The finding that mianserin might be useful in
treating depression was surprising as classical animal pharmacological
tests failed to predict any anti-depressant activity for the compound
(Peet and Behagel, 1978). Mianserin, however, was shown to be
effective in the treatment of depressive illness and anxiety states,
but ineffective in schizophrenia (itil, 1975). It was shown to
possess a similar efficacy to amitripty1ine (Itil, Polvan and Hsu,
1972; Coppen, Gupta, Montgomery, Ghose, Bailey, Burns and de Ridder,
1976; Voge! , Bente, Feder, Helmchen, M'u 1 1 e r-Ober 1 i nghausen , Bohacek,
Mihovilovic, Branli, Fleischhauser and Walcher, 1976; Jaskari, Ahlfors,
Ginman, Lydecken and Tienari, 1977) and imipramine (Murphy, 1975;
Pichot, Dreyfus and Pull, 1978). It has also been demonstrated as
being superior to placebo in the treatment of depressive illness
in general practice (Murphy, Donald and Molla, 1976) and in a double-
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blind trial ir. depressed female in-patients (Smith, Naylor and
Moody, 1978a). However, in one double-blind study of mianserin,
imipramine and placebo in depressed subjects (Perry, Fitzsimmons,
Shapiro and Irwin, 1978), clinical ratings showed that the three
treatment groups improved equivalently during hospitalization.
This may have been due to the fact that all three groups received
intensive psychotherapy during the trial. It should also be noted
that the patients were monitored for only 3 weeks. Drug-placebo
differences might well have emerged if the investigation had
continued for a longer time.
Mianserin appears to have a rather different pharmacological
profile from that of the tricyclic antidepressants. This novel
antidepressant, administered in vivo, has been shown to increase
the turnover of NA in rat brain with no concomitant action on biogenic
amine uptake. This action can be compared with that of the tricyclics
which tend to reduce the turnover of NA and 5-HT and block uptake
(Leonard, 1974; Leonard and Kafoe, 1976; Kafoe, De Ridder and
Leonard, 1976). However, mianserin has been shown to rival both
imipramine and amitriptyline in its ability to block in vitro the
noradrenergic neurone membrane amine pump of rabbit brain stem slices
(Goodlet, Mireylees and Sugrue, 1977)and rat hypothalamic synapto-
somes (Raiteri, Angelini and Bertollini, 1976).
Studies using synaptosomes prepared from rat hypothalamus
have shown the ability of mianserin to inhibit 5~HT uptake in vitro
to be appreciably less than that of the tricyclic antidepressants
(Goodlet et al, 1977). Studies using synaptosomes prepared from rat
striata have revealed that mianserin in vitro can stimulate
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B-5-HT release whereas, imipramine is ineffective (Raiteri et al,
1976). This could be due to either a 'true releasing effect' or
an inhibition of reuptake of the ^H-5~HT spontaneously released.
Raiteri et a/(1976) consider mianserin to have a'true releasing'
action, as imipramine, the strongest inhibitor of 5-HT uptake,
among the drugs they tested, did not stimulate release. However,
the design of their uptake experiments is such that they can only
measure 'net uptake'. They interpret their results as if 'true
uptake' was measured. They also assume that a flow rate of 0.5 ml
per minute, which is used in the perfusion chamber in their release
studies, will prevent re-uptake. They present no evidence for this
assumption. Interpretation of the real differences between the
two drugs is further complicated in their experiments. In the uptake
studies, synaptosomes were exposed to substrate and test drug
simultaneously.
The effect of mianserin on 5ST uptake into platelets has
also been investigated. Mianserin (lOpM) had no effect on 5-HT
uptake into rat platelets (Raiteri et al, 1976) whereas the same
concentration of imipramine produced an uptake inhibition of 85%.
In human platelets, mianserin produced a 50% inhibition of 5-HT
uptake at 170pM, whereas imipramine produced an inhibition of 50%
at 28nM (Bhargava, Matthijsen and Schbnbaum, 1977)» All these
investigations measured net uptake (=amount taken up - amount:
released during experiment).
The pharmacology of other 'novel antidepressants' has been
reviewed by Bridges (1978).
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(c) Monoamine oxidase inhibitors
The MAO inhibitors comprise a rather mixed group of
drugs that have in common the ability to block oxidative
deamination of naturally occurring monoamines. That such comp¬
ounds might be useful in treating depression was revealed when
iproniazid was used in the management of tuberculosis in the
1950s. It was found that iproniazid had mood-elevating effects
in tuberculous patients (.see Oilman, Goodman and Oilman, 1980}.
.following investigations by Crane (1956, 1957) and Loomer et a1
(1957) it was applied in psychiatry for the treatment of depressed
patients., xhis use in psychiatry has now become rather limited
due to often unpredictable interactions with many other
drugs and food-derived- amines, and the tendency to damage the
hepatic parenchyma (Gilman, Goodman and edlman, 1980). Thus, MAO
inhibitors are used when tricyclic antidepressants give an
unsatisfactory result and when ECT is inappropriate or is
re fused.
The capacity of MAO inhibitors to act as antidepressants
has most often been assumed to reflect the increased availability
of one or more monoamines in the CNS, although this assumption
has been difficult to prove. One problem with this theory is
that the acute biochemical and pharmacological actions of MAO
inhibitors precede the antidepressant effect by as long as two
or more weeks. Keasons for this delay remain unexplained. The
situation with regard to inhibition of MAO may be even more
complicated because it appears that MAO exists in at least two
forms with dissimilar substrate preferences and differential
sensitivity to selective inhibitors (see Jain, 1976).
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(d) Tryptophan
The enzyme tryptophan hydroxylase is not normally
saturated with substrate, and administration of tryptophan to
test animals results in increased 5-HT synthesis in the CMS
(Fernstrom and Wurtman, 1971). If a 5-HT deficiency is present
in depression, it is rational to suppose that administration
of tryptophan may correct the proposed deficiency (Van Praag,
1978).
Tryptophan has been considered to be as effective an
antidepressant as ECT and imipramine (Coppen et al , 1967, 1972a;
Jensen, Fruensgaard, Ahlfors, Pihkanen, Tuomikoski, Ose, Dencker,
Lindberg and Nagy, 1975). However, several other groups were
unable to substantiate such a claim (Carroll, Mowbray and Davies,
1970; Bunney, Brodie, Murphy and Goodwin, 1971; Dunner and Good¬
win, 1972; Dunner and Fieve, 1975; Mendels, Stinnet, Burns and
Frazer, 1975).
L-tryptophan has also been administered to manic patients
(Prange, Wilson, Lynn, Alltop, Stikeleather and Raleigh, 1974).
Surprisingly enough, it was found to be more effective than
chlorpromazine. This observation could be used to suggest that
a 5-HT deficiency existed in mania. nowever, the effect could
just as well be explained by the sedative-hypnotic action of the
drug (liilman, Goodman and oilman, 1980).
Administration of tryptophan is possibly not a very
efficient method of increasing the central 5-hT concentration.
jno more than 37o of the tryptophan in the diet is converted to
5-HT, and only a small fraction of this becomes involved in 5-HT
production in the CHS. Most of the tryptophan is acted on by
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tryptophan pyrrolase in the liver. Some tryptophan is used
in protein synthesis and a small quantity is converted to
tryptamine. However, in humans, the probenecid-induced
accumulation of 5-hydroxyindoleacetic acid (the metabolite of
5-HT) in the lumbar CSF shows a marked increase in response to
tryptophan administration (Dunner and Goodwin, 1972). This
indicates that 5-HT synthesis can be stimulated in humans.
However, whether this reflects synthesis in the brain or in the
spinal cord is a matter for some conjecture (see Van Praag, 1978).
It is also necessary to consider the possible compartmentation of
5-HT in the brain (see review by Green and Grahame-Gmith, 1975).
These workers consider it difficult to monitor the functional state
of 5-HT dependent neurons, because two species of 5-hydroxyindole¬
acetic acid may exist, one deriving from released 5-HT and the
other from non-released 5-HT oxidatively deaminated in the
neuron. One example that Green and Grahame-Smith (1975) site
to demonstrate this possible compartmentation is that of
behavioral changes produced in rats by administration of either
tryptophan alone (no effect), or when combined with a MAO
inhibitor (hyperactivity). They suggest that with tryptophan
loading alone the increased 5-HT synthesis does not exert
functional activity because of the binding capacity of intra-
neuronal vesicles and the activity of intraneuronal MAO. When
this enzyme is inhibited, although 5-HT is synthesized at an
equivalent rate, it will presumably saturate storage sites and
spill over into the synaptic cleft to exert a post-synaptic
action. go, it is possible that when tryptophan is administered
to humans, and an increase in 5-hydroxyindoleacetic acid is




The earliest reference to the use of lithium is probably
that by Soranus of Ephesus in the 5th century AD, who advocated
alkaline mineral waters for the treatment of manic excitement
(Johnson and Cade, 1975)- Several spa waters have subsequently been
found to contain high levels of lithium. The first rational
medicinal use of lithium occurred in the 19th century. Lithium
salts were administered to gout-sufferers on account of the high
solubility of lithium urate. In retrospect it has been pointed out
that in certain cases of gout-associated depression, lithium may
have had some beneficial effect on the mental symptoms (Schou, 1957).
Lithium bromide was used as an hypnotic and anti-epi1eptic drug
briefly in the 1920s. In 19^+9 Cade discovered lithium salts had
a tranqui1izing effect when given to guinea pigs and were useful in
the treatment of mania (Cade, 19^9). Cade's original observation
was followed by a series of clinical trials using lithium carbonate
for the treatment of mania and depression. It is now accepted
that lithium carbonate is an effective treatment for mania (Coppen,
1973; Schou, 1973; Mendels, 1975; Peet, 1975) and certain cases
of depression (Goodwin, Murphy, Dunner and Bunney, 1972; Mendels,
Secunda and Dyson, 1972c). Manic depressive disturbances are
recurrent in that untreated episodes will remit spontaneously and
then after a period of time the patient will relapse (Coppen, 1973)•
There is evidence that the interval between episodes decreases as
the patient suffers successive episodes. Lithium appears to reduce
the severity of an episode, the frequency of episodes or abolishes
altogether future attacks (Coppen, 1973; Schou, 1973; Schou and
Thomsen, 1975) .
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The general biology and pharmacology of the lithium ion
have been reviewed in detail by Schou (1957)• Despite extensive
research it is not known how lithium alters the mood of patients
suffering from affective disorders.
The possibilities being pursued include the action of lithium
on the sodium pump, the cellular sodium and potassium concentrations
and the membrane potential (Ploeger, 1974; Boardman, Hume, Lamb and
Poison, 1975; Hesketh et a!, 1978). A most important characteristic
of the lithium ion is that it has a relatively small gradient .of
<!
distribution across biological membranes, unlike sodium and potassium;
while it can replace sodium in supporting a single action potential
in a nerve cell, it is not an adequate substrate for the sodium pump
and it cannot therefore, maintain membrane potentials.
Other investigations have concentrated on the interactions
of lithium with magnesium or calcium in modulating allosteric protein
function (Birch, 1973) •
Further work has dealt with the influence of lithium on
J
synaptic transmission and the metabolism of catecholamines and re¬
lated neurotransmitters. In animal brain tissue, lithium ion
concentrations of 1 to 10 mEq per litre inhibit the depolarization-
provoked and calcium dependent release of HA and DA, but not 5-HT
from nerve terminals (Baldessarini and Lipinski, 1975)® It may also
slightly alter the re-uptake and presynaptic storage of catecholamines
in directions consistent with increased inactivation of the amines.
Although this could explain the action of lithium in
restraining mania, it is difficult; in terms of the catecholaminergic
hypothesis, to thus explain the efficacy of lithium in treating
depression. Chronic lithium treatment has been found to decrease
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5-HT and GABA binding in rat brain with no change in ^-adrenergic
or muscarinic binding (Maggi and Enna, 1980). Hbwever, an earlier
study showed that lithium reduced ^-adrenergic receptor binding in
rat brain too (Treiser and Kellar, 1979)*
Therapeutic concentrations of lithium have almost no
discernable psychotropic effects in normal man (Schou, 1957)* One
must question the relevance of measuring lithium actions on normal
animal brains in the hope of finding out how lithium acts in
affective illness.
Studies investigating metabolic changes in humans after
lithium administration have revealed no consistent trends which




Antipsychotic drugs have been used with some success in
mania and depression. This group of drugs, effective in the treat¬
ment of psychoses, include compounds such as the phenothiazines, the
structurally similar thioxanthenes, and the dibenzidiazepines and
dibenzoxazepines, butyrophenones (phenylbutylpiperidines) and the
newer diphenylbutylpiperidines, indolones and other heterocyclic
compounds, and the rauwolfia alkaloids and related synthetic hetero¬
cyclic amine-depleting agents (Gilman, Goodman and Gilman, 1980).
Haloperidol (a butyrophenone) and chiorpromazine (a represent¬
ative of the phenothiazine-thioxanthene class) are both effective in
the treatment of mania, and are often administered concomitantly with
lithium (see Gilman, Goodman and Gilman, 1980). In fact, it is often
impractical to attempt to treat a manic patient with lithium alone
during the first week of illness, when the antipsychotic drugs are
usually required. To date there has been no controlled study of the
possible long-term prophylactic effects of antipsychotic drugs in
Effective illness. The use of phenothiazines for the treatment of
depression is more controversial. Some studies have demonstrated the
effectiveness of antipsychotic drugs in depressed patients who show
marked agitation or psychotic delusions (Overall, Hollister, Meyer,
Kimball and Shelton, 1964).
The effects of antipsychotic drugs are apparent at all levels
in the nervous system. Theories based on their ability to antagonize
the actions of DA as a neurotransmitter in the basal ganglia and
limbic portions of the forebrain have become most prominent and are




ECT is a treatment which involves the production of a
controlled convulsion. In comparison to other therapies, which
require nothing more than the swallowing of a few pills each day,
ECT is a more complicated procedure. Atropine is administered to
the patient, as a pre-anaesthetic medication, before undergoing ECT,
to dry up salivary and bronchial secretions and reduce the likelihood
of anaesthetic or stress-induced heart irregularities. The patient
is then given an intravenous injection of a short-acting anaesthetic,
usually thiopental, and through the same needle, a muscle relaxant,
usually succiny1choline. Within fifteen to twenty seconds of the
injection, slight rippling of the muscles under the skin can be seen
which serves to indicate that muscle paralysis is imminent. At this
point the anaesthetist takes over respiration of the patient using
a face mask and a pressure bag. When the muscles stop twitching,
the shock can be administered. Two electrodes, dampened with a
bicarbonate solution to prevent skin burns at their points of contact,
are applied to the anterior temporal areas of the scalp (at each
side of the head, above and in front of each ear). A gag is then
put into the patients mouth to prevent the tongue being bitten.
An electric current, usually eightyvolts with a duration of 0.1-0.3
seconds, is given which results in a "modified" convulsion, as shown
by the mild tonic-clonic movements in the facial muscles and in the
muscles of the hands and feet. After the convulsion, the gag is
removed, the patient is turned onto one side, and the anaesthetist
maintains an oxygen supply until the muscle relaxant wears off
(this occurs within several minutes of it having been given) and
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the patient starts to breathe on his own. Within five to twenty
minutes the patient gradually returns to full consciousness although
still may feel sleepy and indeed may sleep for up to an hour after
treatment. The usual course of treatment consists of between five
to twelve treatments, given at a rate of two to three per week
(Clare, 1976).
The use of electricity in treating depression was described
as early as 1792 by John Birch who was a surgeon at St. Thomas's
Hospital (Clare, 1976). Birch treated a porter who had been
suffering from a melancholic state for almost a year. The treatment
Birch gave involved six small shocks which were passed through the
brain in different directions on each of three successive days,
following which the patient regained his spirits, went back to work
and remained perfectly well for seven years.
In more recent times, Cerletti, in 1938, was one of the first
to administer electroconvulsive shock to a mentally deranged person;
in the form of an incoherent "gibbering catatonic schizophrenic"
(impastato, 1960). Such treatment had been considered acceptable,
because of a commonly held belief, at that time, that as schizophrenia
and epilepsy were mutually exclusive diseases, the production of a
seizure in a schizophrenic might well relieve the disturbed mental
state (Meduna, 1938). Such a notion has not stood the test of time.
During the twenty years following that occasion, electro¬
convulsive therapy gradually became established as the major physical
treatment in psychiatric practice. Attention was paid to what
constituted the appropriate number and frequency of induced
convulsions, the optimal strength and type of current, the most
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suitable part of the head to which apply the electrodes, and the
psychiatric conditions for which it seemed the most appropriate.
The use of a group of drugs capable of briefly paralysing muscles
(curare, gallamine, succinylcholine)and of short-acting anaesthetic
agents (thiopental, methohexital) meant that ECT could be administered
with reasonable safety, few side effects, and a minimum of dis¬
comfort. The muscle relaxant ensured that a fit could be induced
without a concomitant and massive spasm of the major muscles
while the anaesthetic relieved the patient's understandable anxiety
during the treatment and much of his post-seizure anxiety as well.
Many physiological and biochemical changes have been recorded
in animals after electroconvulsive shock, and in patients suffering
from affective illness after ECT.
Grahame-Smith, Green and Costain (1978). have examined the
effects of electroconvulsive shock on the behavioural responses of
rats to pharmacological stimuli. Results obtained using MAOIs
and tryptophan (effects of which involve pre-synaptic mechanisms
of synthesis, compartmentation, release and inactivation by, re¬
uptake of 5-HT) and 5-nie'fchoxy-ir,N-dimethyltryptamine (a putative
5-HT receptor agonist which would produce post-synaptic receptor
stimulation) have prompted them to suggest that electroconvulsive
shock enhances post-synaptic responses mediated by 5-HT. This
could be used as evidence for the serotonergic hypothesis, however
using other test systems, electroconvulsive shock enhanced DA and
possibly NA post-synaptic responses. Grahame-Smith eta/ (1978)
appreciate, however, that these effects are difficult to relate
to the therapeutic effect of ECT in depression. In their
experimental set-up, electroconvulsive shock is applied to a pres-
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umably normal rat brain, the function of which is being disturbed.
In man, ECT is applied to a presumably abnormal brain whose function
is presumably being returned to normal. A suitable extension
of these studies would be an examination of the effects of electro¬
convulsive shock in an animal model of depression.
Successful ECT has been found to increase C3E HVA and 5-HIAA
concentrations in depressed patients compared to schizophrenic
patients (Jori, Dolfini, Casati and Argenta, 1975)• However,
other workers (Abrams, Essman, Taylor and Fink, 1976) found nq
change in CSF levels of 5-HIAA, tryptophan and HVA after ECT, '
although all patients investigated showed marked clinical improvement.
Reduced serum magnesium levels in depression have been found
to increase to normal values after treatment with ECT(Carney, Sheffield
and Sebastian, 1973). However, these workers considered that their
results might well have been due to seasonal variation of serum
magnesium combined with an unequal distribution of cases throughout
the year.
j
A transient reduction in serum total calcium has been found
to occur during a successful course of ECT (Carman, Post, Goodwin
and Bunney, 1977)- This group did not investigate control subjects.
However, a comparison of their baseline and post-ECT values with
values reported by other workers (Frizel, Coppen and Marks, 1969)
suggests that their calcium levels are in the normal range.
Erythrocyte membrane Na+ + K+ - and Ca^+ - ATPase activities
were investigated by Choi eta! (1977) in eleven women treated with
ECT for endogenous depression and eleven age-matched control subjects.
Pretreatment ATPase levels in depressives were significantly lower
than in controls, and increased to control levels after a course
of ECT.
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(h) "Comb ination" therapy
It might seem rational to combine different antidepressant
treatments (i.e. those which would be expected to produce an
increase in catecholamine concentration at receptor sites by
different mechanisms) if the catecholamine hypothesis were correct,
in the hope of producing a more definite anti-depressant response.
Tryptophan (l500mg) and a MAO inhibitor (iproniazid) were
administered to twenty endogenously depressed patients. Ten of
these patients received the two drugs simultaneously. The re¬
mainder received tryptophan after a few weeks of unsuccessful
MAO inhibitor treatment. Wo potentiation in response to the MAO
inhibitor was observed (van Praag, 1978)* Interpretation of
these results is difficult. It is probable that only a small
fraction of the tryptophan administered reached the brain.
When larger quantities of tryptophan were administered
(214/kg body weight), depressive patients showed a better response
to a combination of MAO inhibitor (tranylcypromine) with
tryptophan than to a combination of a MAO inhibitor with placebo
(Coppen, 1967). It is possible that the type of MAO inhibitor
used affects any possible potentiation.
Other drug combinations have been reviewed (see van Praag,
1978). Many combinations (i.e. tricyclic antidepressants + MAO
inhibitors and MAO inhibitors + reserpine) although capabable of
testing the monoamine theory of affective disorders, would never




The previous pages have described hypotheses which have been
proposed to explain the nature of affective illness, and the experi¬
mental data which has been used to test these proposals. Unfortunately
the survey is by no means complete. The work discussed reflects the
author's interests, as is the case in most reviews of this nature.
However, the references quoted cover most aspects of biological
research into affective illness.
It is apparent that much uncertainty exists. This uncertainty
may in part be due to differences in psychiatric assessment and
inter-1aboratory variation. It was hoped that by conducting a large
scale study in one establishment it would be possible to reduce this
variation and thus make more definite statements concerning the
nature of the disorder. It was also hoped that additional information
would be gained by using a 'finer' psychiatric classification than
most studies have used in the past, i.e. one according to the course
of the illness (unipolar and bipolar divisions).
It was decided to concentrate on one small aspect of the
affective illness controversy and examine blood platelets and
erythrocytes from suitable patients. It was outwith the scope of
this thesis to test whether changes monitored in blood platelets
and erythrocytes reflected similar changes in the CNS of patients
with affective illness, where it is presumed the 'precipitating lesion'
resides. However, it was hoped that any peripheral changes observed
in these patients might be correlated to their changing mood states.
An examination of the effects of various therapies (Le lithium,
mianserin, amitripty1ine and ECT) on these measures was also under-
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taken. It would be of great value if there was some means of
deciding on the most suitable therapy for a particular subject, by
perhaps identifying various subgroups of patients, using some bio¬
chemical measure. While patients can be differentiated on the basis
of their response to specific therapies, this has the disadvantage
that it can only be done retrospectively. It was hoped that by
examining blood platelets and erythrocytes from patients when ill
and during the course of their recovery,it would be possible to
identify such subgroups.
The investigation to be described was designed to bridge the
gap between electrolyte, catecholamine and indoleamine studies.
Platelet and erythrocyte ATPase activity, platelet adenyl cyclase
activity, platelet 5"HT uptake and whole blood 5~HT levels were
selected as suitable measures for examination.
It was hoped to test a premise basic to the electrolyte
hypothesis. This premise states that a decrease in Na++ K+-ATPase
activity, which has been shown to occur in erythrocytes in affective
illness, is present in all cells. The activity of Na++ K+-ATPase
in platelets was therefore examined.
Mianserin, a drug recently introduced for the treatment of
affective disorders, has been classified as a "novel antidepressant".
It was hoped that by investigating and comparing it with an archetypal
tricyclic antidepressant, i.e ami tr i ptyl i ne, an estimation could be
made of its supposed atypical clinical pharmacology.
It was hoped to obtain some measure of the natural variation
which can occur in the various blood platelet and erythrocyte parameters
examined. To this end blood samples from a female control subject
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1 . CLINICAL DATA
All patients were referred from within the Royal Edinburgh
Hospital which serves a population of A70,000.
(a) Platelet study
Clinicians withheld active treatment from acutely ill patients
until venesection took place, using only a barbiturate for sedation
if necessary. Specimens could be processed on any day of the week
to avoid unacceptable delay before any patient received specific
therapy. Patients who had ingested a tricyclic antidepressant,
neuroleptic, or benzodiazepine within two weeks of venesection were
excluded. Patients had been diagnosed as suffering from an affective
disorder by the referring clinician. They were assessed also by a
research psychiatrist using the glossary developed for the Wing Present
State examination (Wing, Cooper and Sartorius, 197*0 on the basis of
the criteria described by Feighner, Robins, Guze, Woodruff, Winokur
and Munoz (1972) for affective disorders. A previous episode of mania
or hypomania requiring neuroleptic treatment defined a patient as
bipolar. Patients receiving lithium carbonate (500 mg - 2000 mg per
day) were assessed as to whether they were ill or recovered. A group
of normal subjects who received lithium carbonate (500 mg-1500 mg
per day) were not psychologically rated. Hospital and MRC Unit staff
were used as a source of control material, and as far as could be
ascertained they had no family history of psychiatric disorder nor
were they exposed to prescribed drugs.
(b) Comparative study of platelets and erythrocytes
Clinicians withheld active treatment under the same conditions
as in (a). Patients were selected for this study if they were uni-
66
polar depressed or bipolar manic, and had not ingested a tricyclic
antidepressant, neuroleptic, or benzodiazepine within two weeks of
venesection. They had been diagnosed by a research psychiatrist as
in (a). Students and staff of the MRC Unit and the Department of
Pharmacology, Edinburgh University, acted as control subjects. They
had no family history of psychiatric disorder nor were they exposed
to prescribed drugs.
(c) Mianserin and amitripty1ine study
Patients were selected for this study if they had been diagnosed
as suffering from unipolar depression by the referring clinician, as
in (a), and were to be treated with either mianserin or amitriptyline,
and had not ingested a tricyclic antidepressant, neuroleptic or
benzodiazepine within two weeks of being admitted to the study. During
the investigation patients received either 60-100 mg mianserin
hydrochloride or 100-150 mg amitriptyline hydrochloride per day.
Patients receiving mianserin or amitripty1ine were assessed as to
whether they were ill or recovered. Controls were obtained from the
same source as in (b) .
(d) Electroconvulsive therapy (ECT) study
Subjects were recruited to the study from patients referred for
ECT during a lA-week period in 1978. Study criteria were willingness
to take part, depressive illness with no symptoms suggestive of
schizophrenia and no ECT in the previous year. All subjects
investigated were unipolar depressed patients. Concommitant anti¬
depressant therapy was used for nine patients and this is detailed
in the Results Section. ECT was recommended because of poor response
to antidepressant drugs, need for rapid recovery or previous good
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response to ECT. Changes in clinical state were recorded using the
Hamilton Rating Scale (Hamilton, I960) and reports from each patient's
supervising clinician.
Two control groups were used in this study. To examine the
effect of anaesthesia without ECT, patients undergoing the relatively
atraumatic procedure of diagnostic cystoscopy were selected for
investigation. Hospital staff provided another source of control
samples (no anaesthetic, no ECT) and as far as could be ascertained
they had no family history of psychiatric disorder and had been drug
free for at least some weeks prior to sampling.
(e) Arrhenius plots and ouabain binding in erythrocytes
Unipolar depressed patients were selected for this study, as
in (a), and control subjects as in (b).
(f) Other studies
In all other experiments described in this thesis blood samples
from control subjects were obtained from students and staff of the
HRC Unit and the Department of Pharmacology, Edinburgh University.
None of these subjects were taking prescribed drugs at the time of
venesection and none had a family history of psychiatric illness.
2. BLOOD SAMPLING
(a) Platelet study
Patients and controls took only a light breakfast on the morning
of sampling but otherwise there was no dietary control. Those receiving
lithium took no medication on the morning of sampling. Blood samples
were taken from patients receiving lithium therapy, before, 5 days
after, 3 weeks after and 3 months after they had started their courses
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of medication. Control subjects receiving lithium gave blood before,
5 days after and 3 weeks after starting drug administration.
After applying a venous tourniquet, cubital venous blood was
wi th drawn th rough a B-D Yale 20 - g 1-j microlance in to a B-D plasti-
pak sterile polypropylene syringe. Nine millilitre units of blood
were immediately transferred to the bottom of an all-polythene 10-ml
stoppered tube that contained as anticoagulant 1 ml of 3.8% sodium
citrate. The tubes were gently inverted thrice to ensure mixing of
the sodium citrate with the blood. The contents of the tubes were
then used to prepare platelet rich plasma and platelet membranes.
(b) Comparative study of platelets and erythrocytes
Blood sampling was carried out as in (a). Ten millilitre units
of blood were also transferred to the bottom of 10-ml stoppered
sodium heparin blood tubes. The tubes were gently inverted thrice to
ensure mixing of the blood with the heparin coating. This blood was
used in the preparation of erythrocyte membranes.
(c) Mianserin and amitripty1ine study
Blood samples were taken from patients, before, 1 week, 2 weeks
and 3 weeks after they had started their courses of medication.
Patients receiving mianserin or amitriptyline took no medication on
the morning of sampling. Blood sampling was carried out as in (b) ,
the blood being used to prepare platelet rich plasma and platelet
membranes, and erythrocyte membranes. Two-and-a-half millilitre
units of blood were also transferred into al1-polythene tubes
containing 0.1 ml (100 i.u.) heparin in deionized water. The tube was
gently agitated to ensure mixing of the blood with the heparin. This
blood was used for the estimation of whole blood 5~ hydroxytryptamine.
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(d) Electroconvulsive therapy (ECT) study
Blood samples were obtained immediately before and ten minutes
after the first, second and last ECT. Patients received either
unilateral or bilateral ECT under atropine, sodium pentothal and
succinylcholine, with ventilation artificially assisted by the
anaesthetist. A final sample was taken from fasting subjects one
morning twelve weeks after their last ECT. Though 18 patients started
in the study, complete samples were obtained from only b subjects.
This deficiency arose because patients either discontinued ECT (5
subjects), or withdrew their consent (2 subjects), or received a
second course of ECT (2 subjects), lithium (1 subject) or died (1
subject) within the twelve-week follow-up period or from whom samples
could not be processed on one day because of insuffient material
(3 subjects). Consequently, the results refer to 12 patients who were
placed in either or both of two groups. Group I comprised nine
subjects (A, C, D, H, L, M, N, P, Q) from whom samples were obtained
before and after their first, second and last ECT. Group II contained
seven subjects (F, H, J, K, N, P, Q) who provided samples before and
after their first ECT and at a follow-up twelve weeks later. Details
of the patients are given in the Results Section.
Blood samples from the patients undergoing diagnostic cystoscopy
were obtained before and about 15 minutes after the investigation, at
which time the patients had started to recover from the anaesthetic.
The anaesthetic technique used in cystoscopy was different from that
used in ECT. Anaesthesia was induced with sodium pentothal and then
maintained with N2O2/O2 and halothane. No muscle relaxant was
administe red .
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Blood samples were drawn through a Venflow catheter for the
patients undergoing ECT or cystoscopy. Routine venepuncture was used
for the other subjects and patients at follow-up. Blood samples were
collected in stoppered sodium heparin tubes as in (b). The blood
samples were used to prepare erythrocyte membranes.
(e) Arrhenius plots and ouabain binding in erythrocytes
Routine venepuncture was used to obtain blood samples from the
subjects in this study. Blood samples were collected in stoppered
sodium heparin tubes as in (b). This blood was used to prepare
erythrocyte membranes.
(f) Other studies
In all other studies routine venepuncture was used to obtain
blood samples from control subjects.
In most experiments, when platelet rich plasma or platelet
membranes were to be prepared, blood was anti coagul ated with sodium
citrate. In one study, however, platelet membranes were prepared
from subjects' blood samples which were divided and placed into both
'sodium citrate tubes' and heparin tubes.
Erythrocyte membranes were usually prepared from blood anti-
coagulated with heparin. In one experiment erythrocyte membranes
were prepared from sodium citrated blood.
3. PREPARATION OF PLATELET RICH PLASMA
A paper tissue was used to clean the top inner surface of the
10 - ml tubes containing blood. This was to prevent erythrocyte
contamination of the plasma under preparation. The tubes were
centrifuged using a low speed head in a Mistral 2L centrifuge, for
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30 minutes at 800 rpm (125 g) at room temperature (Lingjaerde, 1971)
to produce platelet rich plasma. This was used to measure 5~HT
uptake into platelets.
A. PREPARATION OF PLATELET MEMBRANES
For any one sample, A - ml platelet rich plasma (PRP) were
dispensed into a 10-ml all-polythene tube using an Eppendorf pipette
with a polypropylene pipette tip. To this was added A - ml of 0.38%
sodium citrate. The tube was gently inverted three times. Sodium
citrate was added merely to decrease the viscosity of the plasma, thus
enabling the platelets to be spun down readily. The tubes were
centrifuged using a low-speed head in a MSE Mistral 2L centrifuge at
2000 g for 30 minutes at A°C. This produced a platelet pellet at the
bottom of the tube. The supernatant (platelet - poor plasma) was
decanted off and the tubes inverted and allowed to drain for 10 minutes
onto a piece of tissue paper. At the end of this time a piece of
tissue paper was used to wipe the inner surface of the tube to prevent
plasma contamination. Eight mi 11ilit re s of 0.38% sodium citrate were
added to the tubes containing the pellets and the tubes were then
whirlymixed for approximately 15 seconds. The tubes were centrifuged
as before at 2000 g for 30 minutes at A°C. The supernatant was
decanted off and the tube was allowed to drain as described above.
100 yl 0.1% Triton X100 was added to this platelet rich pellet and
a smooth edged glass rod was used to mix. Two mi 11ilit res of distilled
water were added and the mixture was then whirlymixed for approximately
30 seconds. The tubes were then placed on their sides at -10°C for
approximately 30 minutes, or until the mixture had frozen solid. The
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tubes were then removed and allowed to thaw at room temperature.
They were whirlymixed for 30 seconds and returned to the deep freeze
for a further 30 minutes. When they had been removed from the deep
freeze and allowed to thaw in a similar manner as before, an aliquot
was removed for an assay of adenyl cyclase. The remaining sample was
diluted approximately five times. This solution was used for
measuring ATPase specific activities and protein content.
5. PREPARATION OF ERYTHROCYTE MEMBRANES
Erythrocyte membranes were prepared using the method described
by Hesketh (1976) which is a modified version of the method of Dick,
Dick and Tosteson (1969). The blood tubes were centrifuged for b
minutes at 1000 g on a MSE Mistral 2L centrifuge at room temperature
(20°C). The plasma produced was sucked off using an aspirator. The
remaining erythrocytes were washed three times in ice-cold isotonic
sodium chloride (156 mM) buffered with 5 mM Tris-HCl, pH l.b.
Sufficient NaCl solution was added to give the original volume, ie
10-ml. Washing was by repeated cent r i f ugat i on at 1000 g for b minutes
at room temperature, after mixing. After the third wash the supernatant
and the buffy white coat was removed using an aspirator. The washed
erythrocytes were resuspended in the cell wash solution to give an
approximately b0% haematocrit. 3b - ml 10 mM Tris-HCl buffer, pH 7-^,
was added to 6 - ml cell suspension (to achieve haemolysis) in a MSE
70 - ml polycarbonate centrifuge tube. Half the volume of buffer was
added, the tube opening covered with parafilm, whirlymixed, and the
remaining 17-ml buffer added, and the tube again covered with para-
film and whirlymixed. The haemolysate was left at 0 - b°C for 10 to
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15 minutes (the tubes were placed in a dish containing ice, and then
the dish was placed in a 'cold room1). The outside of the tubes were
wiped dry and placed in the 3 x 70 - ml swing-out rotor of the MSE
Superspeed 65 centrifuge and centrifuged at 15,000 rpm (28,000 g) for
1£ hours at 10°C. The resultant supernatant was removed with an
aspirator, leaving a red membrane pellet at the base of the tube. The
membranes were washed three times by resuspension in 10 mM Tris-HCl
buffer to AO - ml, whirlymixed and centrifuged each time at 28,000 g
for 1 hour at 10°C. At the end of the final centrifugation a layer
of fluffy white or faintly pinkish membranes was present at the bottom
of the tube, together with a pellet of cell debris and haemoglobin.
The membranes were decanted into a fresh tube for storage, leaving the
pellet in the centrifuge tube. This was washed once in 10 mM Tris-HCl
(using approximately 3~ml buffer) and the wash was added to the
membranes in the fresh tube. The membranes were whirlymixed and left
overnight in a 'cold room' before assaying for ATPase activity.
6. PLATELET COUNTING
Platelets were counted in a sodium citrate diluted sample of
platelet rich plasma (20 yl PRP added to 1 - ml 0.38% sodium citrate)
using a Hawksley standard counting chamber in a phase contrast micro¬
scope, at a magnification of A00 times.
7. ESTIMATION OF ATPase SPECIFIC ACTIVITY
(a) Incubation conditions
Na+ + K+ - ATPase, Mg2+- ATPase, Ca2++ Mg2+- ATPase and Ca2+-
ATPase specific activities were measured in the platelet and erythrocyte
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membrane preparations according to the method used by Hesketh (1976).
The amount of inorganic phosphate liberated during incubation of the
membranes with disodium ATP was taken as a measure of ATPase activity.
Enzyme activity was measured under three different sets of ionic
conditions; in the presence of magnesium as the sole cation, in the
presence of calcium and magnesium and in the presence of sodium,
potassium and magnesium. The activity in the presence of magnesium
alone was defined as the Mg2+~dependant ATPase activity (Mg2+- ATPase
activity), which was insensitive to the presence of ouabain. The
difference between activity in the presence of sodium, potassium and
magnesium (defined as total ATPase activity) and activity in the
presence of magnesium alone was defined as the Na+ + K+ - stimulated
Mg2+- dependant ATPase activity (Na+ + K+r ATPase activity) and this
activity could be completely abolished by ouabain. The activity in
the presence of both calcium and magnesium was defined as the Ca2+ +
Mg2+ - dependant ATPase activity (Ca2++ Mg2+- ATPase activity) and
the difference between that and the Mg2+- dependant activity was
defined as the Ca2+- stimulated, Mg2+- dependant activity (Ca2+-
ATPase activity). During the routine estimation of ATPases all
activities were defined in terms of cation activation without the use
of ouabain. The incubation conditions for the reactions are shown in
Tab le 11.1. The tota1 vo1ume of the incubation mediurn was 2.5 ~ ml.
Water was used to make up the volume of the Mg2+-and the Ca2++ Mg2+-
ATPase incubation media. The tubes containing the incubation media,
including the platelet or erythrocyte membrane sample to be assayed,
but excluding ATP, were pre-incubated at 37°C for 10 minutes. The
reaction was started by the addition of ATP and allowed to continue
for 30 minutes. Reaction and enzyme blanks were processed with all
75
assays, water being used instead of the membrane preparation and ATP.
All estimations were carried out in triplicate.
In some experiments the in vitro action of various drugs on
ATPase specific activities in platelet and erythrocyte membranes was
examined. The experimental conditions were as described above, with
the exception that the membrane preparations were pre-incubated in
incubation media which contained the drug to be tested.
TABLE 11.1: Incubation conditions for assay of ATPase
activities in platelet and erythrocyte membranes.
The table shows final concentrations (mM) of






Ca2+ + Mg2+ -
ATPase
activity
Disodiurn ATP 3 3 3
MgC 12 6 6 6
KC1 5 - -
NaCl 100 - -
CaCl2 - - 0.15
Tris - HC1 buffer,





In several experiments, using platelet membranes the concentra¬
tions of MgCl2, NaCl, KC1 and CaCl2 in the incubation media were
altered to see if a change in measured specific ATPase activity
resulted. Mg2+-ATPase activity was measured in the presence of
between 1 mM to 30 mM MgCl2, all other constituent concentrations
remaining as before. Total ATPase activity (from which Na++ K+-
ATPase activity could be calculated) was measured in the absence or
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presence of NaCl (50 mM, 100 mM or 150 mM) and in the absence or
presence of KC1 (2.5 mM, 5 mM or 7-5 mM), in various combinations as
shown in the Results Section, all other constituent concentrations
remaining as before. Ca2++ Mg2+- ATPase activity was measured in
the presence of between 0.05 mM to 100 mM CaCl2, all other constituent
concentrations remaining the same. No attempt was made to correct
for the changing osmolarities of the incubation media.
(b) Est imation of inorganic phosphate
Inorganic phosphate was estimated by the method of Stoward as
described by Naylor, Dick, Dick, Le Poidevin and Whyte (1973). The
ATPase reaction was stopped by placing the tubes in ice and leaving
them there for 10 minutes. Each tube was subsequently reacted in turn.
0.5~ml perchloric aci d - tungstos i 1 i ci c acid reagent (A8.5 to 50 - ml
perchloric acid; Analar 12%, was added to 300 - ml distilled water,
AO g dodecatungstosi1icic acid was added to this and allowed to
dissolve and the solution was made up to 500 -ml) and then 1.5-ml
molybdate reagent (1A.5 g sodium molybdate dihydrate and 131-3 g
sodium chloride were dissolved in 1 litre of distilled water) were
added and the sample whirlymixed briefly. Four millilitres ethyl
acetate (Analar) was added, the mixture whirlymixed for 30 seconds
and the tubes returned to ice. After separation of the two layers,
a 3 - ml aliquot of the upper layer was placed into a clean tube.
Care was taken, when sampling the upper layer, not to disturb the
precipitate of protein at the interface between the layers,lest the
aliquots of the organic layer should become contaminated, and prevent
an accurate optical density reading being taken. The absorbance at
310 nm was measured in the aliquots of the upper layer in 3~ ml quartz
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cuvettes in a Unicam SP 500 Series 2 ultraviolet and visible spectro¬
photometer. The amount of phosphate in the original samples was
calculated by comparison of the optical densities with those from
standard phosphate solutions (Kh^POy in concentrations of 0.1 mM,
0.05 mM, 0.02 mM, 0.01 mM and 0.005 mM was prepared. Aliquots of
2.5-ml gave standards of 250 nmoles, 125 nmoles, 50 nmoles, 25 nmoles
and 12.5 nmoles of phosphate). Standards were processed with each
assay. The ATPase activities are given in this thesis in terms of
nmoles inorganic phosphate liberated per hour per milligram of
protein (nmol Pj/hr/mg protein).
Using this method for estimating inorganic phosphate the ATPase
reaction was found to be linear with respect to time (over 1 hour)
and amount of membrane preparation added (25-200 yg protein). The
amount of ATP present at the start of the reaction was well in
excess of substrate requirements. At most only 2% of the ATP was
hydrolysed, so effects produced by accumulating ADP were minimal.
In view of the high sensitivity of this method sometimes a
batch of ATP could not be used because it produced a high blank value.
(c) Standard ATPase preparation
Periodically a standard Na++ K+- ATPase preparation was assayed
along with the membrane preparation. A sodium iodide extracted fraction
of hog cerebral cortex was used. The purchased preparation (from Sigma
Chemical Co.) was dissolved in water and aliquots placed in separate
tubes. These were freeze-dried and then stored at -20°C. When
required, tubes were thawed and added to incubation medium.
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(d) Erythrocyte Na+ + K+ - ATPase Arrhenius plots
In one study Na++ K+- ATPase specific activities of erythrocyte
membranes were measured at different temperatures to enable Arrhenius
plots to be drawn and apparent activation energies to be calculated.
It was hoped that these activation energies might reflect the lipid
state of the membrane preparation, and that any change in activation
energy values would reveal a change in lipid composition (Schwartz,
Lindenmayer and Allen, 1975)- The Na++ K+- ATPase assay was carried
out as described above, with the exception that the assay was performed
at temperatures of 10°, 15°, 20°, 25°, 30°, 35° and 37°C. Graphs were
constructed for each sample of log^o ATPase specific activity against
Vabsolute temperature (Dixon and Webb, 1965). The activation energy
E (in units of Kcal/mole) 'is given by the gradient of this plot which
is - (AH + RT)/2.303R, where AH + RT is equal to E,and R is the gas
constant (R being in units of 1.98 cal per mole per degree).
(e) Effect of change in platelet preparation on platelet membrane
ATPase specific activities
ATPase specific activities were measured in some control
subjects' platelet membranes which had been prepared in a slightly
different manner from that described before. This was to enable an
examination of the action that Triton, and freezing and thawing had
on the platelet membrane ATPase activity. Table 11.2 shows the
various modifications that were made.
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TABLE 11.2: Modifications made to platelet membrane preparation
"(all other procedures, as detailed before, remained
the same;
Triton X100 Water Freezing -
added added thawing
2 - ml twi ce
- 2 - ml once
- 2 - ml -
100 yl 2 - ml twi ce
100 yl 2 - ml once
100 yl 2 - ml -
200 yl 2 - ml twice
200 yl 2 - ml once
200 yl 2 - ml
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8. ESTIMATION OF ADENYL CYCLASE ACTIVITY
(a) Incubation conditions
Adenyi cyclase specific activities were measured in platelet
membrane preparations. The amount of cyclic adenosine monophosphate
(cAMP) liberated during incubation of the membranes with disodium
ATP was taken as a measure of adenyi cyclase activity. The
incubation medium used in this assay was that of Krishna, Weiss and
Brodie (1968), with the exception that unlabel led ATP was used as
substrate. The incubation media contained AO mMTris-HCl; pH
7-3, 3-3 mM MgSO^, 10 mM NaF, 10 mM theophylline, 3 mM Na2ATP and
an aliquot of the membrane preparation to give a total volume of
0.6-ml. The Eppendorf tubes containing the incubation media, with
the exception of ATP, were pre-incubated at 30°C for 10 minutes.
The reaction was started by the addition of ATP and allowed to
continue for 10 minutes. Reaction and enzyme blanks were processed
with all assays, water being used instead of the membrane preparation
and ATP. All estimations were carried out in duplicate. The
reaction was stopped by placing the incubation tubes in a heating
block at 80°C for 10 mins. The tubes were then spun in an Eppendorf
centrifuge for 6 mins. An aliquot of the supernatant was then
used to measure the concentration of cyclic AMP present.
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(b) Estimation of cAMP
The concentration of cAMP present in the Eppendorf tubes was
estimated using cyclic AMP kits obtained from the Radiochemical Centre,
Amersham. These kits contain tritium labelled cAMP, a binding protein,
an unlabel led cAMP standard solution, Tris/EDTA buffer and a charcoal
adsorbent. The assay is based on the competition between unlabel led
cAMP, present in the sample to be estimated, and a fixed quantity of
the tritium labelled compound for binding to a protein which has a high
specificity and affinity for cAMP. None of the incubation medium
constituents used in the adenyl cyclase assay are known to interfere
with the binding of cAMP to the protein (Product Information,
Radiochemical Centre, Amersham). The amount of labelled protein -
cAMP complex formed is inversely related to the amount of unlabel led
cAMP present in the assay sample. Separation of the protein-bound
cAMP from the unbound nucleotide is achieved by adsorption of the
free nucleotide on to coated charcoal, followed by centrifugation.
An aliquot of the supernatant is then removed for liquid scintillation
counting. Using known concentrations of unlabel led compound a plot
of CD/CX (CD: counts bound in absence of unlabel led compound;
Cx: counts bound in presence of standard compound) against the con¬
centration of unlabel led compound can be made. This gives a straight
line which enables the concentration of unlabel led cAMP in a sample
to be determined. The adenyl cyclase specific activities are given
in units of nmol cAMP produced per 10 minutes per milligram of protein
(nmol cAMP/10 mins/mg protein).
Using this method for estimating cAMP the adenyl cyclase reaction
was found to be linear with respect to time (over 20 minutes) and
amount of membrane preparation added (150-750 yg protein).
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9. MEASUREMENT OF 5 - HT UPTAKE
5 - HT uptake was measured in aliquots of platelet rich plasma
(PRP). Uptake was measured at 37°C and A°C. The difference between
the two values was taken as a measure of active uptake of 5~HT into
the platelets. 100 yl PRP was added to 3-9 -ml of pre-warmed (37°C)
or ice-cold (A°C) Krebs - Henseleit bicarbonate buffer (pH 7.*0,
containing 3H - 5 - HT {5 "Hydroxy (G-3H)} tryptamine creatinine
sulphate from the Radiochemical Centre, Amersham, specific activity
adjusted to 50 mCi/mmol, and various concentrations of unlabel led 5~HT.
Uptake was measured at 5-HT concentrations of 0.25, 0.5, 1-0 and
2.0 yM for each sample. After 5 minutes incubation in a shaking water
bath, the uptake at 37°C was stopped by transferring the test-tubes
to ice-water. Both sets of test-tubes were centrifuged at *»°C for
30 minutes at 18,000 g using a Mistral 2L centrifuge with a high-speed
head. After draining, 1 - ml of distilled water was added to the pellet,
and the 5 ~HT completely released by freezing overnight at -10°C,
followed by thawing, and centrifugation at A°C for 30 minutes at
18,000 g. One-half millilitre of the solution was mixed with 10 -ml
NE 260 scintillant fluid and the radioactivity measured in either a
Beckman LS 100 liquid scintillation system or a Searle Nuclear Chicago
Division mark II liquid scintillation system. The 5 ~HT uptake was
calculated as pmol 3H - 5 - HT/2 x 107 platelets/5 minutes. All estimations
were carried out in duplicate. The double- reciprocal plot of Lineweaver
and Burke (193*0 was used to determine the values of Km (Michael is Menton
constant) and Vmax (maximal reaction velocity). This entails plotting
Vinitial velocity of reaction against Vsubstrate concentration.
The intercept on the y-ax?s is 1 /Vmax and the gradient of the line
83
is Km/Vmax. Km is expressed in units of yM and Vmax in units of pmol
3H - 5 " HT/2 x 107 platelets/5 minutes.
The purity of the labelled and unlabel led 5~HT was checked
using thin layer chromatography. Silica gel plates were used with a
butanol - acetic acid -water (5 : 1 : 4) mixture as solvent. Forma 1dehyde
was used as the developing agent. This induced a yellow fluorescence
in the presence of ultraviolet light (Bartholin! and Pletscher, 1964).
The presence of one spot only on the plate was taken to indicate that
the 5 - HT solution did not contain any oxidized 5~ HT.
In some experiments the in vitro action of various drugs on
5 - HT uptake into platelets was examined. The experimental conditions
were as described above, with the exception that the platelet
preparations were pre-incubated with the drugs for 5 minutes in
pre-warmed or pre-cooled Krebs - Henseleit bicarbonate buffer (pH 7.4).
The reaction was started by the addition of 5~HT.
10. MEASUREMENT OF WHOLE BLOOD 5 - HT
Whole blood 5~HT was estimated according to the method of
Ashcroft, Crawford, Binns and MacDougal1 (1964). One mi 11ilitre of
heparinized blood was added to 5 - ml distilled water in a graduated
10-ml glass stoppered centrifuge tube and mixed thoroughly by repeated
inversion. The tubes were allowed to stand for 10 minutes to ensure
complete lysis. One mi 11ilitre of 10% ZnSO^ was added and the tubes'
contents mixed again. 0.1 - ml 20% NaOH was rapidly introduced from
an Eppendorf pipette and the solution was mixed immediately. The
tubes were centrifuged for 15 minutes at 2000 g on a Mistral 2L
centrifuge. Two mi 1 1 i 1 i t res concentrated HC1 containing 50 mg/100-ml
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ascorbic acid were added to 4 - ml of the supernatant, bringing the
solution to approximately 3 N with respect to HC1. Estimation of 5 - HT
was then carried out using a Perkin- Elmer Fluorescence Spectrophotometer
MPF-3- An activation scan was made from 250 nm to 400 nm recording
at a fluorescence wavelength of 550 nm. A water blank and 5 " HT
standard solutions of concentrations of between 10 ng/ml to 200 ng/ml
were also processed. All estimations were carried out in duplicate.
To check the recovery of this method, 100 ng 5~HT creatinine sulphate
were added to 1 - ml samples of blood. An 80% recovery was found. All
samples were corrected for this value.
In one set of experiments the effect of mianserin and ami-
triptyline on the 5 - HT estimation was tested by processing 5~HT
standard solutions which contained either mianserin HC1 in concentrations
of 25, 50 or 75 ng/ml, or amitripty1ine HC1 in concentrations of 500,
1000 or 1500 ng/ml. Neither mianserin nor amitripty1ine, in the above
concentrations, interfered with the 5 - HT estimation.
11. MEASUREMENT OF OUABAIN BINDING IN ERYTHROCYTE MEMBRANES
Ouabain binding was estimated in erythrocyte membranes in a
manner similar to that described by Erdmann and Hasse (1975).
Erythrocyte membranes were prepared as usual. After the final
centrifugation in their preparation, the membranes, produced from
#
about 20 - ml blood, were decanted into one tube to which 20 - ml 100
mM imidazole - HC1 pH 6.5 was added, and were homogenized in this
mixture at 4°C. This was then used for the binding assay.
Ouabain binding in the membrane preparations was carried out
under two conditions. In one, varying concentrations of 3H - ouabain,
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from the Radiochemical Centre, Amersham, were present (specific
activity 15 Ci/mmol, 10 nM, 20 nM, 30 nM, AO nM, 50 nM, 60 nM, 120 nM
and 160 nM) and in the other 1 mM unlabel led ouabain was present as
well (non-specific binding). By subtracting the value obtained for
the non-specific binding from that obtained when labelled ouabain was
present alone, an estimate of specific binding was made. The
incubations were carried out in MSE 5 " ml polycarbonate centrifuge
tubes. Each assay tube contained 50 mM imidazole - HC1 buffer pH 7-25,
3 mM MgC12, 3 mM imidazole phosphate and either labelled ouabain alone
or labelled ouabain and 1 mM unlabelled ouabain. The incubation
medium was pre-incubated at 37°C for 10 minutes. The addition of
0.5" ml membrane suspension, which brought the volume in each tube
to 2 - ml, started the reaction. The tubes were incubated at 37°C for
2 hours, previously found to be the time taken for equilibrium to be
reached. All estimations were carried out in duplicate. To stop
the reaction the tubes were placed on ice and cooled to 0-A°C.
Following this 2-ml of a 50:50 50 mM imi dazol e - HC1 and 3 mM
imidazole phosphate mixture was added to each tube. To the tubes
containing only the labelled ouabain 1 mM unlabelled ouabain was
added as well. The outside of the tubes were wiped dry and placed
in the 6 x 5 - ml swing-out rotor of the MSE Superspeed 65 centrifuge
and centrifuged at 28,000 rpm (80,000 g) for 30 minutes at 0°C. The
supernatants were decanted and the inside of the centrifuge tubes
were wiped dry with a paper tissue. 0.5-ml of Protosol was added
to each tube and allowed to act at room temperature overnight. The
samples were transferred to scintillation vials and 10-ml NE 260
scintillant was added. The radioactivity was counted on a Searle
86
Nuclear Chicago Division mark II liquid scintillation system.
Scatchard plots were constructed by plotting the ratio of ouabain
bound/ouabain free against the concentration of ouabain bound,
according to Scatchard (1949). The maximal binding sites can be
calculated from the intercept on the ordinate. The gradient of the
line gives -l/Kj, where Kj is the dissociation constant. The number
of binding sites was calculated per mg protein.
12. ELECTRON MICROSCOPY
The morphological characteristics of some platelet and platelet
membrane preparations were studied by electron microscopy using thin
section techniques. Platelet rich pellets, prepared as described
before, but to which no Triton had been added and which had not been
frozen and thawed repeatedly, were examined. Platelet membranes,
prepared as described before, were also examined. When the membrane
preparation had been allowed to thaw for the second time, the tubes
were centrifuged at b°C for 30 minutes at 18,000 g using a Mistral 2L
centrifuge with a high-speed head. The supernatant was decanted off
to reveal a platelet membrane pellet at the base of the tube. The
platelet rich and platelet membrane pellets were then both processed
in exactly the same way for electron microscopic examination. The
pellets were fixed in 1 - ml 2.5% gluteraldehyde in 0.5 M sodium
cacodylate buffer, pH 7.3. The material was left in fixative for
18 hours at 0 - b°C and then washed twice in 10% sucrose in cacodylate
buffer; each wash was for 10 minutes. Tissue was post-fixed in
osmium tetroxide, 1% in cacodylate buffer, for one hour. After
dehydrating the tissue in alcohol, b ten-minute washes in 10% ethanol
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then 4 ten-minute washes in absolute alcohol, the tissue was cleared
in epoxypropane (2 ten-minute washes) and then transferred to a thin
layer of araldite overnight. This layer was heated at 60°C for 35
minutes and the tissue was transferred to fresh embedding araldite.
o 0
This was kept at 60 C for a minimum of 3 days. Sections of 500 A thick
were cut through the embedded material using a LKB III ultra microtome
and the sections stained in saturated uranyl acetate (15 minutes) and
lead citrate (10 minutes). The sections were finally rinsed in 5 mM
NaOH and then distilled water. Sections were examined on an AEI EM6M
electron microscope using copper grids.
13- MEASUREMENT OF PLASMA LITHIUM CONCENTRATIONS
Plasma lithium concentration was estimated by flame atomic
absorption at 670 nm using a Perkin-Elmer 360 atomic absorptiometer.
A standard LiCl solution of 1 mg/ml, obtained from British Drug Houses
Ltd was used to prepare standards of 0.5 mM, 1 mM and 2 mM. Samples
and standards were diluted 1 : 10 for analysis.
14. ESTIMATION OF HAEMOGLOBIN
Haemoglobin concentration was estimated in a certain number of
preparations, as detailed in the Results Section, according to the
method of Bodeman and Passow (1972).
Samples, standards (human haemoglobin, Sigma Chemical Co.,
0.1 - 0.5 mg/ml) and blanks were diluted 1 + 4 with glacial acetic
acid and left at room temperature for 15 minutes. The absorbance of
the solutions was then measured at 398 nm. All estimations were
carried out in duplicate.
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15. ESTIMATION OF PROTEIN
Protein concentration was estimated by a method based on that
of Lowry, Rosenbrough, Farr and Randall (1951) following the procedure
out 1ined be low:
(i) Reagents: (A) 2X (w/v) Na2C03 in 0.1 N NaOH
(B) 1% (w/v) CuS01+.5H20
(C) 2% (w/v) sod iurn potassium tartrate
(D) 50 parts of (A) added to 1 part (B) + (C)
(E) Folin - Ciocalateau reagent diluted 1+1.5
with water
(F) Bovine serum albumin as standard, 15" 75 yg
in 0.3 - ml aliquots
(ii) Procedure: 3~ ml solution (D) was added to 0.3" ml of samples,
standards and blanks (water). After mixing, the solutions were left
at room temperature for 15 minutes. 0.3-ml solution (E) was then
added to each tube and the solutions whirlymixed. After standing at
room temperature for 30 minutes, the absorbance of the solutions was
measured at 750 nm using either a Unicam SP 500 Series 2 ultraviolet
and visible spectrophotometer or a Gilford spectrophotometer. All
estimations were carried out in duplicate. Protein content of the
samples was calculated by comparison of absorbances with those of
standard solutions.
16. LIQUID SCINTILLATION COUNTING
Liquid scintillation counting efficiency was routinely
estimated by counting standard solutions of the radioactive1y labelled
compounds used. Both 3H - 5 " HT (5 -Hydroxy (G-3H)} tryptamine
creatinine sulphate and 3H - ouabain solutions were counted with an
efficiency of 25 - 30 per cent.
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Both 5~ HT uptake and ouabain binding were calculated using
dpm (disintegrations per minute) values. In the cAMP estimation,
results were calculated using counts per minute as recommended by the
Radiochemical Centre, Amersham (Product Information).
17. CHEMICALS
All chemicals used were of Analar grade and most were obtained
from either British Drug Houses Ltd or Sigma Chemical Co. Heparin
BP (mucous) was obtained from Evans Medical Ltd. Mianserin hydro¬
chloride was obtained from Organon Labs. Ltd. Amitripty1ine
hydrochloride was obtained from Allen and Hanburys Ltd. Protosol was
obtained from New England Nuclear, and NE 260 Scintillant fluid from
Nuclear Enterprises Ltd.
18. STATISTICAL ANALYSES
All results in this thesis are given as means ± standard
deviation (SD). When comparisons were made, Snedecor's f value was
evaluated first. In quite a large number of the comparisons the f
value was large enough to indicate that at- test could not be
performed. It was decided therefore to analyse all the data reported
in this thesis with non-parametric statistics. Comparisons were made
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1. PLATELET STUDY
(a) Platelet membrane ATPase and adenyl cyclase specific activities,
5 - HT uptake into platelets and platelet counts were measured in
control subjects and in untreated patients suffering from an affective
illness. The groups of subjects investigated are shown, together
with their age and sex, in Table I I 1.1.
No significant differences between untreated patients with
affective disorders and controls were found in either platelet
membrane ATPase (Table III.2) or adenyl cyclase (Table I I I.3) specific
activities. Ca2+- ATPase activity could not be detected in the
platelet membrane preparations. When the results for each group were
subdivided into male and female, no apparent differences emerged
within each group for either of the parameters measured.
Table I I I.A shows Km and Vmax values for 5_HT uptake into
platelets from controls and untreated patients. There is no difference
in Km values between the groups studied. A significant reduction in
Vmax was noted in both the unipolar and the bipolar depressed group.
Vmax was found to be significantly elevated in the unipolar well
group. Classification of the results in Table I II.A, divided
according to sex, showed no obvious difference between males and
females within each group.
No significant differences were found between the groups in
platelet counts (Table I I 1.5), and no sex difference in counts in
any of the groups could be seen.
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TABLE I I I . 1 : Group, age and sex of participating
controls and untreated patients
Group Age Sex
Controls (26) 37 + 10
18F
8M
Unipolar depressed (13) A9 + 18
8f
5M
Unipolar wel1 (8) *♦3 + 11
2F
6M
Bipolar depressed (25) AO + 30
16 F
9M
Bipolar manic (8) A3 + 8
6F
2M
Bipolar wel1 (8) A6 + 17 5F3M
Values are expressed as means ± SD.
Numbers in parentheses refer to the number
of subjects in each group.
Comparisons made with control values by
Wilcoxon test for two samples.
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TABLE I I I.2 : ATPase specific activities of platelet
membranes from control subjects and
untreated patients
Na+ + K+ - Mg2+-
Group ATPase ATPase
activity activity
Controls (26) —Jk V-O KO 1+ 00 742 ± 36
Unipolar depressed (13) 122 ± 20 691 ± 80
Unipolar we 11 (8) 110 ± 50 713 ± 60
Bipolar depressed (25) 148 ± 26 696 ± 92
Bipolar manic (8) 126 ± 49 704 ± 81
Bipolar wel1 (8) 160 ± 63 710 ± 96
Activities are expressed as nmol Pj/hr/mg protein.
Values given are means ± SD.
Numbers in parentheses refer to the number of
subjects in each group.
Comparisons made with control values by Wilcoxon
test for two samples.
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TABLE II 1.3 : Adenyl cyclase specific activities of platelet
membranes from control subjects and untreated
patients
Group Adenyl cyclase activity
Controls (26) 0.20 + 0.05
Unipolar depressed (13) 0.19 + 0.0k
Unipolar wel1 (8) 0.18 + 0.3k
Bipolar depressed (25) 0.17 + 0.05
Bipolar manic (8) 0.19 + 0.18
Bipolar wel1 (8) 0.19 + 0.11
Activities are expressed as nmol cAMP/10 mins/mg
protein.
Values given are means ± SD.
Numbers in parentheses refer to the number of
subjects in each group.
Comparisons made with control values by Wilcoxon
test for two samples.
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TABLE I I I.A : Km and Vmax values for 5 ~ HT uptake into plate¬
lets from control subjects and untreated patients
Group Km Vmax
Controls (26) 0 .A3 + 0.05 8A + 10
Unipolar depressed (13) O.AA + 0.07 73 + 1 A"
Unipolar wel1 (8) 0.53 + 0.23 98 + 1 A»
Bipolar depressed (25) 0.A6 + 0.10 59 + 35*
Bipolar manic (8) 0.A6 + 0.06 81 + 8
Bipolar wel1 (8) 0.A8 + 0.11 87 + 25
Activities are expressed as pM for Km values and as
pmol 5~HT/2 x 107 platelets/5 mins for Vmax values.
Values given are means ± SD.
Comparisons made with control values by Wilcoxon test
for two samples.
* P < 0.02
Numbers in parentheses refer to the number of subjects
in each group.
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TABLE I I 1.5 : Platelet counts in control subjects
and untreated patients
Group Platelet count
Controls (26) 273 ± 21
Unipolar depressed (13) 322 ± 19
Unipolar wel1 (8) 309 ± 16
Bipolar depressed (25) 329 ± 25
Bipolar manic (8) 261 ± 22
Bipolar wel1 (8) 272 ± 15
Platelet counts are expressed as 103
platelets/mm3 blood.
Values given are means ± SD.
Comparisons made with control values by
Wilcoxon test for two samples.
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Platelet membrane ATPase and adenyl cyclase specific activities
and 5 - HT uptake into platelets were also examined in several groups
of subjects who were receiving lithium carbonate. All results
reported here are from subjects whose plasma lithium concentration
lay between 0.6 and 1. A mEq/1.
(b) Tables I I 1.6, I I 1.7 and 111.8 show platelet membrane ATPase
specific activities, platelet membrane adenyl cyclase specific
activities and platelet 5 - HT uptake, respectively, in preparations
obtained from 7 control subjects (A female, 3 male), age 32± 5 years,
voluntarily taking lithium carbonate. Lithium administration did
not significantly affect any of the platelet parameters studied.
A small group of unipolar depressed, bipolar depressed and
bipolar manic patients were studied at intervals throughout lithium
therapy. Some of the patients examined were prescribed other drugs
during their course of lithium. Results given here are from patients
who were receiving lithium alone. After 3 weeks of lithium treatment,
all the patients, in the groups examined, were classified as unipolar
and bipolar well, ie they had recovered while receiving lithium therapy.
(c) Table I I I.9 gives details of the unipolar depressed patients
investigated. Tables 111.10, 111.11 and 111.12 show platelet membrane
ATPase specific activity, platelet membrane adenyl cyclase specific
activities and platelet 5-HT uptake respectively, in preparations obtained
from these unipolar depressed patients. Lithium therapy and the
recovery process appeared not to affect any of these platelet measures.
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TABLE I I 1.6 : ATPase specific activities of platelet
membranes from control subjects taking
1ithium carbonate
Na+ + K+- Mg2+-
Stage of treatment ATPase ATPase
activity activity
Prelithiurn (7) 12k + 35 758 + bS
5 days on 1ithiurn (7) 137 + 22 750 + 27
3 weeks on lithium (7) 10A + 38 72*+ + 1+6
Activities are expressed as nmol Pj/hr/mg protein.
Values given are means ± SD.
Numbers in parentheses refer to the number of
subjects at each stage.
Comparisons made with prelithium values by
Wilcoxon test for pair differences.
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TABLE I I 1.7 : Adenyl cyclase specific activities of platelet
membranes from control subjects taking lithium
carbonate
Stage of treatment Adenyl cyclase activity
Prelithium (7) 0.19 + 0.05
5 days on lithiurn (7) 0.19 + 0.10
3 weeks on lithium (7) 0.18 + 0.16
Activities are expressed as nmol of cAMP/10 mins/
mg protein.
Values are given as means ± SD.
Numbers in parentheses refer to the number of
subjects at each stage.
Comparisons made with prelithium values by Wilcoxon
test for pair differences.
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TABLE I I I .8 : Km and Vmax values for 5 - HT uptake into
platelets from control subjects taking lithium
carbonate
Stage of treatment Km Vmax
Prelithiurn (7) 0.A5 + 0.05 85 + 5
5 days on 1ithium (7) 0 .AO + 0.05 85 + 5
3 weeks on lithium (7) 0.A6 + 0.05 82 + 13
Activities are expressed as yM for Km values and as
pmol 5 - HT/2 x 10' platelets/5 mins for Vmax values.
Values given are means ± SD.
Numbers in parentheses refer to the number of
subjects at each stage.
Comparisons made with prelithium values by Wilcoxon
test for pair differences.
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TABLE I I 1.9 : Unipolar depressed patients treated
with lithium carbonate
Stage of treatment Age Sex
Prelithium (6) 52 ± 16 3F3M
5 days on 1ithiurn (6) 52 ± 16 3F3M
3 weeks on lithium (3) ± 11
2F
1M
3 months on lithium (2) 35 2F
Values are expressed as means ± SD or mean alone.
Numbers in parentheses refer to the number
of subjects at each stage.
Comparisons made with prelithium values by
Wilcoxon test for pair differences (for '5 days
on lithium' values) and by Wilcoxon test for
two samples (for the other values).
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TABLE 111.10: ATPase specific activities of platelet
membranes from unipolar depressed patients
taking lithium carbonate
Na++ K+- Mg2+-
Stage of treatment ATPase ATPase
> activity activity
Prelithium (6) 107 ± AO 702 ± A3
5 days on 1 ithium (6) 126 ± 38 721 ± 67
3 weeks on 1ithium (3) 101 ± A2 658 ± 33
3 months on 1ithium (2) 96 660
Activities are expressed as nmol Pj/hr/mg protein.
Values are given as means ± SD or mean alone.
Numbers in parentheses refer to the number of
subjects at each stage.
Comparisons made with prelithium values by Wilcoxon
test for pair differences (for '5 days on lithium1
values) and by Wilcoxon test for two samples (for
the other values).
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TABLE 111.11: Adenyl cyclase specific activities of platelet
membranes from unipolar depressed patients
taking lithium carbonate
Stage of treatment Adenyl cyclase activity
P rel i thi urn (6) 0.17 ± 0.02
5 days on lithiurn (6) 0.18 ± 0.0k
3 weeks on lithium (3) 0.16 ± 0.02
3 months on lithium (2) 0.17
Activities are expressed as nmol of cAMP/10 mins/mg
protein.
Values are given as means ± SD or mean alone.
Numbers in parentheses refer to the number of
subjects at each stage.
Comparisons made with prelithium values by Wilcoxon
test for pair differences (for '5 days on lithium'
values) and by Wilcoxon test for two samples (for
the other values).
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TABLE I!1.12: Km and Vmax values for 5~HT uptake into
platelets from unipolar depressed patients
taking lithium carbonate
Stage of treatment Km Vmax
Prel i thi urn (6) 0.47 1+ O o 75 + 15
5 days on 1 i thi urn (6) 0.41 ± 0.07 68 + 29
3 weeks on lithium (3) 0.40 ±0.20 82 + 17
3 months on lithium (2) 0 .42 81
Activities are expressed as yM for Km values and as
pmol 5~HT/2 x 10' platelets/5 mins for Vmax values.
Values given are means ± SD or mean alone.
Numbers in parentheses refer to the number of
subjects at each stage.
Comparisons made with prelithium values by Wilcoxon
test for pair differences (for '5 days on lithium1
values) and by Wilcoxon test for two samples (for
the other va1ues).
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(d) Details of the bipolar depressed group studied are given in
Table 111.13- Platelet membrane ATPase specific activity, platelet
membrane adenyl cyclase specific activities and platelet 5~HT
uptake are shown in Tables ll1.1 A, 111.15 and 111.16. None of the
platelet values in this group seemed to be affected by lithium
therapy and recovery.
(e) Table 111.17 gives details of the bipolar manic patients who
were studied. Tables 111.18, 111.19 and I 11.20 show the values
obtained for platelet membrane ATPase specific activity, platelet
membrane adenyl cyclase and 5 - HT uptake into platelets for this
group. The platelet parameters studied were not significantly
altered by therapy and recovery from illness.
(f) The in vitro action of lithium carbonate on platelet membrane
ATPase specific activities and 5 - HT uptake into platelets was
investigated in platelets from 5 control subjects (1 female, k male),
age 29 ±12 years. Table 111.21 shows the act ion of 1ithiurn on
platelet membrane ATPase specific activities. Ca2+- ATPase activity
could not be detected in either the presence or absence of lithium.
Lithium did not affect Na++ K+- ATPase activity, but did cause a
stimulation of Mg2+- ATPase activity when present in a concentration
of 1 mH or 2 mM. Table 111.22 shows the effect of lithium on Km and
Vmax values for 5 - HT uptake into platelets. No significant change
was noted.
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TABLE 111.13: Bipolar depressed patients treated with
1ithium carbonate
Stage of treatment Age Sex
Prelithium (A) A3 + 16 3F1M
5 days on lithium (A) A3 + 16 3F1M
3 weeks on lithium (A) A3 + 16 3F1M
3 months on lithium (3) 36 + 9
2F
1M
Values are expressed as means ± SD.
Numbers in parentheses refer to the number of
subjects at each stage.
Comparison made by Wilcoxon test for two
samples.
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TABLE III.1A: ATPase specific activities of platelet
membranes from bipolar depressed patients
taking lithium carbonate
Na+ + K+- Mg2+-
Stage of treatment ATPase ATPase
activity activity
Prelithiurn {b) 131 + 32 700 ± 60
5 days on lithiurn (A) \b6 + itO 69^ ± 36
3 weeks on lithium [b) 129 + 53 73b ± b2
3 months on lithium (3) 132 + b3 7b3 ± 39
Activities are expressed as nmol Pj/hr/mg protein.
Values are given as means ± SD.
Numbers in parentheses refer to the number of
subjects at each stage.
Comparisons made with prelithium values by
Wilcoxon test for pair differences (for '5 days'
and '3 weeks on lithium' values) and by Wilcoxon
test for two samples (for '3 months on lithium'
values) .
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TABLE 111.15: Adenyl cyclase specific activities of platelet
membranes from bipolar depressed patients
taking lithium carbonate
Stage of treatment Adenyl cyclase activity
Pre Iithium (b) 0.20 + 0.02
5 days on lithium (b) 0.18 + 0.0b
3 weeks on lithium {b) 0.19 + 0.0b
3 months on lithium (3) 0.18 + 0.05
Activities are expressed as nmol of cAMP/10 mins/
mg protein.
Values are given as means ±SD.
Numbers in parentheses refer to the number of
subjects at each stage.
Comparisons made with pre lithium values by Wilcoxon
test for pair differences (for '5 days' and '3 weeks
on lithium' values) and by Wilcoxon test for two
samples (for '3 months on lithium' values).
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TABLE 111.16: Km and Vmax values for 5~HT uptake into plate¬
lets from bipolar depressed patients taking
1ithiurn carbonate
Stage of treatment Km Vmax
Pre l i thi urn (A) O.kk + 0.06 69 + 20
5 days on lithium (A) 0.A8 + 0.1A 70 + 16
3 weeks on lithium (A) 0. A3 + 0 .OA 8k + 2k
3 months on lithium (3) 0. A3 + 0.09 80 + 10
Activities are expressed as yM for Km values and as
pmol 5 - HT/2 x 10' platelets/5 mins for Vmax values.
Values given are means ± SD.
Numbers in parentheses refer to the number of
subjects at each stage.
Comparisons made with prelithium values by Wilcoxon
test for pair differences (for '5 days' and '3 weeks
on lithium' values) and by Wilcoxon test for two
samples (for '3 months on lithium' values).
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TABLE 111.17: Bipolar manic patients treated with
1ithium carbonate
Stage of treatment Age Sex
Prelithium (5) bb ± 12
bF
1M
5 days on 1ithium (5) bb ± 12
bF
1H
3 weeks on lithium (5) bb ± 12 bF1M
3 months on lithium (b) b3 ± 1A bF
Values are expressed as means ± SD.
Numbers in parentheses refer to the number
of subjects at each stage.
Comparison made by Wilcoxon test for two
samples.
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TABLE 111.18: ATPase specific activities of platelet
membranes from bipolar manic patients taking
1ithiurn carbonate
Na+ + K+- Mg2+-
Stage of treatment ATPase ATPase
activity activity
Prelithium (5) 114 ± 27 733 ± 63
5 days on 1ithiurn (5) 81 ± 42 673 ± 76
3 weeks on lithium (5) 116 ± 35 649 ± 80
3 months on lithium (4) 123 ± 64 697 ± 44
Activities are expressed as nmol Pj/hr/mg protein.
Values are given as means ± SD.
Numbers in parentheses refer to the number of
subjects at each stage.
Comparisons made with prelithium values by Wilcoxon
test for pair differences (for '5 days' and '3 weeks
on lithium1 values) and by Wilcoxon test for two
samples (for '3 months on lithium1 values).
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TABLE III.19: Adenyl cyclase specific activities of platelet
membranes from bipolar manic patients taking
1ithiurn carbonate
Stage of treatment Adenyl cyclase activity
Prelithium (5) 0.20 + 0.07
5 days on lithiurn (5) 0.17 + 0.13
3 weeks on lithium (5) 0.18 + 0.02
3 months on lithium (A) 0.19 + 0.10
Activities are expressed as nmol of cAMP/10 mins/
mg protein.
Values are given as means ± SD.
Numbers in parentheses refer to the number of
subjects at each stage.
Comparisons made with prelithium values by Wilcoxon
test for pair differences (for '5 days' and '3 weeks
on lithium* values) and by Wilcoxon test for two
samples (for '3 months on lithium1 values).
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TABLE I I I .20 : Km and Vmax values for 5~HT uptake into
platelets from bipolar manic patients
taking lithium carbonate
Stage of treatment Km Vmax
Prelithiurn (5) 0. 47 + 0.09 70 + 22
5 days on 1ithiurn (5) 0.43 + 0.18 72 + 22
3 weeks on lithium (5) 0.40 + 0.16 76 + 16
3 months on lithium (4) 0.48 + 0.06 70 + 22
Activities are expressed as yM for Km values and as
pmol 5~HT/2 x 10' platelets/5 mins for Vmax values.
Values given are means ± SD.
Numbers in parentheses refer to the number of
subjects at each stage.
Comparisons made with prelithium values by Wilcoxon
test for pair differences (for '5 days' and '3 weeks
on lithium1 values) and by Wilcoxon test for two
samples (for '3 months on lithium1 values).
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TABLE 111.21: In vitro action of lithium carbonate
on ATPase specific activities of plate-
let membranes from 5 control subjects
(IF, AM)
Concentration Na+ + K+- Mg2+-
of ATPase ATPase
lithium present activity activity
(mM)
Cont rol 132 + 29 759 + 30
0.5 125 + 19 769 + 28
1 141 + 33 780 + 25*
2 139 + 21 840 + 19*
Activities are expressed as nmol Pj/hr/mg
protein.
Values given are means±SD.
Comparisons made by Wilcoxon test for pair
differences.
« P < 0 .02 & P < 0.01
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TABLE 111.22: In vitro action of lithium carbonate
on Km and Vmax values for 5~HT uptake




lithium present Km Vmax
(mM)
Cont rol 0.1+6 + 0.01+ 85 + 12
0.5 0.1+5 + 0.07 80 ± 11+
1 0.1+3 + 0.08 83 + 13
2 0.1+2 + 0.08 81 + 16
Activities are expressed as yM for Km values
and as pmol 5~HT/2 x 107 platelets/5 mins
for vmax values.
Values are given as means! SO.
Comparisons made with control values by
Wilcoxon test for pair differences.
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2. COMPARATIVE STUDY OF PLATELETS AND ERYTHROCYTES
ATPase specific activities of platelet and erythrocyte membranes
were compared in control subjects, untreated depressed patients and
untreated bipolar manic patients. Details of the groups investigated
are shown in Table 111.23.
(a) ATPase specific activities of platelet membranes from the three
groups are shown in Table III.2A. Ca2+- ATPase specific activity
was undetectable. Platelet membrane Na++ K+- ATPase and Mg2+- ATPase
specific activities are not significantly different in either group
when compared with control values.
(b) There is however, a significant decrease in Na+ + K+ - ATPase
specific activity in the erythrocyte membranes of the unipolar depressed
group (Table 111.25). A decrease in Ca2+ +Mg2+ ATPase activity in
erythrocyte membranes of the bipolar manic group was also observed.
When the results were subdivided into male and female for each
group, differences could not be explained on a sex basis.
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TABLE 111.23: Group, age and sex of participating
controls and untreated patients
Group Age Sex
Controls (15) 42 ± 11 7f8M
Unipolar depressed (12) 45 ± 12
8f
am
Bipolar manic (10) CO+1CO-3*
6f
Am
Values are expressed as
Numbers in parentheses
mean ± SD.
refer to the number
of subjects in each group.
Comparisons with control values by Wilcoxon
test for two samples.
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TABLE 111.2*4: ATPase specific activities of platelet
membranes from control subjects and untreated
patients
Na+ + K+- Mg2+-
Group ATPase ATPase
activity activity
Controls (15) 163 ± 50 763 ± 38
Unipolar depressed (12) 1*46 ± *43 730 ± 89
Bipolar manic (10) 132 ± 38 756 ± 93
Activities are expressed as nmol Pj/hr/mg protein.
Values given are means ± SD.
Numbers in parentheses refer to the number of
subjects in each group.
Comparisons made with control values by Wilcoxon
test for two samples.
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TABLE 111.25: ATPase specific activities of erythrocyte membranes
from control subjects and untreated patients
Na+ + K+- Mg2+- Ca2+ + Mg2+-
Group ATPase ATPase ATPase
activity activity activity
Controls (15) 3A2 ± *t9 297 + 61 +lOCO 72
Unipolar depressed (12) 216 ± 36s 317 + 5^ 936 ± 80
Bipolar manic (10) 296 ± 60 330 + 73 726 ±
J.
33*
Activities are expressed as nmol Pj/hr/mg protein.
Values given are means ± SD.
Comparisons made with control values by Wilcoxon test for
two samples.
S P < 0 . 01
Numbers in parentheses refer to the number of subjects in
each group.
123
3. MIANSERIN AND AMITRIPTYLINE STUDY
The action of either mianserin or amitripty1ine on whole blood
5 - HT and platelet 5 - HT uptake was investigated in unipolar depressed
patients receiving these drugs. After three weeks drug therapy most
patients could be classified as unipolar well. The in vitro action
of these drugs on platelet 5 - HT uptake into platelets from control
subjects was also investigated. The groups of subjects investigated,
and the estimations performed, are shown in Table 111.26, together
with their age and sex. The second control group (age 29± 13) was
significantly younger than the other groups.
(a) Figure I I 1.1 shows values obtained for whole blood 5 - HT
content in untreated control subjects and patients treated with
mianserin. Whole blood 5~HT content in untreated patients, before
commencing mianserin therapy, was not significantly different from
that in controls. Mianserin therapy and the recovery process did
not significantly alter the whole blood 5~HT levels.
Whole blood 5 - HT content in untreated control subjects and
patients treated with amitriptyline is shown in Figure I I 1.2. Values
obtained in untreated patients, before commencing amitripty1ine
therapy, did not significantly differ from that in controls. After
one week of amitripty1ine therapy, the 5_HT levels in the treated
patients were significantly reduced compared to control values but
not significantly different from the patients' pre-therapy values
(Wilcoxon test for pair differences). After two weeks of amitripty1ine
therapy the values were reduced even further, to a value significantly
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TABLE IN.26: Group, age and sex of participating controls and patients
Drug therapy group Estimations performed Age Sex
Controls (10)
Whole b1ood 5 ~ HT





In vitro action of
amitripty1ine and
mianserin on platelet
5 - HT uptake
29 + 13 5F
5M
Mianserin (16) Whole blood 5 - HT 57 + 16
10 F
6M




Whole blood 5 - HT
Platelet 5~HT uptake
^3 + 17 5F3M
Values are expressed as means ± SD.
Numbers in parentheses refer to the number of subjects in
each group.
Comparison of second control group with first control group
by Wilcoxon test for two samples P<0.02.
Comparison of second control group with the mianserin groups
by Wilcoxon test for two samples P < 0.01.
Comparison of second control group with the amitripty1ine
group by Wilcoxon test for two samples P<0.02.
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FIGURE Whole blood 5~HT content in untreated control





















Values are expressed as means ± SD.
Numbers in parentheses refer to the number of subjects
in each group.
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FIGURE III.2: Whole blood 5~HT content in untreated control
























Values are expressed as means ± SD.
Comparisons made with controls by Wilcoxon test for
two samples.
* P < 0.02 $ P < 0.01
Numbers in parentheses refer to the number of subjec
in each group.
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lower than either the control value or the pre-therapy value. The
levels obtained here were at the limits of sensitivity for the
detection of 5 ~ HT by this fluorescence technique, therefore standard
deviations are not quoted.
(b) Figure 111.3 shows Km values for 5-HT uptake into platelets
from untreated control subjects and unipolar depressed patients
receiving mianserin. The pre-therapy Km value was not significantly
different from the control value, and the Km value was not affected
when the patients were treated with mianserin and recovered.
Treatment with amitriptyline for two weeks or more, however,
caused an increase in 1^ values (Figure I I I.A). No difference in Km
values was found in the untreated patients when compared with controls.
Vmax values for 5 - HT uptake from patients treated with mianserin
are shown in Figure I I 1.5. A significant reduction was found in
values from untreated patients when compared with controls. Over
the course of treatment Vmax values tend to increase. After 3 weeks
therapy, when the patients had recovered, the values were not
significantly different from those of controls, but were significantly
different from pre-therapy values (P<0.01 Wilcoxon test for pair
differences).
In the unipolar depressed group receiving amitripty1ine, pre-
therapy Vmax values are significantly less than control values
(Figure I I 1.6). Treatment with amitripty1ine, however, can be seen
to cause a further reduction in the value of Vmax. After two weeks
of amitriptyline therapy, Vmax is significantly less than that found
before therapy started (Wilcoxon test for pair differences, P<0.01).
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FIGURE III.3: Km values for 5 - HT uptake into platelets from















(10) 0) 0) (10)
Values are expressed as means ± SD.
Numbers in parentheses refer to the number of subjects
in each group.
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FIGURE \\\.k: Km values for 5 - HT uptake into platelets from






















Values are expressed as means ± SD.
Comparisons made with controls by a Wilcoxon test for
two samples 2 P<0.01
Numbers in parentheses refer to the number of subjects
in each group.
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FIGURE I I I.5: Vmax values for 5~ HT uptake into platelets from





















(10) (10) (10) (10) (10)
Values are expressed as means ± SD.
Comparisons made with controls by Wilcoxon test for
two samples.
+ P < 0.05 $ P < 0.01
Numbers in parentheses refer to the number of subjects
in each group.
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FIGURE I II.6: Vmax values for 5~HT uptake into platelets from































Values are expressed as means ± SD.
Comparisons made with controls by Wilcoxon test for
two samples.
t P < 0.01
Numbers in parentheses refer to the number of subjects
in each group.
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(c) Figures III.7 and III.8 show the in vitro effect of mianserin
and amitriptyline, respectively, on Km values for5_HT uptake into
platelets from control subjects. Mianserin causes a significant
increase in Km for the process at concentrations of 50 and 75 ng/ml.
Amitripty1ine causes an increase in Km values at 50, 100 and 150 ng/ml.
The effect produced by 100 ng/ml, however, is not significantly
different from that produced by 150 ng/ml (Wilcoxon test for pair
differences).
The in vitro action of mianserin and amitripty1ine on Vmax
for 5 ~HT uptake into platelets from controls, is shown in Figures
III.9 and 111.10. Both mianserin and amitripty1ine cause a reduction
in the Vmax values, at the concentrations shown.
(d) Some of the subjects already studied (Table 111.26) were used
to investigate the effect of either mianserin or amitripty1ine on
platelet and erythrocyte membrane ATPase specific activity (Table
111.27). All of the patients investigated here, had recovered after
3 weeks drug administration. The control group was significantly
younger than either of the two patient groups.
Tables 111.28 and 111.29 show values obtained for platelet
membrane ATPase specific activities in unipolar depressed patients
being treated with either mianserin or amitripty1ine. Pre-therapy
values in both patient groups studied were not significantly
different from those in control subjects, and neither mianserin
therapy and recovery nor amitripty1ine therapy and recovery affected
ATPase activity.
ATPase specific activities of erythrocyte membranes from
patients treated with mianserin and amitripty1ine are shown in
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Values are expressed as means ± SD.
Comparisons made with control value by a Wilcoxon
test for pair differences.
* P < 0.02 t P < 0.01
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FIGURE III.8: in vitro action of amitripty1ine on Km values for














Values are expressed as means ± SD.
Comparisons made with control value by a Wilcoxon
test for pair differences.
* P < 0.02 t P < 0.01
135
FIGURE III.9 In vitro action of mianserin on Vmax values for

















Values are expressed as means ± SD.
Comparisons made with control value by a Wilcoxon
test for pair differences.
a P < 0.02 s P < 0.01
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FIGURE 111.10: Jn vitro action of amitripty1ine on Vmax values for



















Values are expressed as means ± SD.
Comparisons made with control value by a Wilcoxon
test for pair differences.
t P < 0.01
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In vitro action of mianserin
and amitriptyline on plate¬





















Values are expressed as means ± SD.
Numbers in parentheses refer to the number of subjects in each group.
Comparisons made with control values by Wilcoxon test for two samples.
* P < 0.02
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TABLE I I I.28: ATPase specific activities of platelet
membranes from untreated control subjects
and unipolar depressed patients receiving
mi anserin
Na+ + K+- Mg2+-
ATPase ATPase
Stage of treatment activity activity
Control (8) 130 ± 21 752 ± AO
Pre-therapy (8) 1A2 ± bS 769 ± 70
1 week on mianserin (8) 136 ± 52 729 ± 68
2 weeks on mianserin (8) 127 ± 36 731 ± 59
3 weeks on mianserin (8) OvO+lLA 75A ± 65
Activities are expressed as nmol Pj/hr/mg protein.
Values given are means ± SD.
Numbers in parentheses refer to the number of
subjects at each stage.
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TABLE 111.29: ATPase specific activities of platelet membranes
from untreated control subjects and unipolar depressed
patients receiving amitripty1ine
Na+ + K+- Mg2+-
ATPase ATPase
Stage of treatment activity act ii vi ty
Control (8) 130 ± 21 752 ± itO
Pre-therapy (5) 128 ± k0 689 ± 63
1 week on amitripty1ine (5) 139 ± 37 699 ± 72
2 weeks on amitripty1ine (5) 126 ± 52 696 ± 62
3 weeks on amitripty1ine (5) 1 AO ± A8 709 ± 70
Activities are expressed as nmol Pj/hr/mg protein.
Values given are means ± SD.
Numbers in parentheses refer to the number of subjects
at each stage.
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Tables 111.30 and 111.31, respectively. Pre-therapy Na+ +K+-ATPase
activities in erythrocyte membranes from the patients were less than
those in control subjects. Over the course of treatment with either
mianserin or amitripty1ine, and subsequent recovery, ATPase activities
approached control values. No differences were detected in the other
ATPase activities measured.
(e) The in vitro action of mianserin and amitripty1ine on platelet
and erythrocyte membrane ATPase specific activities was examined in
preparations from control subjects.
Neither mianserin nor amitripty1ine affected platelet membrane
ATPase activities in the concentrations shown (Tables 111.32 and
I I I.33).
The action of mianserin and amitripty1ine in vitro on
erythrocyte membrane ATPase activities is shown in Tables III. 3^+ and
111.35. It can be seen that neither mianserin nor amitripty1ine,
in the concentrations used, change ATPase activity.
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TABLE I II.30: ATPase specific activities of erythrocyte membranes
from untreated control subjects and unipolar depressed
patients receiving mianserin
Na+ + K+- Mg2+- Ca2+ + Mg2+-
ATPase ATPase ATPase
Stage of treatment activity activity activity
Control (8) 360 + 53 321 ± 57 900 + 84
Pre-therapy (8) 216 + 24* 299 ± 46 872 + 69
1 week on mianserin (8) 223 +
JU
39* 330 ± 58 897 + 70
2 weeks on mianserin (8) 272 + 49* 287 ± 53 921 + 76
3 weeks on mianserin (8) 341 + 60 2Sb ± 60 914 + 93
Activities are expressed as nmol Pj/hr/mg protein.
Values given are means ± SD.
Comparisons made with controls by Wilcoxon test for two samples.
* P < 0.01 * P < 0.02
Numbers in parentheses refer to the number of subjects in each
group.
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TABLE III.31: ATPase specific activities of erythrocyte membranes
from untreated control subjects and unipolar depressed
patients receiving amitriptyline
Na+ + K+- Mg2+- Ca2+ + Mg2+-
ATPase ATPase ATPase
Stage of treatment activity activity activity
Control (8) 360 + 53 321 + 57 900 + 8k
Pre-therapy (5) 25k + kot 339 + k3 896 + 60
1 week on amitripty1ine (5) 269 + *oLA 316 + 36 935 + 71
2 weeks on amitripty1ine (5) 292 + k3+ 3^9 + 60 883 + 5k
3 weeks on amitritpy1ine (5) 323 + 70 299 + 58 899 67
Activities are expressed as nmol Pj/hr/mg protein.
Values given are means ± SD.
Comparisons made with controls by Wilcoxon test for two samples.
£ P < 0.01 * P < 0.02 + P < 0.05
Numbers in parentheses refer to the number of subjects in each
group.
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TABLE 111.32: In vitro action of mianserin on ATPase
specific activities of platelet
membranes from 8 control subjects
Concentration of Na+ + K+- Mg2+-
mianserin present ATPase ATPase
(ng/ml) activity activity
Control 137 + 36 759 + 38
25 146 + 39 770 + 39
50 129 + 40 769 + 37
75 132 + 37 770 + 40
Activities are expressed as nmol P;/hr/mg
protein.
Values given are means ± SD.
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TABLE I I I.33: In vitro action of amitripty1ine on ATPase
specific activities of platelet membranes
from 8 control subjects
Concentration of Na+ + K+- Mg2+-
amitritpy1ine present ATPase ATPase
(ng/ml) activity activity
Control 137 + 36 759 + 38
50 132 + k0 765 + 29
100 1*»3 + U2 760 + 32
150 151 + k0 758 + 30
Activities are expressed as nmol P;/hr/mg protein.
Values given are means ± SD.
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TABLE 111.3**: In vitro action of mianserin on ATPase specific
activities of erythrocyte membranes from 8 control
subjects
Concentration of
x Na+ + K+- Mg2+- Ca2+ + Mg2+-
mianserin present ATPase ATPase ATPase
(ng/ml) activity activity activity
Control 360 + 53 321 + 57 900 + 8A
25 3**2 + **9 300 + 1*8 892 + 79
50 339 + 50 299 + 1*7 897 + 82
75 351 + A8 318 + 1*9 905 + 79
Activities are expressed as nmol P;/hr/mg protein.
Values given are means ± SD.
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TABLE 111.35: In vitro action of amitritpy1ine on ATPase specific
activities of erythrocyte membranes from 8 control
subjects
Concentration of Na+ + K+- Mg2+- Ca2+ + Mg2+-
amitripty1ine present ATPase ATPase ATPase
(ng/ml) activity activity activity
Control 360 + 53 321 + 57 900 + 84
50 352 + 49 329 ± 53 911 + 80
100 3^9 + 53 320 ± 5h 899 + 81
150 369 ± 51 329 ± 51 901 + 83
Activities are expressed as nmol Pj/hr/mg protein.
Values given are means ± SD.
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4. ELECTROCONVULSIVE THERAPY (ECT) STUDY
ATPase specific activities of erythrocyte membranes were
examined in a group of unipolar depressed patients receiving a
course of ECT (details given in Table 111.36), a group of patients
undergoing cystoscopy (four women and seven men; age ^9 ± 19 years)
and a group of control subjects (13 women and three men; age kS - 11
years).
(a) Figure 111.11 shows ATPase values from control subjects,
patients directly before cystoscopy and the total unipolar depressed
patient group before ECT. Na++ K+- ATPase values in pre-ECT patients
were significantly reduced compared with control values. The mean
Hamilton Rating Scale score for these patients, before ECT, was
26 ± 8. This score is consistent with clinical observations of
depression shown by all the patients.
(b) Figure 111.12 shows ATPase activities in the cystoscopy group
before and after examination (anaesthetic given), and the total
group of depressed patients before and after their first ECT. The
only change observed was an apparent stimulation of Na++ K+ - ATPase
activity in the cystoscopy group following anaesthesia.
(c) Results obtained from patient group I (subjects A, C, D, H,
L, M, N, P and Q, seven women and two men; age 50 ± 15 years) for
ATPase activities before and after their first, second and last ECT
are shown in Figure 111.13. A slight reduction in Ca2+- ATPase
activity occurred after their first ECT. Prior to ECT, this group's
mean HRS score was 23 ± 6, and immediately after a course of ECT
this was lowered to 11 ± b, a change consistent with the clinical
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A M AO 6 27 17 2A amitripty1ine
C F 30 6 17 13 - -
D F 56 9 19 18 di ed -
F F 50 A 29 11 7 amitripty1ine
H F 39 8' 28 10 10 -
J F 36 5 37 17 9 amit ripty1ine
K M 55 5 AO 12 18 amit ripty1ine
L F 65 8 31 7 10 amit ripty1ine
M F 67 6 15 5 9 imipramine
N M 57 6 23 8 A amit ripty1ine
P F 28 6 29 10 12 amitripty1ine
Q F 65 5 21 9 5 amit ripty1ine
MEAN A9 6 26 11 11
SD 1A 1.5 8 A 6
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FIGURE 111.11: ATPase specific activities of erythrocyte membranes




Q PRE- ECT (12)
Activities are expressed as nmol Pj/hr/mg protein.
Values given are means ± SD.
Comparisons made with control values by Wilcoxon test
for two samples.
$ P < 0.01
Numbers in parentheses refer to the number of subjects
in each group.
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FIGURE 111.12: ATPase specific activities of erythrocyte membranes
from patients before and after cystoscopy and from the
total depressed patient group before and after their
first ECT
BEFORE CYSTOSCOPY (11)
BEFORE FIRST ECT (12)
AFTER CYSTOSCOPY (11)
AFTER ECT (12)
Activities are expressed as
Values given are means ± SD.
Comparisons made by Wilcoxon
t P <0.01




test for pair differences,
to the number of subjects
FIGURE 111.13: ATPase specific activities of erythrocyte membranes
from depressed patient group I before and after their
first, second and last ECT
10001
Na * + K + -
BEFORE FIRST ECT (9) |££j AFTER FIRST ECT (9)
BEFORE SECOND ECT (9) §H AFTER SECOND ECT (9)
BEFORE LAST ECT (9) [j AFTER LAST ECT (9)
Activities are expressed as nmol Pj/hr/mg protein.
Values given are means ± SD.
Comparisons made by Wilcoxon test for pair differences.
* P < 0.02
Numbers in parentheses refer to the number of subjects
in each group.
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improvement observed during the treatment. This group received
7 ± 1.3 ECT.
(d) Figure 111.14 shows values from patient group II (subjects
F, H, J, K, N, P and Q, five women and two men; age 47 ± 13 years)
for ATPase activities before the first ECT and at follow-up. A
small increase in Ca2++ Mg2+- ATPase activity was observed. This
observed increase was due entirely to an increase in Ca2+-ATPase
activity. In group II HRS scores were: before ECT 29 ± 7,
immediately after a course of ECT 11 ± 3, and at follow-up 12 weeks
later 9 ± 5- These scores parallel the clinical observations of
improvement shown by these patients during the course of ECT. This
group received 6 ± 1.3 ECT.
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FIGURE 111.14: ATPase specific activities of erythrocyte membranes
from depressed patient group II before their first
ECT and at follow-up
B BEFORE FIRST ECT (7)
] FOLLOW - UP ( 7 )
Activities are expressed as nmol Pi/hr/mg protein.
Values given are means ± SD.
Comparisons made by Wilcoxon test for pair differences.
* P < 0.02 + P < 0.05
Numbers in parentheses refer to the number of subjects
in each group.
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5. ARRHENI US PLOTS OF Na+ + K+ - ATPase ACTIVITY AND OUABAIN BINDING
IN ERYTHROCYTES
ATPase specific activities in erythrocyte membranes from
untreated unipolar depressed patients and controls, were measured at
different temperatures, which enabled Arrhenius plots to be con¬
structed, thus allowing calculation of activation energies for the
enzyme. Ouabain binding was also measured in erythrocyte membranes
from these subjects. Table 111.37 gives details of the groups of
subjects investigated (patients in the unipolar depressed group II
are also represented in the unipolar depressed group l). Group I was
significantly older than the control group.
(a) Table 111.38 gives values for Na++ K+- ATPase activities,
measured at 37°C, from the three groups studied. Patient group I
has a signff i cantly reduced Na++ K+ - ATPase activity, while patient
group II has a value which is slightly reduced compared to the control
value.
(b) Apparent activation energies of Na++ K+- ATPase (obtained
from Arrhenius plots) of erythrocyte membranes from control subjects
and unipolar depressed patient group I are shown in Table 111.39. The
Arrhenius plots for the ATPase activities gave two straight lines
which intersected at about 25°C. Activation energies were calculated
for each subject using both lines which gave values for the reaction
above 25°C and values below 25°C. The values for the unipolar
depressed patients do not differ significantly from those of the
control subjects.
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TABLE 111.37: Groups investigated and estimations performed
Subjects Estimations performed Age Sex
Controls (8)
Erythrocyte membrane Na++ K+-
ATPase activities at different
temperatures for Arrhenius
plots.









Erythrocyte membrane Na+ + K+-










Erythrocyte membrane Na+ + k+-
ATPase activity.





Values are expressed as means±SD.
Numbers in parentheses refer to the number of subjects in each
group.
Comparisons made with control values by Wilcoxon test for two
samples.
* p < 0.02
156
TABLE 111.38: Na+ + K+ - ATPase specific activities of
erythrocyte membranes from control













Activities are expressed as nmol Pj/hr/mg protein.
Values are given as means ± SD.
Comparisons made with control value by a Wilcoxon test
for two samples.
I P<0.01 + P < 0.05
Numbers in parentheses refer to the number of subjects
in each group.
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TABLE 111.39: Apparent activation energies of Na++K+-
ATPase (obtained from Arrhenius plots) of
erythrocyte membranes from control subjects
and untreated unipolar depressed patients
Apparent activation
energy (E):
Group above 25°C below 25°C
Controls (8) 16.5 ± 3.3 32.3 ± 5.7
Unipolar depressed
patients I (10) 15.7 ± 1.9 29.5 ± *».8
Activation energies are expressed as Kcal/mole.
Values are given as means ± SD.
Numbers in parentheses refer to the number of
subjects in each group.
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(c) Table 111.40 shows specific ouabain binding in erythrocyte
membranes from controls and the unipolar depressed patient group II.
A Scatchard analysis of the binding gave a straight line indicating
a single population of non-interacting sites. Ouabain binding is
significantly reduced in the patient group compared to controls.
Non-specific ouabain binding amounted to approximately 20% of the
total binding.
Dissociation constants were also calculated using Scatchard
plots. No difference in values was found to exist between controls
and untreated patients (Table 111.41).
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TABLE I I I.AO: Ouabain binding in erythrocyte membranes
from control subjects and untreated
unipolar depressed patients
Group Ouabain binding




M (A) 323 ± 160"
Ouabain binding is expressed as f moles ouabain bound/
mg protein.
Values are given as means ± SD.
Comparison made by a Wilcoxon test for two samples.
* P < 0 .0 2
Numbers in parentheses refer to the number of subjects
in each group.
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TABLE 111.41: Dissociation constant (Kp) of ouabain -
receptor complex in erythrocyte membranes
from control subjects and untreated
unipolar depressed patients






Kq is expressed in units of concentration (nM).
Values are given as means ± SD.
Numbers in parentheses refer to the number of
subjects in each group.
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6. OTHER STUDIES
(a) ATPase activity was measured in platelet membranes, from 10
control subjects (5 female, 5 male; age 31 ±8 years), using
incubation media that contained varying concentrations of magnesium,
sodium, potassium and calcium.
Table III. ^+2 shows Mg2+- ATPase activities when the magnesium
concentration of the media is varied, all other constituent con-
• 9+
centrations remaining constant as detailed in Section II. Mg
ATPase activity increases to a maximum when the magnesium concentration
is between 6 and 10 mM. Increasing the concentration above that
level causes a decrease in activity.
Table I I I.A3 shows Na++ K+- ATPase activities when the con¬
centrations of sodium and potassium in the incubation mixture were
changed. Maximal activities are obtained when the sodium concentration
is 100 mM and the potassium concentration is 5 rnM.
Ca2+-ATPase activity was estimated in the presence of varying
concentrations of calcium (Table III.44), but activity could not be
detected in any of the preparations. Increasing the concentration of
calcium caused a marked decrease in activity of Ca2++ Mg2+- ATPase
activity (values not given), which in the platelet membrane preparation
is equal to the Mg2+-ATPase activity as no Ca2+- ATPase activity
is detected. This presumably was due to either a direct action of
calcium on Mg2+-ATPase activity or a change due to changing
osmolarities of the incubation media.
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TABLE 111.42: Mg2+-ATPase specific activities of platelet
membranes, in the presence of varying concentra¬
tions of Mg^"1- (all other incubation constituents
kept constant), from 10 control subjects (5F, 5M)
. Mg2+-ATPaseconcentration 3
(mM) activity
1 200 + 20
2 31*t + 39
3 400 + 69
4 516 + 54
5 570 + 52
6 742 + 60
10 750 + 37
20 650 + 59
30 526 + 51
Activities are expressed as
nmol Pj/hr/mg protein.
Values given are means ± SD.
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TABLE I I I.A3: Na++ K+- ATPase specific activities of platelet
membranes, in the presence of varying concentra¬
tions of Na+ and K+ (all other incubation con¬
stituents kept constant), from 10 control subjects
(5F, 5M)
Na+ K+ Na+ + K+-
concentration concentration ATPase
(mM) (mM) activity
50 68 ± 17
100 - 101 ± 30
150 - 69 ± 29
- 2.5 AO ± 10
- 5 37 ± 9
- 7.5 A6 ± 17
50 2.5 98 ± 19
50 5 121 ±
50 7.5 1A9 ± A9
100 2.5 139 ± 21
100 5 179+20
100 7.5 163 ± 1A
150 2.5 153 ± 17
150 5 130 ± 21
150 7.5 101 ± AO
Activities are expressed as nmol Pj/hr/mg
protein.
Values given are means ± SD.
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TABLE 111.kk: Ca2+- ATPase specific activities of platelet
membranes, in the presence of varying concentra¬
tions of Ca2+ (all other incubation constituents








0.1 n i 1
0.15 ni 1
0.5 ni 1
1 n i 1




Activities are calculated as
nmol P;/hr/mg protein.
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(b) The effect of different anticoagulants; sodium citrate and
heparin, on platelet and erythrocyte membrane ATPase activities was
investigated in 10 control subjects (5 female, 5 male; age 25 ± 5
years) .
Table IiI .45 shows the ATPase activities found in platelets.
Preparing the membranes from heparinized blood caused a marked
reduction in Na++ K+- ATPase and Mg2+- ATPase activity compared with
citrated blood. Ca2+ - ATPase activity was not detected in platelet
membranes frora either sodium citrated or heparinized blood. Protein
content in the platelet membranes prepared from heparinized blood
was greatly reduced compared with that in citrated blood (Table I I 1.46).
ATPase activity and protein content of erythrocyte membranes
from sodium citrated blood and heparinized blood were not significantly
different (Tables I I 1.47 and 111.48).
(c) Altering the method of preparation of platelet membranes causes
a change in the ATPase activity measured (Table 111.49). Values
shown are from 6 control subjects (4 female and 2 male; age 36 ± 7
years). Maximal activity can be measured when 100 yl Triton X100 and
2 - ml water are added and the preparation is frozen and thawed twice
(the method routinely used for platelet membrane preparation). The
Mg2+- ATPase activity measured does not seem to be affected by the
addition of Triton X100 or freezing and thawing, however Na+ + K+-
ATPase activities are increased by these procedures. Adding 200 yl
Triton X100 results in the same level of activities as that produced
by 100 yl additions. Ca2+_ ATPase activity could not be detected in
any of the preparations.
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TABLE I I I ,k5 ' ATPase specific activities of platelet membranes,
prepared from blood anticoagu1ated with either sodium
citrate or heparin, from 10 control subjects (5F, 5M)
- Na+ + K+- Mg2+- Ca2+-
Preparation ATPase ATPase ATPase
activity activity activity
Sodium citrated blood 163 ± 29 769 ± 50 ni 1
Heparinized blood 5*4 ± 22* 6A2 ± est n i 1
Activities are expressed as nmol Pj/hr/mg protein.
Values given are means ± SD.
Comparisons made by Wilcoxon test for pair differences.
t P < 0.01
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TABLE 111.46: Protein content of platelet membranes, prepared
from blood anticoaqulated with either sodium





Sodium citrated blood 355 ± 30
Heparinized blood 110 ± 46*
Values given are means ± SD.
Comparison made by Wiicoxon test for pair
differences.
I P< 0.01
Concentrations are expressed as yg platelet
membrane protein per ml whole blood.
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TABLE 111.47: ATPase specific activities of erythrocyte membranes,
prepared from blood anticoaqulated with either sodium
citrate or heparin, from 10 control subjects (5F, 5M)
Na+ + K+- Mg2+- Ca2+-
ATPase ATPase ATPase
Preparation activity activity activity
Sodium citrated blood 354 ± 44 300 ± 58 597 ± 60
Heparinized blood 348 ± 42 309 ± 54 589 ± 58
Activities are expressed as nmol P; /hr/mg protein.
Values given are means ± SD.
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TABLE III.48: Protein content of erythrocyte membranes,
prepared from blood anticoaqu1ated with
either sodium citrate or heparin, from
10 control subjects (5F, 5M)
Protein content
Preparation yg protein/ml
Sodium citrated blood 986 ± 89
Heparinized blood 972 ± 95
Values given are means ± SD.
Concentrations are expressed as yg erythrocyte
membrane protein per ml whole blood.
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TABLE I I I .49: Effect of change in platelet membrane preparation on
ATPase specific activities of platelet membranes from
6 control subjects (4F, 2M)
Method of preparation: Na+ + K+- Mg2+-
T riton X100 Wate r Freezing- ATPase ATPase
added added thawing activity activity
_ 2 - ml twi ce 83 + 23 739 ± 29
- 2 - ml once 86 + 19 7^0 ± 32
- 2 - ml - 69 + 21 738 ± 36
100 Pi 2 - ml twi ce 127 + 20 750 ± 31
100 Pi 2 - ml on ce 101 + 20 746 ± 29
100 Pi 2 - ml - 96 + 19 732 ± 30
200 Pi 2 - ml twi ce 129 + 18 739 ± 28
200 Pi 2 - ml once 113 + 19 752 ± 31
200 Pi 2 - ml "" 100 + 22 741 ± 29
Activities are expressed as nmol Pj/hr/mg protein.
Values given are means ± SD.
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(d) Haemoglobin and protein content of platelet and erythrocyte
membrane preparations from 6 control subjects (4 female, 2 male;
age 36 ± 7 years) is shown in Table 111.50. Haemoglobin amounts to
approximately 6% of the total protein content in the platelet
preparation and about 5% of the total in the erythrocyte preparation.
(e) ATPase specific activities of platelet membranes and intact
washed platelets from 10 control subjects (5 females, 5 males; age
bl ± 9 years) are shown in Table 111.51. Ca2+- ATPase activity
could not be detected. Na++ K+- ATPase and Mg2+- ATPase activities
are significantly less in the intact washed platelets than in the
platelet membrane preparation ('intact values' are approximately 37%
and 10% respectively of the 'membrane values').
(f) Electron micrographs shown are typical examples obtained from
samples processed from 35 control subjects (15 female, 20 male; age
39 ± 10 years.
Figures I I 1.19 and 111.20 show electron micrographs of isolated
intact platelets. Figure 111.21 shows an enlargement of an intact
platelet present in Figure 111.19- 5 - HT containing granules,
glycogen particles and pseudopodia can be identified.
Platelet membrane preparations (routinely prepared; 100 pi
Triton X100 added, frozen and thawed twice) were also examined.
Figure I I 1.22 shows that the preparation is well disrupted (compare
with Figures 111.19 and I I I .20) . Not all fields viewed in the
electron microscope, of these preparations, showed quite as much
disruption. Figure I I 1.23 shows a typical example. The 5 - HT
granules are easily identified in this micrograph, having a
characteristic 'bulls-eye' appearance.
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TABLE I I 1.50: Haemoglobin and protein content of platelet
and erythrocyte membrane preparations from




Platelet membranes 21 ± 7 368 ± k2
Erythrocyte membranes 50 ± 12 965 ± 89
Values given are means ± SD.
Concentrations are expressed as yg haemoglobin
or protein per ml whole blood.
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TABLE 111.51: ATPase specific activities of platelet membranes and
intact washed platelets from 10 control subjects
(5F, 5M)
Na+ + K+- Mg2+- Ca2+-
Preparation ATPase ATPase ATPase
activi ty activity activity
Platelet membranes 124 ± 42 732 ± 69 ni 1
Intact washed platelets 46 ± 15* 76 ± 26* ni 1
Activities are expressed as nmol Pj/hr/mg protein.
Values given are means ± SD.
Comparisons made by Wilcoxon test for pair differences.
* P < 0.01
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FIGURE 111.21: Electron micrograph of an isolated intact human
platelet. 5 ~HT granules (Gra), glycogen particles
(Gly) and pseudopodia (P) can be identified
Magnification x 10^,850
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FIGURE III.22: Electron micrograph of human platelet membrane
preparation. Mitochondria can be identified (M)
Magnification x 69,000
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FIGURE 111.23: Electron micrograph of human platelet membrane
preparation with 3~HT granules arrowed
Magnification x 66,500
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(g) The variation which occurred in various platelet and erythrocyte
parameters was examined in a female control subject over the course
of a year (subject was 22 years old at start of study).
i) Tables 111.52 and 111.53 show seasonal and menstrual cycle
variation, respectively,in ATPase activities in platelet membranes.
In Table 111.53 day 1 refers to the day on which menstruation
started. There appears to be more variation in Na++ K+ - ATPase
activity during one menstruation cycle than in different seasons
of the year. Mg2+- ATPase activities do not seem to vary much.
Tables 111.5^ and 111.55 show seasonal and menstrual cycle
variation in ATPase activities in erythrocyte membranes. There
again appears to be more variation during the menstrual cycle in
Na+ + K+ - ATPase activities than from season to season. Mg2+ -
ATPase and Ca2+- ATPase activities vary during the menstrual cycle
but not to quite the same extent as does the Na++ K+- ATPase
activity. Ca2+- ATPase activities do not seem to vary much from
month to month. Mg2+- ATPase activities, however, show a slightly
greater seasonal variation.
ii) A big variation during the menstrual cycle and seasonal fluctuations
can be seen in whole blood 5 " HT content (Tabl es I 1 I.56 and I I I.57)•
iii) Variation during the menstrual cycle and seasonal fluctuation can
be seen in 5~ HT uptake and platelet counts (Tables 111.58 and
I I I.59).
It should be noted that when seasonal variation was examined, blood
samples were taken from the subject at approximately the same point in
the menstrual cycle in any month.
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TABLE I I I.52: Seasonal variation of ATPase specific
activities of platelet membranes from





















Activities are expressed as nmol P j/
hr/mg protein.
Numbers in parentheses refer to the
activity expressed as a percentage of
the value obtained in February.
181
TABLE 111.53". Variation of ATPase specific activities
of platelet membranes during the menstrual
cycle of a control subject
Day of Na+ + K+- Mg2+-
blood sampling ATPase ATPase
(April -May 1978) activity activity
1 153 (100%) 769 O O <5^
6 109 (71%) 758 (98%)
13 200 (131%) 7^9 (97%)
22 296 (193%) 750 (97%)
30 1A9 (97%) 772 oo
Activities are expressed as nmol Pj/hr/mg
protein.
Numbers in parentheses refer to the activity
expressed as a percentage of the value
obtained on day 1 of the cycle.
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TABLE 111.5**: Seasonal variation of ATPase specific
activities of erythrocyte membranes from a
female control subject
Na++K+- Mg2+- Ca2+-
Month ATPase ATPase ATPase
(1978) activity activity activity
February 372 OO 259 O O cN? 601 (100%)
May 297 (80%) 272 (105%) 589 (98%)
August 290 (78%) 321 (12*»%) 562 (93%)
November 329 (88%) 299 (115%) 578 (96%)
Activities are expressed as nmol Pj/hr/mg protein.
Numbers in parentheses refer to the activity
expressed as a percentage of the value obtained in
February.
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TABLE 111.55: Variation of ATPase specific activities of
erythrocyte membranes during the menstrual
cycle of a control subject
Day of Na++ K+- Mg2+- Ca2+-
b1ood samp 1ing ATPase ATPase ATPase
(Apri1 - May 1978) activity activity activity
1 264 (100%) 246 (100%) 650 (100%)
6 287 (109%) 259 (105%) 609 (94%)
13 379 (1*43%) 272 (110%) 569 (87%)
22 300 (114%) 269 (109%) 532 (82%)
30 152 (57%) 276 (112%) 691 (106%)
Activities are expressed as nmol Pj/hr/mg protein.
Numbers in parentheses refer to the activity expressed as
a percentage of the value obtained on day 1 of the cycle.
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TABLE I I 1.56: Seasonal variation of whole blood




5 ~ HT content
(ng/ml)
January 209 (100%)




Numbers in parentheses refer
to the concentration expressed
as a percentage of the value
obtained in January.
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TABLE 111.57: Variation of whole blood 5~ HT content
during the menstrual cycle of a control
subject
Day of
blood sampling 5 - HT content






Numbers in parentheses refer to the concentration
expressed as a percentage of the value obtained
on day 1 of the cycle.
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TABLE III.58: Seasonal variation of 5~ HT uptake (Km
and Vmax values) into platelets and





January 0.44 oM>OO 99 (100%) 389 (100%)
Apr i 1 0.51 (116%) 87 (87%) 362 (93%)
June 0.147 (107%) 90 (91%) 299 (77%)
September O -fc- OO (109%) 89 (90%) 345 (89%)
November 0.43 (98%) 97 (98%) 309 (79%)
Km values are expressed in units of pM,
Vmax in units of pmol 5~HT/2 x 107 platelets/5 mins
and platelet counts as 103 platelet/mm3 blood.
Numbers in parentheses refer to the activity or count
expressed as a percentage of the value obtained in
January.
187
TABLE 111.59: Variation of 5~ HT uptake (Km and
Vmax values) into platelets, and
platelet count, during the menstrual






1 0.40 (100%) 89 (100%) 269 (100%)
8 0.39 (97%) 75 (84%) 273 (101%)
15 0.43 (107%) 63 (71%) 300 (111%)
23 0.47 (117%) 52 (58%) 309 (115%)
30 0.41 (102%) 61 (68%) 240 (89%)
Km values are expressed in units of pM,
^max 'n units of pmol 5"HT/2 x 107 platelets/5 mins
and platelet counts as 103 platelets/mm3 blood.
Numbers in parentheses refer to the activity or count
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1. PLATELET AND ERYTHROCYTE MEMBRANE ATPase ACTIVITIES
The results of the platelet study (described in Section III,
part 1 of this thesis) show that blood platelets from patients
with affective disorders do not differ to any great extent from
those of corresponding control subjects in activities of the
different ionic ATPases. This result is interesting in view of the
proposal of Naylor et al (1973) that depression involves a general
decrease in Na++ K+ - ATPase activity. These workers found that an
increase in erythrocyte membrane Na+ + K+ - ATPase activity was
associated with a recovery from depression. That erythrocyte
membranes from depressed patients do indeed have a reduced Na+ + K+-
ATPase activity, compared to control subjects, was shown by Hesketh
et al (1977).
It was considered necessary to confirm the observations made
in the platelet study by simultaneously examining platelet and
erythrocyte membrane ATPase activities from the same patients
(Section I I I,part 2 of this thesis). In this study the number of
groups investigated was restricted. A unipolar depressed group of
patients was included because Hesketh et al (1977) had found the
most marked reduction in erythrocyte membrane Na+ + K+ - ATPase
activity in this group. It was hoped that by selecting such a group,
the probability would be increased of detecting any Na++ K+ - ATPase
abnormality. A bipolar manic group was selected for study because
an ATPase activity change was not expected in these patients and
it was hoped that they might act as hospitalized controls. However,
bipolar manics are not a group that have been investigated much,
probably because of the difficulty in obtaining blood samples from
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them and the need to administer treatment quickly. The inclusion
of this group, provided in any case, valuable additional information.
The finding in this study that there is a reduced activity in
erythrocyte membrane Na++ K+- ATPase confirmed the work reported by
Hesketh et al (1977). It was shown, once again, that patients'
platelet membrane ATPase activities seemed no different from those
of control subjects.
A reduced Na++ K+ - ATPase activity in erythrocyte membranes
from unipolar depressed patients was also found in three other
studies reported in this thesis. Ill patients prior to mianserin
or amitripty1ine therapy (Section I II, part 3 (d)), patients about
to receive ECT (Section I I I, part A) and a small group whose blood
samples were used to investigate lipid content and ouabain binding
in erythrocytes (Section I I I, part 5 (a)), all showed Na+ + K+ - ATPase
activity less than normal. In the study reported in Section III,
part 3 (d), platelet ATPase activities were also estimated. They
were found to be no different from those in control subjects.
The question of why such a change occurs in the erythrocyte
membrane and not in the platelet is to some extent unresolved.
However, various explanations can be offered, but the most important
deduction from these studies is that changes in ATPase activity in
the erythrocyte membrane associated with depressive illness may not
be general to all cell membranes in the body. This implies that
detection of changes in a peripheral cell membrane and extrapolation
of such changes to central neurones is still an open question.
There are, however, certain differences between the erythrocyte
and the blood platelet membrane preparations used for ATPase assays.
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Platelet membranes assayed in this study were heterogeneous in
nature, having membrane components from the plasma membrane, mito¬
chondria, granule membranes and dense tubular, microtubular and
cannalicular systems. Separation and purification of subcellular
components was not carried out, due to restrictions in the volume
of blood sample which could be obtained. In fact, carrying out
enzyme assays on separated platelet plasma membranes would require
fairly large volumes of blood (Barber and Jamieson, 1970; Siegel,
Burri, Weibel, Bettex-Ga11 and and Luscher, 1971); which would have
been totally impracticable with this patient material. On the other
hand, it is relatively easy to obtain sufficient isolated washed
plasma membranes from erythrocytes from a sample of ten to twenty
millilitres of blood.
It would appear from results presented in Section I I I, part 6,that
optimal conditions were used for the estimation of Na++ K+- ATPase
activity. The use of 6 mM Mg2+, 100 mM Na+ and 5 mM K+ in the
incubation medium would have been expected to produce maximal
activity in any samples assayed.
Using sodium citrate as anticoagulant, compared with heparin,
which was used when erythrocyte membranes were prepared, did not
decrease observable Na++ K+ - ATPase activity. In fact, it is
interesting to observe that the use of heparin anticoagulant, when
platelet membranes were to be prepared, produced quite a large
reduction in platelet membrane Na+ + K+ - ATPase activity. As the
protein content was found to be reduced in such samples, it is
possible that the difference observed is due to heparin being
a less efficient anticoagulant. Platelets might therefore aggregate
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more readily, and these aggregates might be spun down into the red
blood cell fraction. Such an explanation necessitates that the
platelets, left unaggregated in the platelet rich plasma, have a
lower ATPase activity than those removed. Day, Scrutton and Holmsen
(1973) have provided evidence that there are populations of platelets
having differing contents of calcium and magnesium. It is possible
there are also platelet populations showing differing ATPase
activities. It may also be that heparin has a direct action on
platelet ATPase activity, which persists even when the heparin is
no longer in contact with the membranes. Heparin does not, however,
seem to affect erythrocyte membrane ATPase activity. An anomaly
exists in the observation that the protein content of the erythrocyte
membrane fraction prepared from heparinized blood is not greater
than that prepared from blood anticoagu1ated with sodium citrate.
This might be expected due to contamination by platelet aggregates.
However, it is quite possible that these aggregates are lighter than
the erythrocytes, and are removed in the washing stages during the
preparation of erythrocyte membranes.
The use of Triton X100, and the process of freezing and thawing,
although not affecting platelet membrane Mg2+ - ATPase activity
greatly, seemed to activate Na++ K+- ATPase activity. However, it
should be noted that Triton X100 was not used to disrupt the erythrocyte
membrane preparation. In view of the studies of Bramley, Coleman and
Finean (1971) and Hanahan, Ekholm and Hildenbrandt (1973), who
showed that the properties of the erythrocyte membrane preparation
depended markedly on the conditions used during preparation, the
procedure described in this thesis for the preparation of erythrocyte
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membranes would be expected to produce membranes exhibiting their
total ATPase capacity. Similar studies, however, have not been
carried out using platelet membranes.
Platelet and erythrocyte membranes showed approximately the
same degree of haemoglobin contamination. it seems unlikely, then,
that haemoglobin could cause spurious differences between platelet
and erythrocyte preparations.
Na++ K+- ATPase activity could be detected in intact washed
platelets. It is not known if this activity represents a true ecto-
ATPase (i.e. an enzyme which splits ATP on the outer face of the
cell membrane) or if it is due to the Na+ + K+ - ATPase activity of the
sodium pump (i.e. the enzyme which splits ATP on the inner face of
the cell membrane) in the platelet. It would be interesting to know
if the intact washed platelets used had an increased permeability
to ATP, which would enable sodium pump Na++ K+- ATPase activity to
be observed. No estimate can be made, on the basis of the results
given here, of the contribution of any true ecto-ATPase to Na+ + K+ -
ATPase activity measured in disrupted platelets.
Electron micrographs of platelet membranes showed that the
isolation procedures used produced samples which were well disrupted,
which would hopefully thus allow full expression of any Na+ + K+ -
ATPase activity present. However, it is interesting to consider the
micrographs of intact platelets. The morphological appearance of
these platelets (Figure 111.19) is very similar to those used by
Siegal et al (1971), prior to homogenization. Many pseudopodia
are seen in both preparations. However, platelets prepared by
Kinlough-Rathbone, Mustard, Packham, Perry, Reimers and Cazenave
(1977) appear to have retained their normal disc shape. Such observed
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differences may be due to differences in preparation of samples for
electron microscopic analysis. It is worth considering, though,
the possibility that platelet membranes used in studies described
in this thesis, might have been prepared from platelets which had
undergone the first stages of aggregation. It is quite possible
that such transformations would influence the observed activity of an
enzyme which is known to span the plasma membrane. It would have
been useful to prepare platelet membranes from reversibly and
irreversibly aggregated platelets to observe if a change in Na+ + K+ -
ATPase activity resulted.
Another factor may lie in the different relative distribution
of the ATPases in the erythrocyte and platelet membrane. In the
blood platelet the Mg2+ - /Na++ K+ - ATPase ratio was found to be
approximately 6:1, while in the erythrocyte the corresponding ratio
was 1:1. It would appear that the relatively lower activity of
Na+ + K+ - ATPase does not necessarily prevent detection of activity
changes occurring in illness, since McCoy, Segal, Bayer and Strynadka
(197*0 observed a reduction in Na++ K+- ATPase activity in blood
platelets from patients with Down's syndrome. Their preparation was
also heterogeneous since ultrasonic disintegration was used to
disrupt the platelet pellets and no subsequent purification was
carried out. However, it should be noted that McCoy et al (197*0
measured Na++ K+- ATPase activity in the presence of sodium, potassium
and magnesium. In terms of the conditions used in this thesis, such
activity would be designated as 'total'. It is interesting to note,
though, that McCoy et al (197*+) detected a reduced i nt rap 1 atel e t
potassium and an increased intraplatelet sodium concentration in
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platelets from patients with Down's syndrome. These findings would
suggest that Na+ + K+ - ATPase activity was in fact reduced in these
platelets. Values obtained in this thesis for platelet ATPase
activities are in approximate agreement with those obtained by other
workers (Table IV.1). It should be noted that Moake et al (1970)




Barber and Jamieson, 1970
Moake, Ahmed, Bachur
and Gutfreund, 1970
measured Mg2+- ATPase activity in the presence of MgCl2 and NaCl,
whereas results in this thesis refer to activities in the presence
of MgCl2 alone. Values given by McCoy et al (197*0 could not be
compared as these workers quoted their activities in units of nmoles
AT32P/hr/108 platelets.
Ca2+- ATPase activity could not be detected with the platelet
preparation used in this study. This enzyme activity has been
measured in human platelets by several workers (Chambers, Salzman
and Neri, 1967; Mason and Saba, 1969; Barber and Jamieson, 1970;
French, Holmsen and Stormorken, 1970; Coffrey and Middleton, 1975).
Intact washed platelets (Chambers et a1, 1967; Mason and Saba,
1969; Coffrey and Middleton, 1975), pure membrane fractions from
platelets which had been hypotonica11y lysed after loading with




which had been frozen and thawed, and subcellular fractions prepared
from these lysates (French et al, 1970) and soluble and particulate
fractions from platelet preparations which had been subjected to
sonication (Coffrey and Middleton, 1975) were used by these workers
in the estimation of ATPase activity.
These workers all used different anticoagulants. Chambers
et al (1967) and Barber and Jamieson (1970) used acid citrate
dextrose, which was also used by French et al (1970), with the
addition of EDTA. The anticoagu1 ant used by Mason and Saba (1969)
contained trisodium citrate dihydrate, citric acid and glucose.
Heparin was used by Coffrey and Middleton (1975).
Concentrations of ions present in the ATPase incubation media
also varied between the groups. Chambers et al (1967) and Barber
and Jamieson (1970) both used 2.5 mM Mg2+, 1.25 mM Ca2+ and 1 pM
ATP. Mason and Saba (19&9) state in their paper that concentrations
of Ca2+, Mg2+, Na+, K+ and ATP were varied to determine optimal
conditions, but unfortunately they do not state what those optimal
conditions were. French et al (1970) used either 10 mM Ca2+ or Mg2+
and A00 pM ATP. Coffrey and Middleton (1975) employed concentrations
of 5 mM Ca2+ or Mg2+ and 2 mM ATP. It is interesting to note that
French et al (1970) found that the ATPase activity in platelet
lysates in the presence of Ca2+ and Mg2+ together, was less than with
either ion separately. This suggested to them "that one enzyme and
not two major ATPases were involved". They found that increasing
concentrations of Mg2+, acting alone, produced an increase in
enzymic activity up to 6 mM Mg2+, and above this concentration no
r\ X
change was observed. In contrast, increasing concentrations of Caz
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were found to give no significant change below 5 mM. Above 5 mM,
the ATPase activity increased with increasing Ca2+ concentration,
and did not level off below 15 mM. However, Chambers et al (1967)
found that in intact washed platelets, in the presence of Mg2+,
addition of Ca2+, stimulated enzyme activity. Both groups found
that Mg2+ alone stimulated activity more than Ca2+ alone. It is
interesting to note that Chambers et al (1967) investigated the
action of 1.25 mM Ca2+ at only three Mg2+ concentrations, namely:
1.25, 2.5 and 5 mM. From their results it would appear that (5 mM
Mg2+ + 1.25 mM Ca2+) produced less activity than (2.5 mM Mg2+ +
1.25 mM Ca2+). It may be that if this group had used higher
magnesium concentrations they would have got results similar to those
of French et al (1970). It is also possible that the two groups are
monitoring activities of two distinct ATPases.
As Chambers et al (1967) give their ATPase activities in cpm
and in moles P|/hr/ml and Mason and Saba (1969) give their values
in units of mg Pj/hr/Ax108 platelets, it is rather hard to compare
their results with those presented in this thesis. There exists
some confusion in the results quoted by Barber and Jamieson (1970).
It is not clear from their paper if values quoted are for Mg2+- or
Ca2+ - ATP ase activities, so once again a comparison is difficult.
However, values quoted by Coffrey et al (1975), for non-asthmatic
children, can be readily compared with activities quoted in this
thesis (Table IV.2). It can be seen that the value Coffrey and
Middleton (1975) obtain for Mg2+- ATPase activity in sonicated
platelets is approximately half the value reported in this thesis
for platelet membranes, and a quarter of that reported by Moake
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TABLE IV.2: ATPase activities measured in platelet preparations





Intact platelet Mg2+ - ATPase 160
Intact platelet Ca2+- ATPase 100
Sonicated platelet Mg2+- ATPase 328
Sonicated platelet Ca2+ - ATPase 208
et al (1970). The subjects used by Coffrey et al (1975) were
children. This may be the reason for the discrepancy. Values
obtained by French et al (1970) for Mg2+-ATPase activity are in
better agreement (Table IV.3). The value reported by French et al
TABLE IV.3: ATPase activities measured in platelet lysates by
French et ~al (1970)
ATPase activity
nmol Pj/hr/mg protein
No divalent cations present 22k
10 mM Mg2+ 876
10 mM Ca2+ 399
10 mM Mg2+ + 10 mM Ca2+ 2k]
8 mM EDTA 28
(1970) for Ca2+-ATPase activity is slightly higher than that
reported by Coffrey and Middleton (1975). This may be due to the
slightly different Ca2+ concentrations used in each case. It is
interesting that the value obtained by French et al (1970) when no
divalent cations were present, and presumably no Na+ or K+ either,
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is very similar to the values reported in this thesis for Na++K+-
ATPase activities. Activities of platelet Na+ + K+ - ATPase reported
in this thesis are definitely sensitive to Na+ and K+, as shown in
Section 111, part 6 (a). It is possible to compare results obtained
by Chambers et al (196?) with those obtained by Mason and Saba
(1969) (Table IV.A), after recalculation of their data. Chambers
TABLE IV.A: Ca2+- ATPase activities in intact washed platelets
Chambers et al (1967) 1270 nmol P]/hr/6x105 platelets
6A0 nmol P;/hr/5x105 platelets
Mason and Saba (1969) 7789 nmol P;/hr/Ax10® platelets
et al (1967) report two different values in their paper which are
70 to 100 times greater than the activity quoted by Mason and Saba
(1969). It can be seen that there exists some variation in values
quoted by workers, which may be due to differences in preparation
of the platelet samples and in the ATPase assay conditions employed.
It has been suggested that the Ca2+- and Mg2+ - stimu1ated
ATPase activity present in the platelet is due to the presence of
thrombosthenin, a contractile protein (Bettex-Ga11 and and Luscher,
1961 ; Hanson, Repke, Katz and Aledort, 1973). Bettex-Ga11 and and
Liischer (1961) have shown that thrombosthen i n purified from human
blood platelets is activated by magnesium and by calcium; the
latter having the more pronounced effect. Hanson et al (1973),
however, measured activity in either the presence of MgC12 and CaCl2
together (138 nmol P;/hr/mg protein) or MgC 1 2 alone (108 nmol P;/hr/
mg protein). It is somewhat surprising that a purified thrombosthenin
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preparation does not have a higher specific activity when one
considers values obtained in platelet lysates by other workers.
There exists some controversy as to the function of these ATPases.
Holmsen, Day and Stormorken (1969) consider there to be an intimate
relationship between thrombosthenin and the explosive platelet
release reaction. Other workers have suggested that ecto- ATPases
may play a part in cell adhesion. Jones (1966) and Salzman, Chambers
and Neri (1966) have suggested that aggregation or adhesion occurs
when a membrane bound contractile protein relaxes due to a decrease
in its ATPase activity. However, Robinson, Kress, Wagner and
Brinkhous (1965) consider that aggregation is due to an increase in
ATPase activity which produces a decrease in membrane bound ATP
and a resultant decrease-in surface charge of the platelet. Several
workers, using sulfhydryl inhibitors, ouabain, DTNB and DNP (Mason
and Saba, 1969; Saba, Rodman and Mason, 1969) have suggested that
there may be several ATPases present, but they are uncertain as to
which is the most important in aggregation. It has also been
suggested that the Ca2+- ATPase activity in the human platelet
reflects the presence of a calcium membrane pump (Robblee, Shepro and
Be 1amarich, 1 973) .
It is interesting to speculate why Ca2+- ATPase activity could
not be detected in the platelets of either patients with affective
illness or control subjects. Changing the concentration used in the
incubation medium (Table I I 1.44), using a different anticoagulant
(Table II 1.45), changing the platelet membrane preparation (Table
I I 1.49) and using intact washed platelets (Table 111.50 failed to
reveal any Ca^+- ATPase activity. It should be pointed out that in
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all assays performed, when Ca2+ was used in the incubation medium,
Mg2+ was always present at a concentration of 6 mM. It is possible
that if Mg2+ had been omitted, Ca2+- ATPase activity may have been
uncovered.
It can be appreciated that controversy arises because of the
relatively complex nature of the platelet. However, erythrocytes
can be used to produce membrane fractions which are free from
contamination by subcellular organelles. It is well established
that the Na+ + K+ - ATPase activity present in the erythrocyte membrane
is associated with active transport of sodium and potassium (Dunham
and Glynn, 1961; Skou, 1965; Whittam and Wheeler, 1970). In
addition to this ATPase activity dependant on Mg2+, stimulated by
sodium and potassium and' sensitive to ouabain, Dunham and Glynn
(1961) also detected an activity dependant on magnesium alone, which
was insensitive to ouabain. In addition they found calcium to
cause a stimulation of the ouabain-insensitive activity. Such
magnesium dependant (Mg2+- ATPase) and calcium stimulated magnesium
dependant activities (Ca2+ + Mg2+- ATPase) were also reported by
Wins and Schoffeniels (1966). As pointed out by Wins and Schoffeniels
(1966), the physiological function of the Mg2+- ATPase is unknown.
It could possibly reflect adenyl cyclase activity since adenyl
cyclase produces pyrophosphate which might be detected in the analysis
of inorganic phosphate.
Using potassium iodide fractionation Nakao, Nagano, Adachi and
Nakao (1963) were able to obtain two preparations from erythrocyte
membranes. One possessed Na+ + K+ - ATPase activity, which was
sensitive to ouabain, and the other contained an ouabain-insensitive
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Mg2+-ATPase which was not stimulated by sodium or potassium. These
workers suggested that the Na+ + K+ - ATPase and Mg2+-ATPase were
separate enzymes.
Drickamer (1975) studied ATPases by examining erythrocyte
membrane protein phosphorylation in the presence of magnesium alone,
calcium and magnesium, and finally sodium, potassium and magnesium.
Using gel electrophoresis he was able to separate three different
phosphory1ated proteins corresponding to the different ionic conditions.
He concluded that the three ATPases were distinct enzymes. The
available evidence suggests that in the erythrocyte, Mg2+- ATPase,
Na++ K+ - ATPase and Ca2+ + Mg2+- ATPase are distinct enzymes.
It has been suggested that the Ca2+ + Mg2+- ATPase and the
calcium pump of the erythrocyte membrane are manifestations of the
same system (Schatzmann, 1975). However, it has also been proposed
that this enzyme is associated with actomyosin-1ike protein in
erythrocyte membranes (Wins and Schoffenie1s, 1956). The physiological
function of this ATPase might be to maintain the biconcave disc
shape of the red blood cell.
Ca2+ + Mg2+- ATPase activity could be measured in erythrocyte
membranes from patients and control subjects, although such activity
was not observed in their platelet membranes. A reduction in Ca2+ +
Mg2+- ATPase activity was observed in erythrocyte membranes from
bipolar manics (Section III, part 2). Ca2++ Mg2+- ATPase activity
was found to be normal in all groups of unipolar depressed patients
examined. Considering the importance of calcium in cell function,
this observation is interesting. Calcium plays a crucial role in
neurotransmitter release (Katz and Miledi, 1970; Rahamimoff,
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Rahamimoff, Binah and Meiri, 1975). However, it seems unlikely that
Ca2+ + Mg2+-ATPase activity in the erythrocyte could reflect events
concerning calcium movements in neuronal tissue (i.e. in the brain).
It is not known from the estimations performed, if the change observed
in Ca2+ + Mg2+ - ATPase activity, was due to a change in the activity
of the calcium pump or of the proposed contractile protein of the
erythrocyte.
The effects of various therapies on platelet and erythrocyte
membrane ATPase activities were investigated. Hesketh et al (1977,
1978) had found that in unipolar depressed patients with reduced
erythrocyte membrane Na+ + K+ - ATPase activity, long term treatment
with lithium and subsequent recovery, caused the activities to return
to normal. They also folind that Mg2+- ATPase activity in the
erythrocyte membranes was increased above control values, after
lithium therapy. It was shown by these workers that the change in
activity of Na++ K+- ATPase was due to the recovery process, and that
the Mg2+- ATPase change was solely a drug effect, i.e. lithium-
treated patients who had not recovered from their depression had
reduced Na++ K+- ATPase activities. Hesketh et al (1978) had found
changes in Mg2+- ATPase activities after three weeks of lithium
administration, when recovery in these patients "was at most only
partial". At this time no change was observed in Na+ + K+ - ATPase
activity.
It had been hoped to extend Hesketh's observations, and possibly
monitor an earlier change, by studying platelets at five days, three
weeks and three months after lithium therapy had commenced. However,
it was shown that lithium administration and recovery did not appear
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to influence platelet ATPase activity. Although an action by lithium
on platelet Na+ + K+ - ATPase activity was perhaps not to be expected,
as the activities were normal when the patients were ill, an effect
on Mg2+- ATPase activity might have been expected. Unfortunately, it
was possible to investigate only a few patients receiving lithium.
As a result, conclusions drawn from this part of the study can only
be tentative. No change in platelet Mg2+ - ATPase activities was
observed in control subjects taking lithium. This would affirm that
lithium administration does not affect the Mg2+- ATPase of the platelet.
However, lithium in a concentration expected to be present in plasma
therapeutically, produced an in vitro stimulation of Mg2+- ATPase
activity in platelet membranes from control subjects. This result
is interesting in view of the fact that lithium in vitro has been
shown to have no effect on Mg2+ - ATPase in other tissues (Gupta and
Crollini, 1975). The stimulation shown by lithium would tend not to
support the view that lithium exerts its effects by means of competition
with magnesium for magnesium-dependant enzymes (Birch, 1973).
Neither mianserin nor amitripty1ine was found to influence
platelet ATPase activities when present in vivo or in vitro.
However, when erythrocyte membranes were prepared from unipolar
depressed patients receiving either mianserin or amitripty1ine, it
was found that drug treatment and recovery resulted in Na++ K+ -
ATPase activities approaching normal values. No effect was observed
in the activities of the other ATPases present in the erythrocyte
membrane. However, as all patients in this study recovered, it was
not possible to dissociate drug effects from the recovery process,
as Hesketh et al (1978) had done. Neither mianserin nor amitripty1ine
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was shown to affect erythrocyte membrane ATPase activity in vitro.
It is quite possible that in the groups studied the increase in
activity of Na++ K+-ATPase was due to the recovery process.
However, it should be remembered that the in vitro action of mianserin
and amitripty1ine was tested in preparations from control subjects,
not patients with affective disorder.
It is interesting that in these studies a change in Na + +K+-
ATPase activity occurred over a period of about three weeks. Although
Hesketh et al (1978) observed a stimulation of Na++ K+-ATPase activity
in erythrocyte membranes from depressed patients after long term
treatment with lithium, such a change was not seen after 2- A weeks
of treatment.
Since the lifespan-of the human erythrocyte is approximately
120 days in control subjects (Harris and Kellermeyer, 1970) and in
patients with affective illness (Bille, Jensen, Kaa1und-Jensen and
Paulsen, 1975) the increase in Na++ K+-ATPase activity observed after
3 weeks of treatment with either mianserin or amitripty1ine suggests
that the effect of recovery on the specific enzyme activity was not
dependent on the synthesis of new red blood cells. This is also the
conclusion Hesketh et al (1978) came to when they considered observed
changes in Mg2+-ATPase activities. The Na++ K+-ATPase activity change
observed here after 3 weeks may be due to activation of the enzyme
by some unknown factor.
It is interesting to compare results presented here with those
of Naylor, Buckley, Boardman, Smith and Moody (1978) who found that
mianserin therapy did not affect erythrocyte membrane Na++ K+-ATPase
activity. This group carried out their biochemical estimations after
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two weeks of treatment, at a time when their patients were "showing
signs of clinical improvement". As Naylor ef al(1978) did not
investigate a control group at the same time, it is not known if these
patients had a reduced erythrocyte membrane Na+ + K+ - ATPase activity
before treatment commenced.
When patients receiving ECT were examined, an increase in
Na+ + K+ - ATPase activity was not observed. It can be seen by the
HRS scores of these patients, that most of the patients in this
study improved during a course of ECT. This would tend to suggest
that a stimulation of the reduced Na+ + K+ - ATPase activity in the
erythrocyte membrane in unipolar depression is not necessarily
related to the recovery process. The group of patients in this study
had been selected for ECT because, for the main part, other therapies
had been ■unsuccessful. It is possible that these patients, although
classified as unipolar depressed, are distinct from those that are
successfully treated with drugs alone.
It is useful to compare the results of this ECT study with
those obtained by Choi et a/(l977)« This group studied 5 bipolar
and 6 unipolar depressed patients. The activity of both Na+ + -
and Ca^+ - ATPase was found to be reduced in these patients. After
a course of ECT, when all of their patients had at least moderately
improved, the activity of these two enzymes was found to be
indistinguishable from that in control subjects. A reduced Ca T -
ATPase activity was not observed in the total patient group (A C D F
H J K L M N P Q) or in group 1 or group 11. However, results
obtained for patient group 11 showed an increase in Ca^+ - ATPase
activity twelve weeks after their last ECT. This increase was fairly
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small in comparison to that obtained by Choi et a/(l977) in
patients after a successful course of ECT. It should be remembered
that Choi et a/(1977) investigated both unipolar and bipolar
depressed patients, whereas results quoted in this thesis were ob-
2 + 2+
tained from only unipolar depressives. A reduction in Ca + Mg -
ATPase activity was observed in erythrocyte membranes from bipolar
manics (see Section 111, part 2 of this thesis).
It is difficult to determine, in this study, the effect of
anaesthetic on the ATPase measurements. In the cystoscopy control
group a stimulation in Na+ + K+ - ATPase activity was observed.
No such acute stimulation was observed in the ECT group, and in fact
patient group 1 showed a slight reduction in Ca^+ - ATPase activity
after the first ECT. These observations probably highlight
unfortunately the difference in the anaesthetic procedures used in
the two groups. Psychiatric information was not available for the
cystoscopy controls, a proportion of whom were suffering from
serious medical conditions. They were all likely to be apprehensive
before induction of anaesthesia, so unfortunately information
obtained from this group will not reveal the effect of anaesthesia
alone on erythrocyte membrane ATPase activity. However, it is
interesting that over the period of approximately ten minutes a
change in erythrocyte ATPase activity was observed. These short
term changes may be due to rapid changes in the concentration of
"enzyme modulators", as considered by Hesketh et a/(l978).
As the only consistent finding in the ATPase studies was a
reduced Na+ + K - ATPase activity in erythrocyte membranes in
unipolar depressed patients, further studies were undertaken to try
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and. explain why such a decrease occurred. These studies involved
-f- -f-
estimating activation energies of the Na + K - ATPase, using
Arrhenius plots. Discontinuities in Arrhenius plots of membrane
bound enzyme activities have been correlated with lipid phase
changes (Raison, Lyons, Mehlforn and Keith, 1971; Wisniesky, Parkes,
Huang and Fox, 1974; Wynn-W.il liams, 1976) and it has been shown that
Na+ + K+ - ATPase activity is sensitive to its lipid environment
(Schwartz et al, 1975)* if was hoped that if a change in lipid
composition was responsible for the reduced Na+ + K+ - ATPase activity,
it would be detected in these plots. However, unipolar depressed
patients seemed no different from controls. It is worthwhile to
consider that fairly gross changes in lipid composition would be
necessary before a change could be detected in a plot of this sort
(see Taniguchi and Iida, 1972).
Ouabain binding was also estimated. A significant reduction in
ouabain binding to erythrocyte membranes was observed with no
concomitant change in the dissociation constant K . The value obtained
for K^ in both control subjects and patients was very similar to that
obtained by Erdmann and Hasse (1975) an4 indicated a binding site with
high affinity for the drug. It is rather harder to compare the B
max
(maximal number of membrane-bound ouabain binding sites) obtained in this
thesis with that estimated by Erdmann and Hasse (1975)* These workers
reported their values as number of sites per single erythrocyte (228 +
28 per single erythrocyte). Red blood cell counts were not performed
in the studies reported in this thesis. However, taking the inform¬
ation given in Table 111.50 of this thesis as being representative of
protein concentrations in erythrocytes from control subjects, and
2.2
assuming 5 x 10 /litre as the average erythrocyte concentration in
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whole blood (Richmond and Davies, 1968), one can calculate that values
reported here for ouabain binding in erythrocytes from control subjects
are approximately half that reported by Erdmann and Hasse (1975)- The
discrepancy may be due in part to the assumption in these calculations
that each erythrocyte has the same protein concentration.
The reduction in ouabain binding could explain the reduced
Na+ + K+ - ATPase activity seen in the erythrocyte membranes of unipolar
depressed patients. However, it must be remembered that only four
patients were investigated. This observation warrants further study.
The measurement of ouabain binding during treatment and subsequent
recovery would provide valuable additional information to the observat¬
ions that erythrocyte membrane Ea+ + K+-ATPase activity either increases
towards a normal value when patients are successfully treated with
lithium (Hesketh et a/, 1978), mianserin (Section III, part 3 of this
thesis) and amitriptyline (Section III, part 3 of this thesis) or
remains reduced when ECT is administered (see Section III, part 4)-
It is interesting to speculate upon the cause of the reduced
+ +
Na + K -ATPase activity and ouabain binding. It is possible that the-
reduction in enzyme activity is due either to the removal of an
'enzyme activator' normally present or to the presence of an 'enzyme
inhibitor'. It would be necessary to show that such a substance, as
well as modulating Ha+ + K+-ATPase activity, also affected ouabain
binding. Erdmann and Hasse (1975) have discussed in their paper which
hormone or substance it is that naturally binds to the ouabain receptor
and thereby regulates, or influences at least, the active transport of
Ha+ and K+. If such a substance could be isolated, it would be
interesting to see if its concentration in the bloodstream correlated
with psychological ratings of depressed patients.
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2. platelet membkane ajjenyl cyclase activities
It has been proposed that a monoamine receptor
abnormality occurs in certain depressed patients (Ashcroft,
Eccleston, Murray, Glen, Crawford, Pullar, Shields, Walter,
Blackburn, connechan and Lonergan, 1972). One group that has
tested this proposal examined platelet adenyl cyclase responses
to noradrenaline and prostaglandin Ep in 11 male depressed
patients (4 unipolar depressed, 3 bipolar depressed, 4 with
depressive neurosis; 10 of the 11 patients shown to be
moderately depressed by Hamilton and Heck rating scales) and
8 male control subjects (Wang, Pandey, Mendels and Frazer, 1974a).
Prostaglandin Ep stimulates the net synthesis of cAMP in platelets.
Noradrenaline induces a decrease in this stimulation. Wang et al
(1974a) selected the biochemical response to noradrenaline as
suitable for examination as they considered the adrenergic receptor
to be closely related to and possibly even part of adenyl cyclase,
the enzyme which catalyzes the conversion of ATP to cAMP. They
adopted this strategy (examination of a response to a monoamine)
in preference to measuring concentrations of monoamines or their
metabolites in body fluids, studies which in the past had not
produced unequivocal results (see Section I of this thesis). How¬
ever, they appreciated that noradrenaline has an excitatory action
on adenyl cyclase in the brain, suggesting that platelets may not
be a suitable system in which to evaluate responses to mono¬
amines.
The study described in this thesis extended their observations
I.Wang et al, 1974a) by examining platelet adenyl cyclase activity
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in 62 male and female patients suffering from affective disorders
(13 unipolar depressed, 8 unipolar well, 25 bipolar depressed, 8
bipolar manic and 8 bipolar well) and 26 control subjects, and by-
measuring the action of lithium on the activity of this enzyme,
fluoride was used in these studies to stimulate basal adenyl cyclase
activity (see Section II, part 8a of this thesis) not prostaglandin
E^. Both compounds are thought to act by increasing the affinity
of the enzyme for magnesium (Wang, Pandey, Mendels and Frazer,
1974b).
The specific activity of adenyl cyclase in platelet membrane
preparations in this study was of a similar order to that described
by Mendels and jrazer (1974). No change in adenyl cyclase activity
was found in any of the patient groups studied when compared
with control subjects (Section III, part 1 of this thesis), which
agrees with the observation of Wang et al (1974a) on basal adenyl
cyclase activity.
Investigation of the inhibitory action of noradrenaline
by Wang et at (1974a) revealed no difference between patients
and controls either.
Administration of lithium to either control subjects or
certain groups of patients (Section III, part 1 of this thesis)
revealed no modification of platelet adenyl cyclase activity.
This observation can be usefully compared to the work of Wang
et at (1974b). Lithium in vitro was shown by this group to
have an inhibitory action on platelet adenyl cyclase activity
which had been stimulated by prostaglandin L, . The results
presented in this thesis suggest that this inhibitory action of
lithium is not irreversible.
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3. 5-HT UPTAKE INTO PLATELETS AND WHOLE BLOOD 5"HT
A significant reduction was observed in the Vmax value
(maximum transport rate under given experimental conditions) for
5_HT uptake into platelets from unipolar depressed (Section III,
part 1 and 3) and bipolar depressed patients (Section III, part l).
The Km value (Michael is constant, considered to express the affinity
of the substrate for the membrane carrier; the lower the Km, the
greater the affinity for the carrier) for this process was found not
to differ from that in control subjects. These findings are similar
to those reported by Hallstrom, Linford Rees, Pare, Trenchard and
Turner (1976), Mulgirigama (1976) and Tuomisto and Tukianen (1976).
Values obtained for platelet 5~HT uptake (as characterized by
Vmax and Km) in control subjects here, are in close agreement with
those reported by Lingjaerde (1969, 1971) and Tuomisto and
Tukianen (1976). However, estimates made by Coppen, Ghose, Swade and
Wood (1978), Gordon and Olverman (1978) and Stahl and Meltzer (1978)
for this process are rather different.
Disagreement exists among various workers as to the biochemical
characteristics, and the kinetic and pharmacological properties of
5~HT transport in blood platelets (see Sneddon, 1973, for review).
Sneddon has suggested that much of this variation could be attributed
to varying and poorly controlled experimental conditions.
5-HT is thought to enter platelets by two mechanisms; an active
transport process which predominates at low substrate concentrations,
and simple diffusion which predominates at high substrate concentra¬
tions (Fuks, Lanman and Schanker, 196A). Thus, results obtained
under conditions where diffusion could make a significant contribution
to the total uptake should be treated cautiously.
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Many workers use PRP, considering it more physiological than
artificial media. However, plasma pH is difficult to control and the
pH tends to rise throughout an incubation as the plasma loses carbon
dioxide. Variations in 5"HT uptake may occur as a result.
If the sensitivity of the transport system to various inhibitors
is being assessed using PRP, interpretation may be complicated by
the adsorption of metabolic inhibitors and drugs by plasma proteins.
This will result in a reduced effectiveness, especially at low
concentrations of these compounds.
Divergent results may also occur if the experimental protocol
does not allow a pre-incubation period, during which time inhibitors
may act to establish their full effect. This is especially important
when the actions of metabolic inhibitors are being considered.
In the studies reported in this thesis a five minute incubation
time was chosen when 5~HT uptake into platelets was measured. When
the initial rate of uptake is to be measured, as was the case in this
study, the incubation time must be short enough to secure a nearly
linear time-uptake plot. Several workers, using 5~HT concentrations
of 1 ug/ml and upwards, have found that the uptake is nearly linear
for one hour (Born and Gillson, 1959; Hughes and Brodie, 1959;
Weissbach and Redfield, 1960; Crawford, 1967). With the procedure
used in the investigations reported in this thesis, however, the
uptake was usually linear for 10 minutes. Therefore, an incubation
time of 5 minutes was selected as being suitable. This is a rather
longer incubation time than that employed by other workers (Gordon
and Olverman, 1978) using low 5~HT concentrations. The difference is
probably due to the lower rate of substrate depletion in this set of
experiments, which existed as a result of the use of a more dilute
suspension of platelets.
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Uptake into platelets was measured using 3H-5-HT in a con¬
centration range of 0.25-2 pM. The investigations reported were
concerned with active uptake only, and with substrate concentrations
in this low range, passive uptake is thought to be virtually non¬
existent. This has been shown by the lack of any net uptake in the
presence of imipramine in concentrations which do not increase outflux
(Lingjaerde, 1971), and by the lack of any net uptake in the absence
of chloride or sodium (Lingjaerde, 1969). Some workers measure 5~HT
uptake at 0°-A°C and designate the amount of radioactively-1abe11ed
5-HT found in the extracted platelets as that due to passive diffusion
(Coppen et al , 1978). As the cell membrane constituents are likely
to undergo considerable changes in physico-chemical properties in the
transition from 37O-0°C -it seems unlikely that such measurements will
reflect passive diffusion at 37°C. As these workers used low 5-HT
concentrations it seems likely that the value they obtained was
actually a measure of 'trapped1 and 'externally bound' 5-HT.
In the experiments reported in this thesis, an estimation was
made of the small amount of 3H-5~HT trapped in pellets when platelets
were isolated by centrifugation after incubation, and that bound onto
the external face of the platelet plasma membrane during incubations.
This binding may be to specific 5~HT receptors which play a part in
platelet aggregation (Boullin, Holyneux and Roach, 1978) or it may
be due to binding at non-specific sites. The 'blank' value was
measured by estimating the amount of 3H-5~HT present after incubation
for 5 minutes at 0° to k°C. It is realized that such a measurement
is only an approximation of the trapped and externally bound 3H~5"HT.
The membrane changes occurring between 37° and 0°C may affect these
parameters, as well. This 'blank' value could have been eliminated
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by 'washing1, i.e. by repeated resuspensions and recentrifugations.
However, this procedure would have resulted in a loss of platelets
and of platelet-granule bound 5~HT, and was therefore not used.
Uptake of 5"HT by platelets was measured in diluted PRP in the
studies reported in this thesis. The pH was found to be stable
during the course of 5 minute incubations which was probably due to
the ratio of PRP added : total incubation volume, which was 1 :40.
Although some consider it acceptable to treat transport kinetics
analogously with enzyme kinetics (Stein, 1967), when 5~HT uptake into
platelets is measured it is possible that several processes could be
contributing to the observed effects. This may be important when
interpretating the reduced Vmax value for 5_HT uptake into platelets
from depressed patients.-
The reduction observed could be due to a true reduction in
5-HT uptake at the plasma membrane (i.e. as a result of a decrease
in the number of 5-HT 'carriers') or it could be due to an increase
in 5"HT outflux as a result of, for example, increased intraplatelet
5-HT degradation by MAO or of decreased intragranu1 ar binding.
In the experiments reported here net uptake of 5-HT was
measured. However, the true uptake would be obtained only when an
estimate of outflux was made. Therefore, it is essential to know the
rate of outflux which occurs in the experimental conditions used.
It is often taken for granted that there is practically no outflux
of 5~HT from platelets unless some releasing agent is present in the
incubation medium. Pletscher, Bartholini and Da Prada (1966) found
that when rabbit platelets were incubated in plasma or Tyrode solution,
they lost only 1-2% of their 5"HT during 4-6 hours. Lingjaerde (1971)
found that human platelets, preloaded with radio-actively labelled
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5~HT, lost very little 5-HT when they were isolated and then
resuspended and reincubated for one hour in phosphate buffer with
NaCl and KC1 added in suitable amounts. However, this does not
constitute proof that there is no outflux going on during such an
incubation, because the 5-HT leaking out of the platelets could be
taken up again very rapidly, provided that the medium allows uptake
of 5~HT. To measure outflux, it would be necessary to block the
reuptake of 5~HT from the medium. This could be done by incubating
the platelets in a medium lacking one of the ions necessary for
active uptake, incubating in a medium containing a 5~HT uptake
inhibitor (i.e. imipramine) or using platelets, preloaded with
radioactive1y-1abe11ed 5~HT, which would be subsequently resuspended
in a medium containing a-high concentration of unlabel led 5-HT. This
would have the effect of blocking reuptake of labelled 5_HT by
competition. None of these methods are ideal, because it is difficult
to be sure that the composition of the medium does not influence the
rate of outflux, besides blocking the reuptake. Studies performed
by Lingjaerde (1971) suggest that in human platelets net uptake
seems to be a fairly accurate measure of influx, the ratio of 5-HT
influx to 5~HT outflux being about 12 : 1. However, it is quite
possible that in platelets from patients with affective illness, the
rate of outflux could be greater than that found in control subjects.
It would be useful to estimate rates of outflux in platelets from
patients who showed a reduction in platelet uptake.
Platelet MAO activity has been reported as being decreased
in bipolar depressed patients. However, the activity may be increased
in unipolar depressed patients (Buchsbaum, Landau and Murphy, 1973;
Nies, Robinson and Harris, 197*0- It is possible that the reduced
218
5-HT uptake observed in unipolar depressed patients may be explained
by an increased MAO. However, platelets of all species tested so
far (including man) metabolize 5~HT very slowly; more than 30% of
the radioactivity in the platelet represents unmetabolized amine
(Stacey, 1961; Pletscher, 1968; Solomon, Spirt and Abrams, 1970).
Platelet MAO activity would have to be greatly increased in depressed
patients before an effect was seen in 5~HT uptake.
It is thought that 5"HT is stored in platelet granules in
5~HT - ATP - Mg2+ micelles (Pletscher, Da Prada, Berneis and Tranzer,
1971). It is possible that a reduction in the ATP or Mg2+ content
of platelet granules might produce a reduction in intraplatelet 5~HT
binding. It is interesting to note that in Down's syndrome, a
condition where a reduced platelet 5_HT uptake is also observed, a
reduction in platelet ATP has been found (Boullin and O'Brien, 1971).
However, to date there have been no investigations of ATP or magnesium
content of platelets in affective illness. It is interesting that
in depressed patients who showed reduced 5-HT uptake, whole blood
5~HT levels were not significantly different from control values
(Section III, part 3 of this thesis). As platelets contain more than
99% of whole blood 5-HT (Pletscher, 1968), this suggests that there
is no abnormality in the granule 5"HT binding capacity of these
platelets. So, although these platelets do not take up 5-HT as fast
as those from controls, they are still able to attain a normal 5"HT
1evel.
It is possible that the defect seen in depression is due to a
change in 5~HT transport across the platelet granule membrane. This
process is often deemed to be unimportant in a consideration of overall
5-HT uptake. Recent work (Costa, Murphy and Reveille, 1977) has
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shown that the dynamics of the human platelet amine uptake and storage
system are complex, suggesting that this aspect might be important
in an evaluation of total uptake.
In connection with the results obtained for 5~HT uptake it
is interesting to reconsider work by McCoy et al (197*0. These
workers found Na++ K+-ATPase activity to be low in platelets from
patients with Down's syndrome. They considered this to be the cause
of the reduced platelet 5~HT uptake observed in these patients. The
transport of 5_HT into platelets is known to be an active process
coupled to Na++ K+-ATPase and absolutely dependent on sodium (Sneddon,
1969, 1971). McCoy et al (197*0 proposed that the diminished
Na++ K+-ATPase activity in Down's syndrome would lead to elevated
intraplatelet Na+ levels, and diminished intraplatelet 5"HT levels.
This could be explained in terms of the model proposed by Sneddon
(1973) for 5~HT uptake into platelets. The proposed transport
carrier is thought to have two binding sites, one for 5-HT and the
other for monovalent cations. The carrier is assumed to migrate
freely between the interfaces of the platelet plasma membrane. When
one sodium ion and one molecule of 5-HT bind to the carrier it can
migrate through the membrane so that both Na+ and 5-HT appear at
the inner membrane face. In this position it is thought that intra¬
cellular K+ competes for the Na+ binding site, displacing Na+ and
so reducing the affinity of the carrier for 5_HT, which would now
dissociate from the carrier and be bound by the intracellular storage
granules or metabolized by monoamine oxidase. The carrier could now
freely migrate back across the membrane, where in an environment
of high Na+ the cycle could start again. An essential feature of this
proposed Na+-dependent uptake process is that the intracellular Na+
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concentration must be maintained at a low level relative to K+.
If the internal Na+ was allowed to rise, the Na+ - K+ exchange
process at the inner face of the membrane would be reduced. Thus,
5-HT would not be able to dissociate from the carrier as readily as
before, and transport of 5~HT would thus be reduced. However,
Na++ K+-ATPase activity was found to be normal in platelets from
unipolar and bipolar depressed patients (Section III, part 1 of this
thesis). It is therefore assumed that a low intracellular Na+ con¬
centration was present in these platelets, and that this could not
be the cause of the reduced 5"HT uptake observed.
It is interesting to speculate if the reduction observed in
platelet 5"HT uptake parallels a change in 5-HT uptake in the central
nervous system. It has been suggested that the blood platelet can
serve as a model for transport processes in 5"hydroxytryptaminergic
neurones in the CNS (Pletscher, 1968; Sneddon, 1973; Stahl, 1977).
However, it has not been rigorously demonstrated that the accumulation
of 5-HT in both tissues proceeds by analogous kinetic mechanisms which
share the same pharmacological characteristics (Sneddon, 1973).
Smith, Hanson and Omenn(1978b) have tried to resolve these
difficulties by examining 5-HT uptake into both platelets and
synaptosomes using the same experimental protocol, i.e. a 2 minute
incubation period and 5~HT concentrations in the range 0.025-1 pM.
They found that in five strains of mice and in rhesus macaques although
the Km values recorded are similar in platelets and synaptosomes, to
the nearest order of magnitude, the two apparent Km values for
synaptosomes are both significantly different from the single apparent
Km value in platelets (Table IV.5). These workers also found that a
specific 5"HT uptake inhibitor, Lilly compound 1 1 014 0 , inhibited 5-HT
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TABLE IV.5: Km values reported by Smith et al (1978b) for
5~HT uptake into platelets and synaptosomes
Platelets Synaptosomes
M i ce
(average for 5 strains) 15^ 55 and 610
Macaques 370 140 and 770
uptake much more effectively in platelets than in synaptosomes.
Interpretation of their results is complicated by the fact that
synaptosomes and platelets are isolated by different procedures.
Smith et al (1978b)checked the action of anticoagulant on 5~HT-
uptake in synaptosome preparations and found it to have no effect.
However, it is interesting to note that they detected a small
molecular weight factor in plasma, which was capable of inhibiting
the high affinity uptake of 5~HT into synaptosomes. Apparently, the
presence of this factor does not prevent the expression of the high
affinity uptake of 5"HT into platelets. Their findings suggest that
the transport systems for 5"HT into synaptosomes and platelets are in
fact different.
Stahl and Meltzer (1978) have suggested that discrepancies in
the reported values of 5~HT uptake into platelets and synaptosomes
are due to incorrect kinetic analyses and differences in the con¬
centration range of 5_HT studied. They suggest that an accurate
measure of active saturatable 5~HT uptake can be made by subtracting
the linear component (obtained by extrapolating to zero, uptake
measured at high 5~HT concentration) from the total uptake. They
consider this linear component to represent non-saturatable passive
diffusion. Their results (Stahl and Meltzer, 1978; Figure 3) would
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suggest that at fairly low 5-HT concentrations (1-2 pM) passive
diffusion can contribute as much as 50-75% of total uptake. This
finding disagrees with that of other workers (Lingjaerde, 1971;
Le Fur and Uzan, 1977; Gordon and Olverman, 1978). Stahl and
Meltzer (1978) quote IC50 values for inhibition of 5-HT uptake
into platelets by tricyclic antidepressants which they estimated
from log probit plots constructed from six different drug concentra¬
tions. It would be interesting to know if these workers achieved
100% inhibition at low 5-HT concentrations (i.e. 1-2 pM) using a
concentration of tricyclic which affected uptake only. If they did,
it would suggest that either their experimental procedure or their
method of calculating active uptake is incorrect.
It has been shown -that a deficiency in platelet 5~HT level
observed in Fawn-Hooded rats is not reflected by a similar reduction
in 5"HT in the central nervous system (Joseph, 1978). This may be
relevant to inferences concerning the central nervous system, drawn
from the observation that platelet 5"HT uptake is reduced in depressed
patients. However, it is not known if a reduction in 5~HT uptake
exists in the platelets from Fawn-Hooded rats. These platelets are
known to have a greatly reduced ATP content, so it is probable that
the platelet abnormality seen in these rats is more akin to that of
'storage pool disease' in humans, and thus does not shed any light
on aberrations present in the brains of patients with affective
disorders.
It must be remembered that even if it could be shown conclusively
that platelets and synaptosomes used the same type of 5-HT carrier,
changes occurring in platelets in affective illness could still be
due to the presence of a substance in the blood which might not have
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access to the central nervous system. It would be useful to know
if platelet and brain 5~HT transport systems are expressed by the
same or different genes, and if they are expressions of the same gene,
to what extent the two mechanisms are differentially modified in the
two tissues.
The action of lithium, mianserin and amitripty1ine therapy was
investigated in unipolar depressive patients to see if these drugs
modified the reduced platelet 5-HT uptake. Lithium administration
and recovery did not affect 5-HT uptake in any of the patient groups
or controls studied (Section IN, part 1), except for a tendency to
increase the rate of uptake in the unipolar and bipolar depressed
group. Murphy, Colburn, Davis and Bunney (1969, 1970) found that
lithium therapy stimulated uptake of monoamines into platelets from
depressed patients. It is possible that if a larger number of patients
taking lithium had been investigated it might have been possible to
observe the definite effect of lithium reported by this group (Murphy
et al
f 1969, 1970). Control subjects were not investigated (Murphy et ai,
1969, 1970) so it is not known if platelet 5"HT uptake was less than
normal before therapy commenced. It is also unclear from their paper,
if after two weeks of lithium administration, the patients investigated
had recovered. Thus, it is not known if these workers were invest¬
igating true lithium actions or if recovery effects were being
observed. This group also investigated the in vitro action of lithium
and found that 5~HT uptake into platelets from control subjects was
not increased. The results presented in this thesis are in agreement
with this finding.
The lithium concentrations investigated invitroviere in the
range expected in plasma when the drug is given therapeutically.
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It is known that lithium binding to plasma proteins is negligible
(Gilman , Goodman and Gilman, 1980). It is not known, however, if
the difference between 1ithium in vivo and in vitro is due to a
difference in intrap 1 ate1et lithium concentration. It would be
useful to measure this concentration in platelets from control
subjects after a ten minute incubation period with the drug, and make
a comparison with values obtained in platelets from patients receiving
lithium. It is possible that the difference is due to differences
in the time the platelets are exposed to the drug. Imandt, Genders,
Wessels and Haanen (1977) have shown that lithium requires 90 to 120
minutes to reach an equilibrium concentration across platelet membranes.
It is possible that if lithium in vivo truly stimulates 5~HT
uptake it may be producing the effect indirectly as a result of the
recovery process or indirectly via some other mechanism. As 5"HT
uptake is not stimulated in control subjects taking lithium it seems
unlikely that it is as a result of some unidentified indirect activation.
Whether the change observed is due to a recovery effect could be tested
by comparing 1ithium-treated patients who recovered with lithium-
treated patients who remained ill. This could not be carried out in
this study as suitable patients were not available.
Results presented in Section III, part 3 showed that mianserin
and amitripty1ine administration and subsequent recovery had marked
effects on platelet 5"HT uptake. However, it was shown that mianserin
produces quite a different effect from amitripty1ine. Although all
patients in both groups recovered, it can be seen that the Vmax
values in the mianserin treated group approached control values while
in the amitripty1ine treated group Vmax values were reduced still
further, with a concomitant increase in Km values. It would have
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been useful to investigate mianserin and amitripty1ine treated
patients who failed to recover. It would then have been possible to
dissociate drug effects from 'recovery from illness1 effects.
However, some measure of this is available from an examination
of the in vitro action of these drugs on platelets from control
subjects. The in vitro action of amitripty1ine was shown to be
identical to its in vivo action. The concentration of amitripty1ine
used for in vitro studies on platelet 5~HT uptake was between 50-150
ng/ml (160-480 pM). It is not known what the plasma concentration
of amitripty1ine was in the patients receiving the drug in this study.
Coppen (1976) estimated amitripty1ine plasma levels to be in the
order of 25-200 ng/ml (80-6^+5 pM) when patients received 150 mg
of the drug per day. It would appear that the concentration of
amitripty1ine required to appreciably inhibit 5~HT uptake is consider¬
ably less than that present therapeutically. Work by Todrick and Ta i t
(1969) established that the ID50 for amitripty1ine was 5.3 pM.
However, it is known that plasma binding of tricyclic antidepressants
occurs (Campbell and Todrick, 1970). This binding was calculated by
these workers as reducing the effective concentration by 73~92%.
Taking these estimates into account it is still probable that the
'free' concentration in the plasma (6-17^ pM) is much higher than
that required to inhibit 5-HT uptake.
The in vitro action of mianserin, which is entirely different
to its effect in vivo, is similar to the action of amitripty1ine.
Concentrations of mianserin chosen to investigate the in vitro action
of the drug (25-75 ng/ml; 8*1-252 pM) are in the range found in the
plasma of patients receiving 60 mg of the drug per day (Coppen, Gupta,
Montgomery, Ghose, Bailey, Burns and de Ridder, 1976; Montgomery,
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McAuley and Montgomery, 1978; Perry, Fitzsimmons, Shapiro and
Irwin, 1978). The difference between in vivo and in vitro effects
might be explained by the proposal that a metabolite of mianserin is
producing the effects seen in vivo (Coppen et al, 1978). It would
have been more informative if an examination of the in vitro nature of
these drugs on platelets from ill untreated patients had been made.
Platelets from control subjects differ from those of ill patients,
and could react in a different manner to these drugs.
Coppen et al (1978) investigated the in vivo and in vitro
actions of mianserin on 5"HT uptake into platelets from depressed
patients. They found that mianserin administration in vivo resulted
in an increase in Vmax values while the opposite effect occurred
in vitro. They found that mianserin caused Km values to increase
both in vivo and in vitro. It is difficult to explain why Km values
increase in the Coppen et al (1978) study after in vivo administration
while no such change was observed in the study reported in this thesis.
Coppen et al (1978) measured plasma mianserin levels and knew for sure
that their patients had taken their medication. However, if a
mianserin metabolite is responsible for the effects observed, this
measurement is irrelevant unless mianserin is metabolized in the same
manner by all patients. It was not known in the study reported in
this thesis if patients ingested their medication. If the patients
failed "to comply" but still recovered, it is possible that some
effects of the drug may have been missed.
A consideration of the uptake kinetics after exposure of these
drugs to platelets suggests that in vitro both amitripty1ine and
mianserin act as non-competitive inhibitors. This implies that the
two drugs effect their inhibition not by modifying binding of 5~HT
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to the carrier system, but by reducing movement of the carrier
through the membrane (Wold, 1971).
Kinetic studies of the effects of tricyclic antidepressants
have usually shown the inhibition to be competitive in nature
(Stacey, 1961; Yates, Todrick and Tait, 196A; Tuomisto, 197^;
Gordon and Olverman, 1978). This implies a direct action on the
5-HT binding site, with inhibition being reduced at higher substrate
concen t rations.
However, Le Fur and Uzan (1977) considered imipramine, clomi¬
pramine, desipramine and amitripty1ine to be uncompetitive inhibitors.
It is probable that these authors have made a typographical error.
Their plots of '/v against '/s show non-competitive inhibition
(change in Vmax, no change in Km).
Coppen et al (1978) obtained the same in vitro effect for
mianserin as described here, but described the inhibition as com¬
petitive.
It is interesting that when amitripty1ine was administered
whole blood 5"HT levels were shown to decrease to a very low level,
as the Vmax values decreased. As the decreased Vmax values found in
untreated ill patients do not occur concomitantly with low whole
blood 5-HT levels it. would appear that ami t r i pty 1 i ne in vivo has
actions unrelated to its blockade of 5~HT uptake. It is possible
that at the concentrations present in plasma it causes release of 5~HT
from platelets. It is also possible that it interferes with the
production of 5~HT by the enterochromaffin cells in the gut, thereby
reducing the amount of 5-HT available for entry into platelets.
Platelet bound 5~HT is thought to be decreased by 3-30% during passage
through the lungs (Crawford, 1965). It is possible that in
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amitriptyline treated patients this percentage is greatly
increased. Platelet-bound 5-HT has been reported as having
a shorter half-life in the body than the platelets themselves,
and that this is caused by an exchange of platelet 5-HT with
5-HT depots elsewhere in the body (Marcus and Zucker, 1965).
Amitriptyline may interfere with these processes. As the decrease
in whole blood 5-HT occurs over a period of two weeks, it is
quite likely that amitriptyline has either an action at the
megakaryocyte level directly and is affecting platelets as they
are being manufactured or that young platelets are more susceptible
to changes in other systems that may be affected by the drug.
It is possible that the reduction in whole blood 5-HT
is due merely to a change in the ratio of influx: outflux of
5-HT. After amitriptyline administration, V values are
max
reduced even further below those found in ill untreated patients.
It is possible that if in this situation the influx (i.e. uptake)
is less than the outflux, platelet 5-HT levels would be
expected to drop.
Work by other groups on platelet 5-HT uptake and the
action of tricyclic antidepressants, have revealed rather different
effects.
Tuomisto and Tukianen (1976) carried out an investigation
on 5-HT uptake and the effect of imipramine on the uptake in
blood platelets obtained from depressed patients. They found
that after four weeks treatment the V for the process increased.
max
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towards normal values, whereas the K was increased above normal.' m
In vitro, addition of the drug to the platelet suspension (in
a concentration equivalent to that expected in the plasma) led
to K values being increased without a concomitant V change,
m max
They concluded that the V change observed in treated patients
max
was associated with recovery from depression and was not a drug
effect. This is not a valid conclusion. It is quite possible
that the administered drug acts at some unknown site in the
body, which can then subsequently exert an influence on platelet
5-HT uptake. This process may be totally unrelated to the
recovery of the patient from depression.
In an earlier study by Murphy et al (1969), imipramine
therapy had also been found to cause an increase in values,
with a reduced initial rate of uptake but no change in V
max
values. However, not all of the patients studied by this group,
recovered during the investigation period. In keeping with the
observation of Murphy et al (1969), Marshall, Stirling, Tait
and Todrick (i960) found that imipramine administraion caused
an 84I fall in platelet 5~HT levels. This suggests that imipramine
was acting as a competative inhibitor, and it was present in
sufficient concentration to prevent most of the 5-HT, to which
the platelets were exposed in the body, from being taken up.
It would appear from results presented in this thesis,
that an increase in V does not necessarily occur as a patient
max
recovers from depression. However, it is not known whether this
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is due to the different therapies used. An examination of plate¬
lets from depressed patients being treated successfully by
behavioural therapy would be useful in differentiating recovery
from drug effects.
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A. VARIATION IN SERIAL PREPARATIONS OF PLATELETS, ERYTHROCYTES
AND WHOLE BLOOD 5-HT
There was considerable variation in ATPase activities in
platelet and erythrocyte membranes prepared from a single control
subject on successive occasions. This variation was especially
obvious in Na++ K+-ATPase activities measured at intervals during
a menstrual cycle. Substantial changes in activity occurred in
some cases in the course of a week. A standard ATPase, assayed
together with the membrane preparations, showed little variation in
enzyme activity so providing evidence that the variation in membrane
ATPase activities was not due to methodological error in the ATPase
assay. The variation in activity must therefore have been due either
to in vivo variation, to variation in the sample of blood cells
taken or to variation produced during the preparation of the membranes.
Sampling variation could have occurred if successive samples
contained different populations of platelets and erythrocytes in
respect to cell age. It has been suggested that the age distribution
of erythrocytes could be a cause of variation in membrane preparations
(Hanahan, 1973). However, Cohen, Ekholm, Luthra and Hanahan (1975)
were unable to show any consistent relationship between erythrocyte
cell age as judged by cell density and ATPase activities in freeze-
thawed cells. Other workers have shown Ca2+-ATPase activity in
erythrocyte membrane preparations to depend on cell age and in addition
have found Mg2+-ATPase activity to be increased in people with high
(10-30%) reticulocyte counts (Feig and Guidotti, 197A). It is
thought that platelets undergo considerable changes as they age in
the circulation (Karpatkin and Amorosi, 1977). However, it is not
known if different levels of ATPase activity are associated with
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'young' and 'old' platelets. As the life of the mature human
erythrocyte is known to be approximately 120 days (Harris and
Kellermeyer, 1970), it seems unlikely that changes observed in the
course of a week are due to changes in the population of red blood
cells. The platelet is thought to have a life span of 8-11 days
(Richmond and Davies, 1968), so in this case, it is possible that
variation occurring over a short time could be due to cell turnover.
Variation in specific enzyme activity in the erythrocyte could
have arisen from variation in the enzyme or protein content of the
membrane. Hanahan and Ekholm (1972) showed that under preparative
conditions similar to those used in these experiments, Mg2+-ATPase
and Ca2+-ATPase activity was lost during preparation but there was
no loss of Na++ K+-ATPase activity. Variation in such loss could
lead to variation in enzyme activity in the final preparation.
Using identical preparative conditions, Hesketh and Reading
(1978) investigated the cause of variation seen in ATPase activity
of erythrocyte membranes. They found on a given day membrane
preparations from a single haemolysate were reproducible in terms of
protein yield and ATPase activities. This suggests that the
centrifugation steps employed in the membrane preparation were
reproducible. Using an angle head rotor, membrane yield was found
to be drastically increased. However, they found that the specific
activities of the ATPases were unchanged, suggesting that the membrane
suspensions during preparation were not heterogeneous. Membrane
ATPase activities determined on successive occasions and expressed
per litre of original cells and per milligramme of protein were shown
to be definitely correlated. This observation implies that variation
between individuals is not due to either variation in membrane yield
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in terms of protein or in terms of enzyme. This conclusion is
supported by the lack of correlation between protein yield and
ATPase specific activities. The only variable step in their prepara¬
tion was the haemolysis. Cells were lysed in a constant volume-to-
volume ratio, but the haematocrit of the cell suspension was shown
to vary. However, this is probably unimportant as the cells were
always suspended in iso-osmolar NaCl.
If the study of Hesketh and Reading (1978) can be applied to
results given in this thesis, and it surely can as identical
procedures were employed, it suggests that no methodological explana¬
tion exists to explain the observed variation in ATPase activities
in successive samples. Hesketh and Reading (1978) suggest that the
variation observed might-be due to enzyme activation. Activators
of Ca2+-ATPase are known to exist (Jarrett and Penniston, 1978),
although their presence might not be expected after the extensive
washing procedures used in the membrane preparation. Results
presented in Section III, part A of this thesis, suggest that changes
in erythrocyte membrane ATPase activity can occur within minutes.
Such a rapid change could be explained in terms of fluctuating
plasma levels of activators.
Variation (up to 50%) in ATPase activity in platelet prepara¬
tions has been reported by Moake et al (1970). They did not offer
an explanation for this, but did state that there were no differences
in basic properties of the preparations or in the effects of added
inhibitors.
Results presented illustrate that serial samples can show
considerable variation in ATPase specific activities, suggesting
that interpretations made on a single preparation should be treated
234
with caution. Considerations of this nature are important in studies
when enzyme activities are compared between different individuals,
even although the value may be absolute for any particular individual
at any particular time.
A large variation was seen in whole blood 5-HT levels in a
single subject, especially during the course of a menstrual cycle.
This disagrees with the findings of Ashcroft et al (196A). These
workers found that although there was a large variation in the blood
5-HT concentration between individuals, whole blood 5_HT proved
remarkably constant in a given individual on successive occasions.
Whole blood 5-HT is known to be susceptible to changes in
diet (Ashcroft et al , I96A). It is conceivable that such an influence
was responsible for the variations observed.
Wi rz-Justice, Feer and Richter (1977a) measured platelet 5-HT
at monthly intervals in subjects for an entire year. Fluctuations
of greater than 300% were found, 5-HT levels being highest in late
autumn and spring.
Platelet 5"HT has been shown to have a diurnal rhythmicity
(Sauerbier and von Mayersbach, 1976; Wirz-Justice, Lichtsteiner and
Feer, 1977b). No significant differences in whole blood 5_HT between
men and women were seen in these studies, although changes related
to the menstrual cycle were observed, but the sample was too small to
be s ignificant.
It would appear that data collected from individuals at a few
time intervals requires a great deal of caution in interpretation,
as allowance must be made for circadian, hormonal and seasonal
determinants. Swiss researchers have suggested that this caution
must be extended to studies involving patients with affective disorders.
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Wirz-Justice and Pllhringer (l978a,b) investigated manic-depressed
patients to see if variations in whole blood 5-HT levels occurred.
They found that the diurnal rhythm (but not the absolute level)
of 5-HT was different in unipolar depressed patients compared
to control subjects. Patients with bipolar illnesses were
shown to have a similar diurnal rhythm as controls. However,
these patients had higher absolute levels of whole blood 5-HT
which was shown to be independent of clinical state.
Wirz-Justice and PUhringer (1978a) considered that the
altered diurnal rhythm in platelet 5-HT did not appear to be
related to changes in either platelet MAO activity or 5-HT uptake.
Platelet MAO activity did not show a diurnal rhythm and there
was no difference in 5~HT uptake when unipolar depressed patients
were compared with controls. They observed a positive
correlation between 5-HT uptake and platelet 5-HT content when
measured at 8am, in both controls and unipolar depressed patients.
However, they did not estimate this correlation in measurements
made at 4pm, at a time when the greatest difference in platelet
5-HT is seen.
Wirz-Justice and Phhringer (1978a) feel that their observ¬
ations (altered rhythms but no change in concentrations of two
peripheral serotonergic parameters) are of interest 'in the
light of the concept of a desynchronization phenemenon under¬
lying depressive states *' They feel that the changing rhythm
seen in platelet 5-HT parallels similar changes in the CNS.
However, they can provide no evidence for this.
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The variation in 5-HT uptake (as measured by V values)
max
into platelets from a single subject (see this thesis Section 111
part 6 (g) (iii)) was seen to be greatest during the course of
a menstrual cycle. It is possible that hormonal changes are
responsible for this variation.
No attempt was made to estimate the methodological error
which occurred when 5-HT uptake was measured, other than
carrying out estimations in duplicate. A suitable standard,
similar to the kind used when the ATPase activity estimations
were checked, was obviously not available. It is possible
that the method used for stopping 5-HT uptake into platelets
(transfer of tubes from 37°C to 0 - 4°C) was not consistently
reproducible. Other methods are available. Costa and Murphy
(1975) have investigated the use of fixatives, and have shown
a 1.5$ solution of formaldehyde to be satisfactory in stopping
uptake and release very quickly.
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5. CONCLUDING REMARKS
The first aim of this project (see page 61-62 of this thesis)
was to conduct a large scale study in one establishment in an
attempt to reduce variation in psychiatric assessment and lab¬
oratory procedures. Results reported in this thesis were obtained
from 153 control, 77 unipolar depressed, 8 unipolar well, 29 bipolar
depressed, 23 bipolar manic and 8 bipolar well subjects; a not
inconsiderable total of 298 individuals.
It had also been hoped that by using 'finer' psychiatric
classification than many previous studies had employed, valuable
information would have been obtained. Patients in this study were
rated according to the course of their illness (i.e. unipolar or
bipolar),!, but unfortunately, except in the EOT study (Section 111,
part 4), no measure of the degree of severity of their illness
was made. This is a major limitation. In the studies reported
in Section 111 parts 1 and 2, patients had been drug-free at least
2 weeks. No HEEL values were obtained for these patients. It is
probable that they were not so severely ill as some other patients
studied, as they could be 'maintained' for this length of time
without medication.
All patients receiving treatment recovered. It was there¬
fore not possible to dissociate recovery effects from therapy effects,
in the way that Hesketh et al (1978) had done. However, it is
pertinent to consider that patients who fail to recover when treated
in a certain manner, may well belong to a different 'sub-class'
of the total population of depressed patients. Plasma levels of
mianserin and amitriptyline were unfortunately not measured in
patients receiving these drugs. It is therefore not known if the
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patients ingested their prescribed medication.
Red blood cells and platelets from patients suffering from
affective disorders were found to be different, in several respects,
from those from control subjects.
The reduction in Na+ + K+ - ATPase activity in red blood cells,
which occurred in both unipolar and bipolar depression, was not
observed in platelets. Caution should thus be exercised when extra¬
polating changes seen in the periphery (i.e. change in one cell in
periphery = change in all cells) to changes expected in the CNS.
After some treatments the reduced Na+ + K+ - ATPase activity
in erythrocytes increased to normal. However, no such change occurred
after ECT. Prom results presented here, it is not possible to say
if this reflects a difference between patients who require ECT and
those who are satisfactorily treated with drugs.
The reduced Na+ + K+ - ATPase activity was found to be assoc¬
iated in 4 patients with a reduction in ouabain binding (and therefore
in Ha+ pump sites). This observation coupled with that of rapid
changes seen in ATPase activity would suggest looking for an
endogenous substance capable of modifying both enzyme activity and
binding sites. It would then be useful to see if mood was positively
correlated with the plasma concentration of this substance. Work
very recently published (Baylor, Smith, Dick, Dick, McHarg and
Chambers, 1980) suggests that a reduction in ouabain binding does
not occur in affective illness. These workers investigated both
depressed and manic patients. Although they did not observe any
significant difference in Na+ + K+ - ATPase activity when ill
patients were compared with recovered, they did observe a decrease
in the ATPase activity per pump site. They suggest as well that
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some endogenous substance must be influencing the Na+ pump, and
have suggested vanadium as a likely candidate. They have shown that
plasma vanadium is increased in manic-depressives compared to controls
(Dick, Dick and Naylor, 198l) and that a low vanadium diet supple¬
mented with ascorbic acid and EDTA has beneficial effects on manic-
depressed patients (Naylor and Smith, 1981). It is known that
vanadium can inhibit Na + K+ - ATPase activity (Cantleyef a/ , 1978).
However, values obtained in both patients and controls for plasma
vanadium are well within the normal range. When patients' improved
on a low vanadium diet no estimate was made of their plasma vanadium
levels. Also no details of the low vanadium diet were given. It is
difficult to draw any conclusions from this work, on the importance
of vanadium in the aetiology of affective illness.
Platelets from depressed patients were shown to have a reduced
^max ^°r "k*18 uP^a^e process. In mianserin-treated patients this re¬
turns to control values, whereas in amitriptyline-treated patients
the values fall still further. As all patients recovered it is not
possible to say what effects are due to treatment. It would be inter¬
esting to try and find out which controlling factor of 5-HT uptake
sites is deranged in these patients, and see if that control varied
with changing mood.
The work presented in this thesis has revealed that there are
several interesting abnormalities in the blood cells of patients with
affective illness. It is imperative that the cause of these changes
be found. It is possible that this may reveal the cause of the
illness i.e. high levels of vanadium may indeed cause affective illness.
Over the last 30 years psychiatrists have searched for the key to
affective illness. No treatment, which has been shown to be unequiv¬
ocally successful, has been introduced as a result of all this expensive
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